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Summary 
 
Toll-like receptors (TLRs) mediate evolutionary conserved immune responses against 
invading microorganisms by recognizing specific pathogen-associated molecules. Major 
inflammatory pathways elicited upon engagement of TLRs and interleukin-1 receptor (IL-1R) 
proceed through the bipartite adaptor, MyD88. The adaptor is comprised of an N-terminal death 
domain (DD, residues Thr17 to Gln120 in the human protein) and a C-terminal Toll–IL-1R (TIR) 
domain (Glu159 to Pro296), connected by a long, unstructured linker. TLR•MyD88 and IL-
1R•MyD88 complexes bind protein kinases IRAK-1 and 4 to trigger a phosphorylation cascade 
that eventually culminates with NF-κB activation and downstream transcription of pro- and anti-
inflammatory genes. This inflammatory response, in turn, is down-regulated by the catalytically 
disabled member of the family, IRAK-M, although the mechanisms underlying this process are 
currently unknown. In addition, although it is known that formation of MyD88•IRAK complexes 
depends upon homotypic interactions of their death domains, the architecture of these complexes 
also remains in dispute. A truncated splice variant of the adaptor, MyD88s, which lacks residues 
Glu110 to Leu154, cannot recruit IRAK-4 and fails to elicit inflammatory responses. 
In the present work, with the aim of elucidating the interactions between MyD88 and 
IRAK proteins in the TLR/IL-1R signaling pathway, we have cloned, overexpressed, purified and 
characterized recombinant proteins comprising the death domains of MyD88, IRAK-1, IRAK-M 
and IRAK-4, both alone and extended by the linker to C-terminal TIR or kinase domains, 
respectively. Using these recombinant fragments, we have shown that the DDs of MyD88 and 
IRAK proteins form large aggregates in solution. In addition, we have demonstrated that the death 
domain of the adaptor is able to interact with similar domains from IRAK-M and IRAK-4. Of 
particular note, both forms of recombinant MyD88 are able to bind to the linker-extended variant 
of IRAK-4 death domain and pull down native, full-length IRAK-4 from monocyte extracts. 
Specifically, we show that residues Glu110-Gln120 including the C-terminal helix α7 of MyD88, 
but not the irregular DD-TIR linker, are required for IRAK-4 recruitment, while residues up to 
Lys115 in the DD–kinase linker of IRAK-4, and not beyond, are needed for strong interactions 
with the adaptor. Further, we demonstrate that residues beyond Glu143 in the MyD88 DD-TIR 
linker, at least, are dispensable for IRAK-M binding to MyD88. Altogether, the current findings 
can be integrated in a model for sequential assembly of membrane-proximal MyD88 complexes, 
as we propose, and provide a straightforward explanation for the negative regulation of innate 
immune responses mediated by MyD88s. 
 
  
 
  
  
Resumen 
 
Los receptores tipo Toll (TLR) median las respuestas inmunes evolutivamente 
conservadas contra microorganismos invasores, reconociendo moléculas específicas asociadas a 
patógenos. Los mecanismos inflamatorios más importantes que se activan tras la unión de los 
TLR y el receptor de interleukina-1 (IL-1R) proceden a través del adaptador bipartito, MyD88. 
Este adaptador se compone de un dominio globular DD, (residuos N-terminales Thr17-Gln120 en la 
proteína humana), y un dominio C-terminal Toll-IL-1R (TIR) (Glu159-Pro296), unidos entre sí por 
un conector largo y carente de estructura secundaria. Los complejos TLR•MyD88 e IL-
1R•MyD88 se unen a las proteínas quinasas IRAK-1 y 4 para desencadenar una cascada de 
fosforilación que culmina eventualmente con la activación de NF-κB y la transcripción de genes 
pro- y anti-inflamatorios. Esta respuesta inflamatoria, a su vez, está regulada negativamente por el 
miembro catalíticamente inactivo de la familia, IRAK-M, aunque los mecanismos que subyacen a 
este proceso se desconocen actualmente. Asimismo, aunque es sabido que la formación de los 
complejos MyD88•IRAK se basa en las interacciones homotípicas entre sus dominios DD, la 
arquitectura de estos complejos también permanece en disputa. Una variante truncada del 
adaptador, MyD88s, carente de los residuos Glu110-Leu154, no puede reclutar IRAK-4 y es incapaz 
de producir respuestas inflamatorias.  
En el presente trabajo, con el objetivo de elucidar las interacciones entre MyD88 y las 
proteínas IRAK en la ruta de señalización de TLR/IL-1R, hemos clonado, sobreexpresado, 
purificado y caracterizado proteínas recombinantes que comprenden los dominios DD de MyD88, 
IRAK-1, IRAK-M e IRAK-4, tanto solos como extendidos por el conector entre los dominios DD 
y los dominios C-terminales TIR o quinasa, respectivamente. Utilizando estos fragmentos 
recombinantes, hemos demostrado que los dominios DD de las proteínas MyD88 e IRAK forman 
grandes agregados en disolución. Además, hemos demostrado que el dominio DD del adaptador 
es capaz de interaccionar con dominios similares de IRAK-M e IRAK-4. De especial relevancia 
es que ambas formas recombinantes del DD de MyD88 son capaces de unirse a la variante de 
IRAK-4 extendida por el conector, y reclutar proteína IRAK-4 nativa y completa, procedente de 
extractos de monocitos. Específicamente, hemos demostrado que los residuos Glu110-Gln120, que 
incluyen la hélice C-terminal α7 pero no el conector irregular DD-TIR, son necesarios para el 
reclutamiento de IRAK-4, mientras que los residuos hasta Lys115 en el conector DD-TIR de 
IRAK-4, y no más allá, son necesarios para establecer interacciones fuertes con el adaptador. 
Además, hemos demostrado que los residuos del conector DD-TIR de MyD88, como mínimo a 
partir de Glu143, son prescindibles para la unión del adaptador con IRAK-M. En conjunto, los 
resultados aquí presentados pueden integrarse en un modelo de ensamblaje secuencial de 
complejos de MyD88 próximos a la membrana, como proponemos, y proporcionan una 
explicación directa a la regulación negativa de la repuesta inmune innata mediada por MyD88s. 
  
 
  
Table of Contents 
 
List of Figures      ........................................................................................................................     21 
List of Tables      ..........................................................................................................................     25 
Abbreviations      .........................................................................................................................     27 
 
1. Introduction      .......................................................................................................................     29 
1.1 The Innate Immune System      ...............................................................................................     31 
1.1.1 Overview of the Innate Immune System      ..............................................................     31 
1.1.2 Cell Surface Receptors of the Innate Immune System      ........................................     31 
1.2 Toll-Like Receptors      ...........................................................................................................     32 
1.2.1 General Aspects of TLRs      .....................................................................................     32 
1.2.2 TLR Classification      ...............................................................................................     32 
1.3 TLR Signaling Pathway      ....................................................................................................     33 
1.3.1 MyD88-Independent Signaling Pathway      .............................................................     33 
1.3.2 MyD88-Dependent Signaling Pathway      ...............................................................     34 
1.4 The DD Superfamily      .........................................................................................................     36 
1.5 DD-Containing Proteins in the TLR/MyD88/IRAK System      ............................................     38 
1.5.1 Protein Adaptor MyD88      ......................................................................................     38 
1.5.2 IL-1 Receptor Associated Kinase Family      ............................................................     39 
1.6 Negative Regulation of the TLR/MyD88/IRAK Pathway      ................................................     42 
1.7 Known Three-Dimensional Structures in the Toll/TLR Signaling Pathway:
MyD88 and IRAK-4      ...........................................................................................     44 
1.7.1 Structure of Individual Domains of MyD88/IRAKs      ............................................     44 
1.7.2 Multimeric Structures      ..........................................................................................     46 
1.8 Involvement of the TLR/MyD88/IRAK System in Disease      .............................................     49 
 
2. Objectives      ...........................................................................................................................     51 
 
  
3. Materials and Methods      .....................................................................................................      55 
3.1 Recombinant Protein Expression      ......................................................................................      57 
3.1.1 Sequence Alignments and Secondary Structure Prediction      ................................      57 
3.1.2 Cloning of Death Domains      ..................................................................................      57 
3.2 Site-Directed Mutagenesis      ................................................................................................      58 
3.2.1 Primer Design      ......................................................................................................      58 
3.2.2 PCR Conditions      ...................................................................................................      60 
3.2.3 DNA Extraction and Sequencing      ........................................................................      61 
3.3 Heterologous Expression of MyD88, IRAK-1, IRAK-4 and IRAK-M Variants      .............      62 
3.3.1 Escherichia coli Strains      .......................................................................................      62 
3.3.2 Transformation of Competent Cells      ....................................................................      62 
3.3.3 Preparation of Starter Cultures      ............................................................................      63 
3.3.4 Preparation of Glycerol Stocks      ............................................................................      63 
3.3.5 Preparation of Larger Cultures      ............................................................................      63 
3.4 Extraction and Renaturation of Recombinant Fragments      .................................................      64 
3.4.1 Extraction of MyD88 and IRAK Recombinant Fragments      .................................      64 
3.4.2 Renaturation of Recombinant Proteins      ................................................................      64 
3.5 Purification of Recombinant Fragments of MyD88 and IRAK Proteins      ..........................      65 
3.5.1 Purification of MyD88 and its Complexes by Affinity Chromatography      ...........      65 
3.5.2 Ion-Exchange Chromatography of IRAK Proteins      .............................................      67 
3.5.3 Size-Exclusion Chromatography      .........................................................................      67 
3.6 Ultrafiltration of Protein Solutions and Determination of Protein Concentration      ............      68 
3.6.1 Determination of Protein Concentration from the Absorbance at 280 nm      ..........      68 
3.6.2 Ultrafiltration of Protein Solutions      ......................................................................      69 
3.7 Protein Detection      ..............................................................................................................      71 
3.7.1 Protein Separation by SDS-PAGE      ......................................................................      71 
3.7.2 Protein Gel Staining      ............................................................................................      72 
3.7.3 Protein Immunodetection by Western Blot      .........................................................      73 
3.8 Monocyte Isolation and Culture      .......................................................................................      75 
  
3.9 Heterocomplex Formation of MyD88 and IRAK Proteins in Solution      .............................     76 
3.9.1 Binding Assays Performed with Soluble MyD88/IRAK-4 
Recombinant Fragments      .....................................................................................     76 
3.9.2 Demonstration of Recombinant MyD88 Interaction with Natural 
Full-Lenght IRAK-4 Kinase      ...............................................................................     77 
3.9.3 Detergent Screening to Enhance MyD88(L)-IRAK-4(L) Complex 
Formation      ............................................................................................................     77 
3.9.4 Co-renaturation of MyD88 and IRAK Recombinant Domains      ...........................     77 
3.10 Protein Characterization      ..................................................................................................     78 
3.10.1 Dynamic Light Scattering      ..................................................................................     78 
3.10.2 Limited Proteolysis      ............................................................................................     78 
3.10.3 Surface Plasmon Resonance Studies      ..................................................................     80 
3.10.4 Analytical Ultracentrifugation      ...........................................................................     81 
3.11 Crystallization of MyD88 DD Recombinant Fragments and Their 
Complexes with IRAK-4(L)      .........................................................................................     82 
3.11.1 Protein and Complex Preparation for Crystallization      ........................................     82 
3.11.2 Finding Optimal Crystallization Conditions for Crystal Growth      .......................     82 
3.11.3 Crystal-quality Optimization Methods      ...............................................................     83 
3.11.4 Crystal Harvesting and Cryopreservation      ..........................................................     86 
3.11.5 X-Ray Diffraction Data Collection      ....................................................................     86 
3.11.6 Diffraction Data Processing: Integration and Data Reduction      ...........................     88 
3.11.7 Crystal Structure Determination      ........................................................................     89 
3.12 Three-Dimensional Modeling of MyD88 and IRAK-4 Death Domains      .........................     90 
 
2. Results       ............................................................................................................................     91 
4.1 Preliminary Studies on MyD88 and IRAK Recombinant Proteins      ...................................     93 
4.1.1 Sequence Comparisons Indicate the Presence of a Seventh C- 
Terminal Helix in the Death Domain of MyD88, in Addition to the 
Conserved Six-Helix Bundle      ..............................................................................     93 
4.1.2 Expression and Characterization of MyD88 and IRAK Death Domains      ............     94 
  
 
4.1.3 Purified Death Domains of MyD88 and IRAK-4 Form Large 
Aggregates in the Absence of Detergents      ..........................................................      97 
4.2 Interactions Between MyD88 and IRAK-4 Recombinant Variants      .................................      99 
4.2.1 The Isolated Death Domains of MyD88 and IRAK-4 Form a Stable 
Complex in Solution      ..........................................................................................      99 
4.2.2 The Death-Domains of MyD88 and IRAK-4 Can Be Co-renatured to 
Form a Stoichiometric Complex      ......................................................................      101 
4.2.3 The Unstructured Death Domain-TIR Linker of MyD88 Is Not 
Required for IRAK-4 Recruitment      ...................................................................      103 
4.2.3.1 The Isolated Death-Domain of MyD88 Interacts with Native 
IRAK-4      ........................................................................................................      104 
4.2.3.2 SPR Analysis of DD-Mediated MyD88–IRAK-4 Interactions      ............      105 
4.2.4 Residues up to Ser114 in IRAK-4 DD-Kinase Linker Are Required 
for MyD88 Binding      ..........................................................................................      106 
4.2.5 MyD88•IRAK-4 Complexes Form Large Aggregates in Solution      ...................      108 
4.2.6 Recombinant Death Domain-Only Variants of MyD88 Can Be   
Crystallized      ......................................................................................................      112 
4.3 Interactions Between MyD88 and IRAK-M Recombinant Variants      ..............................      115 
4.3.1 The Linker-Extended Versions of MyD88 and IRAK-M Form a Stable   
Complex in Solution      ........................................................................................      115 
4.3.2 Residues Beyond Glu143 in the DD-TIR Linker of MyD88 Are Not   
Required for IRAK-M Recruitment      .................................................................      117 
 
5. Discussion      ........................................................................................................................      119 
5.1 Overexpression and Characterization of Death Domains of MyD88 and IRAK   
Proteins      ..........................................................................................................................      121 
5.2 Death Domain Interactions Between MyD88 and IRAK Proteins      .................................      126 
5.3 A Proposed Mechanism for MyD88•IRAK-4 Complex Assembly      ................................      129 
 
 
 
  
6. Conclusions      ......................................................................................................................     135 
6.1 Conclusions      .....................................................................................................................     137 
6.2 Conclusiones      ...................................................................................................................     139 
 
7. Appendices      .......................................................................................................................     141 
Appendix I: Structure and Classification of Amino Acids      ....................................................     143 
Appendix II: Structure-Based Sequence Alignment of Death Domains from   
MyD88 and IRAK-4      ...................................................................................................     145 
Appendix III: Putative protein-protein interaction sites in MyD88 death domain      ................     147 
Appendix IV: Putative protein-protein interaction sites in IRAK-4 death domain      ...............     149 
Appendix V: pET-3a Restriction Map      ..................................................................................     151 
Appendix VI: DNA Sequences of MyD88 and IRAK Recombinant Fragments      ..................     153 
Appendix VII: Buffers and Solutions      ....................................................................................     155 
Appendix VIII: FoldIt Screen      ...............................................................................................     161 
Appendix IX: Detergent Screen 1 Formulation      ....................................................................     163 
Appendix X: Crystallization Conditions      ...............................................................................     165 
Appendix XI: Supplemental Figures      .....................................................................................     173 
Appendix XII: Articles Published During the PhD Period      ...................................................     177 
 
8. References      ........................................................................................................................     179 
 
 
 
 
 
 
  
 
 
 
 21 
 
List of Figures 
 
Figure 1.1 Schematic representation of TLR/MyD88-dependent signaling pathways      ..........     35 
Figure 1.2 Ribbon diagrams of selected modules of each subfamily within the DD
superfamily     ..........................................................................................................     37 
Figure 1.3 Schematic representation of human MyD88 structural organization      ....................     38 
Figure 1.4 Domains of the human receptor-associated kinases (IRAKs)      ..............................     40 
Figure 1.5 Negative regulation of TLR signaling      ..................................................................     44 
Figure 1.6 NMR solution structure of human MyD88 TIR domain      .......................................     45 
Figure 1.7 Schematic representation of IRAK-4 DD      .............................................................     46 
Figure 1.8 Conservation and divergence of TLR-mediated innate immune response
in insects and mammals     .......................................................................................     47 
Figure 1.9 Three-dimensional crystal structure of Drosophila Tube DD•Pelle DD
complex     ...............................................................................................................     48 
Figure 1.20 Structure of the ternary Myddosome complex      ....................................................     49 
Figure 3.1 Generated mutations over the MyD88(L) and IRAK-4(L) nucleotide
sequences     .............................................................................................................     59 
Figure 3.2 Schematic representation of the interaction between neighboring
residues in the 6xHis tag and the Ni-NTA matrix     ...............................................     66 
Figure 3.3 Ultrafiltration devices used for protein concentration and dialysis      ......................     70 
Figure 3.4 Schematic representation of the “sandwich” assembly for transferring
proteins to a synthetic membrane     ........................................................................     74 
Figure 3.5 Ni2+-NTA interaction with polyhistidine-tagged ligands      ......................................     80 
Figure 3.6 Hanging- and sitting-drop vapor diffusion crystallization methods      .....................     83 
Figure 3.7 Schematic illustration of a protein solubility phase diagram      ................................     84 
Figure 3.8 Micro-seeding technique for growing protein crystals      .........................................     85 
Figure 3.9 Typical X-ray diffraction unit      ...............................................................................     87 
Figure 4.1 Schematic representation of domain organization in human MyD88
and IRAK proteins     ...............................................................................................     93 
Figure 4.2 Overexpression of human death domains from MyD88 and IRAK proteins      .......     95 
 22 
 
Figure 4.3 Preferential cleavage of interdomain linkers in recombinant proteins
suggests correct folding of MyD88 and IRAK variants     ......................................      96 
Figure 4.4 Human MyD88 and IRAK-4 death domains have a strong tendency 
to form aggregates     ...............................................................................................      97 
Figure 4.5 DLS analysis of purified recombinant proteins      ....................................................      98 
Figure 4.6 Gel filtration analysis of recombinant MyD88(L) samples      ..................................      99 
Figure 4.7 Formation of MyD88(L)•IRAK-4(L) heterodimer in solution      ...........................      100 
Figure 4.8 Several non-ionic detergents support formation of stoichiometric
MyD88(L)•IRAK-4(L) complex     .......................................................................      101 
Figure 4.9 MyD88(L) and IRAK-4(L) co-renaturation trial by rapid dilution in
refolding solutions     .............................................................................................      102 
Figure 4.10 The isolated death domains of MyD88(L) and IRAK-4(L) form a
stable complex in solution     .................................................................................      102 
Figure 4.11 The death domain-TIR linker of MyD88 is not required for kinase
recruitment, but the DD-kinase linker of IRAK-4 is important for 
heterodimer formation     .......................................................................................      103 
Figure 4.12 The death domain of MyD88 pulls down natural IRAK-4 from
monocyte extracts     ..............................................................................................      104 
Figure 4.13 Surface plasmon resonance studies of MyD88(S)–IRAK-4(L)
interactions     ........................................................................................................      105 
Figure 4.14 Residues up to Glu116 in IRAK-4 linker are protected from  
proteolytic attack in the complex with MyD88     .................................................      107 
Figure 4.15 Similar kinetics of chymotrypsin cleavage of free and complexed
IRAK-4(L)     .........................................................................................................      107 
Figure 4.16 Residues beyond Ser114 in IRAK-4 linker do not contribute to
complex formation with MyD88     .......................................................................      108 
Figure 4.17 AUC analysis of MyD88 and IRAK-4 recombinant fragments and
their complexes     .................................................................................................      109 
Figure 4.18 FPLC analysis on MyD88(L)•IRAK-4(L) and MyD88 E143X•IRAK-4(L)
complexes     ..........................................................................................................      111 
Figure 4.19 Orthogonal images of diffraction patterns obtained from MyD88 E143X
crystals     ...............................................................................................................      113 
 23 
 
Figure 4.20 Formation of MyD88(L)•IRAK-M(L) heterodimer in solution      ........................     115 
Figure 4.21 MyD88 and IRAK-M(L) co-renaturation trials by rapid dilution in
refolding solutions     .............................................................................................     116 
Figure 4.22 The linker-extended variants of MyD88 and IRAK-M form a stable
complex     .............................................................................................................     116 
Figure 4.23 Residues beyond Glu143 in the DD-TIR linker of MyD88 are not
required for IRAK-M recruitment     .....................................................................     117 
Figure 5.1 Overexpressed MyD88 is localized in the cytoplasm as large condensed
forms     ..................................................................................................................     123 
Figure 5.2 Aggregation is a common feature of members of the DD superfamily      ..............     125 
Figure 5.3 Partial sequence comparison between human IRAK-4 and IRAK-M      ................     127 
Figure 5.4 Hypothetical model of death domain-mediated heterocomplex
formation between MyD88 and IRAK-4      ..........................................................     131 
Figure 5.5 Different arrangements of death domain heterodimers      .......................................     133 
 
Supplemental Figure 1 Overexpression of MyD88 E143X and IRAK-4 K115X 
truncated variants      ..............................................................................................     173 
Supplemental Figure 2 Gel filtration analysis of MyD88 E143X variant      ..........................     173 
Supplemental Figure 3 Electrophoretic analysis of MyD88(L)•IRAK-4(L) and
MyD88(L)•IRAK-4 K115X complexes under native conditions      .....................     174 
Supplemental Figure 4 Formation of MyD88 E143X•IRAK-4(L) complex in solution      ....     174 
Supplemental Figure 5 Orthogonal images of diffraction patterns obtained for
MyD88(L) and MyD88 E143X crystals      ...........................................................     175 
  
 25 
 
List of Tables 
 
Table 1.1 Some of the proposed ligands for the different TLRs identified      ............................     33 
Table 3.1 Designed MyD88 and IRAK-4 primer sequences for site-directed
mutagenesis     .........................................................................................................     60 
Table 3.2 Main characteristics of the ESRF beamlines used for X-ray diffraction 
analysis of protein crystals      ..................................................................................     87 
Table 4.1 Summary of expression, renaturation and purification conditions for 
MyD88 and IRAK recombinant fragments generated in the current
investigation      ........................................................................................................     94 
Table 4.2 Major physicochemical parameters of recombinant proteins 
generated for the current study      ...........................................................................     95 
Table 4.3 Summary of experimental set-up and solutions used for SPR analysis 
of MyD88(S)–IRAK-4(L) interactions      .............................................................     106 
Table 4.4 Main characteristics of samples and buffers used for AUC analysis      ...................     110 
Table 4.5 Summary of crystallization conditions used on MyD88 recombinant
fragments      ..........................................................................................................     112 
Table 4.6 Summary of used and calculated parameters during data collection of
MyD88 E143X crystals      ....................................................................................     114 
 
 
 
 
 
 
 
 
  
 
 
 
  
27 
 
Abbreviations 
 
Akt (also known as PKB): Protein kinase B 
AP-1: Activating protein-1 
Apaf-1: Apoptotic protease activating factor-1 
APC: Antigen presenting cell 
CARD: Caspase recruitment domain 
CD: Cluster of differentiation 
DD: Death domain 
DED: Death effector domain 
DISC: Death-inducing signaling complex 
ERK: Extracellular signal-regulated kinase 
FADD: Fas-associated protein with death domain 
HSP: Heat shock protein 
IB: Inclusion body 
IKK: Inhibitor of NF-κB kinase 
IL-1R: Interleukin-1 receptor 
IPTG: Isoporpyl β-D-1-thiogalactopyranoside 
IRAK: Interleukin-1 receptor-associated kinase 
IRF: Interferon regulatory factor 
LB medium: Luria Bertani medium 
LBP: Lipopolysaccharide binding protein 
LRR: Leucine-rich-repeat 
Mal: MyD88-adaptor-like 
MyD88: Myeloid differentiation factor 88 
NF-κB: Nuclear factor kappa B 
NK: Natural killer 
NTA: Nitrilotriacetic acid 
PAMPs: Pathogen-associated molecular patterns 
PI3K: Phosphatidylinositol 3- kinase 
PIDD: p53-induced protein with a death domain 
PYD: Pyrin domain 
RAIDD: RIP-associated ICH-1/CED-3 homologous protein with a death domain 
 28 
 
 
SIGIRR: Single immunoglobulin IL-1R-related protein 
SOB medium: Super optimal broth medium 
SOC medium: SOB medium with catabolite repression 
SOCS: Suppressor of cytokine signaling 
TIR: Toll–IL-1R 
TLR: Toll-like receptors 
TNF-α: Tumor necrosis factor α 
TOLLIP: Toll interacting protein 
TRAF6: TNF receptor-associated factor 6 
TRAM: TRIF-related adaptor molecule 
TRIF: TIR domain-containing adapter inducing IFN-β 
β-OG: n-octyl-β-D-glucopyranoside 
 
  
  
 
  
1. Introuduction 
  
 
  
 Introduction 
 
 
31 
 
1.1 The Innate Immune System 
 
1.1.1 Overview of the Innate Immune System 
 
Although we are constantly in contact with potentially pathogenic microorganisms, we 
rarely become ill. This is because the microorganisms that penetrate the epithelial surface of the 
body are initially recognized and attacked by defense mechanisms that do not require a prolonged 
period of exposure, as they do not depend on the clonal expansion of lymphocytes in response to 
certain antigens. These defense mechanisms act immediately after infection and are part of the 
innate immune response. Moreover, the innate immune system plays a critical role in controlling 
infections during this first period, because there is a delay of four to seven days before the initial 
adaptive immune response takes place [1]. Until recently, it was thought that the innate immune 
system was not specific [2]. The specificity of the innate immune system was shown, however, 
with the initial description in Drosophila melanogaster of the Toll gene product, involved in both 
antifungal defense and dorsoventral development in insects [3-8]. The innate immune system is 
activated not only in the presence of microorganisms but also as a result of external damage such 
as burns, contusions, bone fractures and wounds [9], as well as internal changes that accompany 
tumor formation [10]. This defense mechanism is present in all multicellular organisms and is 
phylogenetically conserved [11]. 
The main cells involved in the innate immune response are those of the myeloid lineage, 
among them Antigen Presenting Cells (APCs) such as monocytes (macrophages precursors), 
dendritic cells and neutrophils; although the latter lack antigen presenting ability, they possess 
phagocytic activity. Natural killer (NK) cells, of lymphoid origin, appear also to be involved in 
innate immune defense against intracellular pathogens. Macrophages and neutrophils, besides 
being the first line of defense against many common microorganisms, are crucial in initiation and 
subsequent direction of the adaptive immune system, and also in removing pathogens captured by 
this type of response [1]. 
To initiate an inflammatory immune response, macrophages and neutrophils count on cell 
surface receptors able to recognize and bind to common elements of many different pathogens. 
These receptors are crucial for antigen recognition and, therefore, are essential at the initial stages 
of the immune response. 
 
1.1.2 Cell Surface Receptors of the Innate Immune System 
 
A number of cell surface receptors can specifically recognize molecular structures 
collectively referred to as pathogen-associated molecular patterns (PAMPs) [1]. Among these 
receptors, it is worth mentioning the macrophage mannose receptor, exclusive to these cells; the 
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scavenger receptors, which bind to many charged ligands; CD14 and LBP (lipopolysaccharide-
binding protein), which are found mainly in monocytes and macrophages [1]; and the Toll-like 
receptors (TLRs), expressed in monocytes, dendritic cells, and other mucosal and endothelial 
cells. TLRs have been identified in plants and mammals as proteins homologous to the 
Drosophila Toll protein [8], and major inflammatory responses that take place after infection 
evolve through these receptors [12]. 
 
1.2 Toll-Like Receptors 
 
1.2.1 General Aspects of TLRs 
 
Toll-like receptors are transmembrane proteins of the Interleukin-1 (IL-1) Receptor (IL-
1R) family. This family of receptors belongs, in turn, to a superfamily that includes receptors of 
the proinflammatory cytokines IL-1 and IL-18, and their co-receptors [3-8]. TLRs have an N-
terminal, ligand-binding, extracellular domain with several LRR (Leucine-Rich-Repeat) motifs, a 
transmembrane domain, and a well-conserved intracellular, C-terminal domain through which 
they interact with signal transduction proteins. This TLR cytoplasmic domain is homologous to 
the cytoplasmic domains of e.g. human IL-1R and Drosophila Toll, and it is thus termed TIR 
(Toll-IL-1 Receptor) domain [5, 11, 13-15]. 
 
1.2.2 TLR Classification 
 
In humans, at least ten TLRs of known function are present, all of them with the ability to 
recognize specific ligands and activate an inflammatory immune response [16]. These receptors 
are expressed in a wide range of cell types, including macrophages, dendritic cells, B-cells, some 
T-cell types, and even in non-immune cells such as fibroblasts and epithelial cells [11, 14]. These 
receptors, either as monomers or as homo/heterodimers, are specialized in the recognition of 
different PAMPs [17]. TLRs can be both intra and extracellularly expressed, depending on the 
ligands they recognize. In this manner, TLRs responsible for detection of bacterial products and 
endogenous ligands (TLRs 1, 2, 4, 5 and 6) are expressed on the cell surface, while those able to 
detect viral components (TLRs 3, 7, 8 and 9) are located at the endosome membranes (Table 1.1) 
[14, 18]. Noteworthy, some TLRs can recognize ligands that are neither structurally nor 
functionally related with each other. TLR4, for example, recognizes a number of exogenous 
ligands such as bacterial lipopolysaccharides (LPS) and respiratory syncytial virus fusion protein, 
but also self-proteins such as fibronectin and heat shock proteins [14] (Table 1.1). 
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Table 1.1 Some of the proposed ligands for the different TLRs identified. The ligand for 
TLR10 remains unknown up to date. ND, Not determined. HSP, Heat Shock Protein. 
TLR  Bacterial Ligand  Endogenous Ligands 
TLR1/2 Triacylated lipoproteins [19]  ND  
TLR2  Lipoteichoic acid [20], Peptidoglycan [21] HSP-60 [22], -70 [23-25], -90 [26] 
TLR2/6 Diacylated lipoproteins [19], Zymosan [27, 28] ND 
TLR4 Lipopolysaccharide [15, 29-34] Fibronectin [35], HSP-22 [36], HSP-60 [22, 37, 38], HSP-70 [23-25], HSP-90 [26] 
TLR5 Flagellin [39] ND 
TLR9 CpG motifs [40, 41] DNA [42, 43] 
TLR  Viral Ligands Endogenous Ligands 
TLR2 Hemagglutinin [44] ND 
TLR4 F-protein (respiratory syncytial virus ) [45] ND 
TLR3 dsRNA [46] mRNA [47] 
TLR7/8 ssRNA [48-50] ssRNA [51, 52] 
TLR9 CpG motifs [53-56] DNA [57, 58] 
 
TLR activation can lead, through transcription Nuclear Factor kappa B (NF-κB) to 
production of inflammatory cytokines or even of costimulatory molecules, which activate the 
adaptive immune system [59, 60]. The mechanisms through which these molecules are produced 
downstream of TLR ligand recognition are known as the TLR signaling pathway, which is briefly 
explained below. 
 
1.3 TLR Signaling Pathway 
 
Engagement of TLRs allows activation of different signaling cascades, which are crucial 
for the innate immune response to work properly [59]. Activation of almost all TLRs, with the 
exception of TLR3 [61], stimulates an intracellular signaling pathway that involves the initial 
recruitment of the adaptor protein Myeloid Differentiation Factor 88 (MyD88). There are also 
alternative, MyD88-independent pathways, but these are specific for TLR3 and TLR4 receptors 
[62, 63]. Both MyD88-dependent and independent signaling pathways culminate with the 
induction of proinflammatory cytokines and interferons [64]. 
 
1.3.1 MyD88-Independent Signaling Pathway 
 
The MyD88-independent signaling pathway, specific for TLR3 and TLR4, relies on 
protein adaptors other than MyD88, such as TRIF (TIR domain-containing adapter inducing IFN-
β) and TRAM (TRIF-related adaptor molecule), as well as the interferon regulatory factors (IRF) 
3 and 7, which induce type I IFN expression and costimulatory molecules [55, 65]. This signaling 
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pathway is involved in the late phase of NF-κB and mitogen-activated protein kinase (MAPK) 
activation [66, 67], as well as in the transcription of target genes such as type I interferons [68, 
69],  which are critical for proper anti-viral and anti-bacterial responses [70, 71]. 
 
1.3.2 MyD88-Dependent Signaling Pathway 
 
The MyD88-dependent signaling pathway is characterized by the recruitment of the 
bipartite adaptor MyD88, upon TLR interaction with its corresponding ligand and subsequent 
receptor multimerization [72-74]. This adaptor features a C-terminal TIR domain that interacts 
with the membrane proximal TIR domain of the TLR, and an N-terminal death domain (DD), 
responsible for the recruitment of  Interleukin (IL)-1 receptor-associated kinases (IRAK) 1 and 4, 
via homotypic DD interactions [75]. High protein concentrations due to the formation of 
MyD88•IRAK-4•IRAK-1 multimers trigger a complex cascade of phosphorylation reactions, 
conceptually similar to the induced proximity mechanism of caspase activation (reviewed in [76, 
77]). As a result of this cascade, hyperphosphorylation of IRAK-1 occurs at several positions of 
the DD-Kinase linker [78]. MyD88 plays a crucial role in this pathway, because it mediates a 
close interaction of the two related IRAK molecules, which is essential to allow IRAK-4 to 
phosphorylate IRAK-1 [79]. This probably triggers IRAK-1’s own kinase activity, resulting in 
multiple autophosphorylation events [80]. Conformational changes induced thereupon eventually 
allow IRAK-1 to bind to the signal transducer TRAF6 (Tumor Necrosis Factor (TNF) Receptor-
Associated Factor 6) [62, 81], and to dissociate from its membrane-proximal complex with 
MyD88 [82]. The IRAK-1/TRAF6 complex can then activate downstream targets [82, 83], 
through three different signaling pathways that regulate the balance between cellular viability and 
inflammation [14, 84]. These pathways are the IKK (inhibitor of NF-κB kinase) pathway, the 
MAPK pathway, and the PI3K (Phosphatidylinositol 3- Kinase)/Akt (also known as Protein 
Kinase B) pathway [85, 86]. These signaling pathways culminate in the nuclear localization of 
NF-κB/AP-1 (Activating Protein-1) and the transcription of several genes that regulate pro- and 
anti-inflammatory responses [81, 87] (Figure 1.1). It is important to emphasize that IRAK-1 is not 
only phosphorylated but also degraded upon IL-1 stimulation [88, 89]. IRAK-1 degradation leads 
to a shutdown of the IL-1 response, initiating a negative feedback loop in this signaling pathway 
[88, 90]. 
 
a) IKK signaling pathway 
IKK proteins initiate a kinase activation cascade in which two kinases, IKK-α e IKK-β, 
which form the IKK dimer, are activated and phosphorylate an inhibitory protein known as 
inhibitor of NF-κB (IκB)-α. Under normal conditions, IκB-α binds to NF-κB to form a cytosolic 
complex that inhibits NF-κB nuclear translocation. Phosphorylation of IκB-α causes its 
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degradation, upon which NF-κB is released and translocated to the nucleus of the cell, where it 
activates transcription of several genes responsible for the expression of proinflammatory 
cytokines such as TNF-α, IL-1β, IL-6, and IL-12 [14, 84] (Figure 1.1). 
 
b) MAPK signaling pathway 
The MAPK pathway is initiated with the activation of MAPKKK (MAPK Kinase Kinase) 
proteins. These proteins phosphorylate MEK 1/2 (mitogen-activated or extracellular signal-
regulated protein kinase kinase -MAPKK-) which, in turn, activates ERK 1/2 (extracellular 
signal-regulated kinase 1/2). This signaling pathway culminates with AP-1 nuclear translocation. 
Although the response of this pathway to LPS through the TLR4 receptor is not well 
characterized yet [91], it is known that AP-1 activation requires TRAF6 activation in endothelial 
cells [92], while it requires a serine/threonine kinase termed TLP-2 (Tumor Progression Locus-2) 
in macrophages [93]. TLP-2 acts as a MAPKKK ultimately inducing ERK 1/2 activation and the 
subsequent AP-1 nuclear translocation, thus modulating the expression of proinflammatory genes 
[91] (Figure 1.1).  
 
c) PI3K signaling pathway 
PI3Ks constitute a family of kinases classified in three subfamilies according to their 
structure and specific substrates. The most thoroughly studied of these subfamilies is the one 
known as class I PI3Ks, which are activated by cellular receptors and mediate  phosphoinositide 
phosphorylation [94]. The phosphorylated lipidic products act as a second messenger that 
activates a wide variety of mediators including Akt, which is responsible for IκB-α 
phosphorylation and subsequent NF-κB activation (Figure 1.1). 
 
 
Figure 1.1 Schematic representation of TLR/MyD88-dependent signaling pathways. The illustration 
covers the IKK, MAPK and PI3K signaling pathways, which initiate with the recruitment of MyD88 to 
TLR and culminate in the nuclear localization of NF-κB/AP-1 (see text for more details). (Based on [85]). 
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The axis of the MyD88-dependent signaling pathway, as it has been discussed, is the 
TLR/MyD88/IRAK system, common to almost all TLRs. This pathway plays a critical role in the 
regulation of inflammation, antiviral response and subsequent activation of the adaptive immune 
response, but has also been implicated in autoimmune diseases. Downstream signaling in this 
pathway strongly relies on protein-protein interactions through their different domains, TIRs and 
DDs. The latter motifs are among the most important domains involved in protein-protein 
interactions, and pertain to a larger superfamily of structurally related domains, termed the DD 
superfamily. 
 
1.4 The DD Superfamily 
 
The DD superfamily is one of the largest and most studied domain superfamilies [95], and 
comprises four subfamilies: the death effector domain (DED) [96], the caspase recruitment 
domain (CARD) [97, 98], the pyrin domain (PYD) [98, 99], and the death domain (DD) 
subfamilies [98]. All these domains share a six-helical bundle fold, as revealed by X-ray 
diffraction and/or NMR structural studies of at least one member of each subfamily. 
Representative structures of each subfamily are given in Figure 1.2: the FADD DED [100] (Fig. 
1.2a), the RAIDD CARD [101] (Fig. 1.2b), the NALP1 PYD [102] (Fig. 1.2c) and the Fas DD 
[103] (Fig. 1.2d). Although this six-helical bundle fold is evolutionarily conserved in many 
multicellular organisms from insects to mammals, individual subfamilies also exhibit distinct 
structural and sequence characteristics. While some proteins are composed only of motifs from 
the same DD superfamily (e.g. FADD), most often DD superfamily domains are found within the 
protein combined with other adapter motifs (e.g. MyD88), or domains with catalytic activity (e.g. 
caspase 8, IRAK-1) [104]. 
Proteins that belong to the DD superfamily usually play critical roles in the assembly of 
molecular complexes and subsequent “proximity induced activation”. Indeed, formation of these 
complexes drives quite different physiological processes such as apoptosis via caspase activation 
[76], or innate immune responses through trans-phosphorylation of IRAK proteins. Interactions 
between DD superfamily members are usually homotypic, i.e. only domains within the same 
subfamily interact with each other [104]. The main structural features of each subfamily are 
described below. 
 
a) DED subfamily 
DEDs have two conserved surface features that distinguish them from other members of 
the DD superfamily. The first one is a conserved, hydrogen-bonded charge triad involving Arg 
and Asp residues in helix H6 and its preceding loop [105], and a negatively charged residue in 
helix H2 [106]. These hydrogen bonds are likely involved in maintaining the organization of the
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Figure 1.2 Ribbon diagrams of selected modules of each subfamily within the DD 
superfamily. The DED domain of FADD (a), the CARD domain of RAIDD (b), the PYD domain 
of NALP1 (c) and the DD domain of Fas (d) are represented in approximately the same 
orientation. (Modified from [104]). 
 
side chains, which may be functionally important. It is also possible that they play a local 
structural role in maintaining the conformation of this DED region. The second conserved feature 
is a hydrophobic patch formed mostly by residues on helix H2, used extensively in DED–DED 
interactions [104]. 
 
b) CARD subfamily 
CARD domains are unique because the helix H1 tends to be either bent or broken into 
two separated helices. The orientation and length of several helices may be somewhat different 
among the different CARDs, but one important feature is that the surfaces of CARDs are 
polarized with both basic and acidic surfaces, which may be used for protein-protein interactions. 
Unlike other DD subfamilies, it is possible that CARDs, at least those that form the prodomains of 
some caspases, do not possess the ability for stable self-association but are rather mostly involved 
in interactions with other CARDs [104]. 
 
c) PYD subfamily 
PYD domains, although possessing also the classical six-helical bundle fold, are special in 
that they have an altered helix H3. This helix can be completely or partially replaced by a flexible, 
elongated loop, as in the PYD domain of NALP1 (Fig. 1.2c). Since helix H3 seems to play a 
critical role in protein-protein interactions in the DD superfamily [107, 108], PYD–PYD 
interactions could significantly differ from classical modes of interaction in the DD superfamily. 
 
d) DD subfamily 
DD domains are involved in protein-protein interactions and have a strong tendency to 
aggregate. This is why many so far available structures of isolated DDs were determined under 
non-physiological conditions such as extreme pH and/or with “disaggregating” mutations. The 
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NMR structures of Fas DD [103, 109] and FADD DD [109, 110], as well as the crystal structures 
of IRAK-4 DD [111] and RAIDD DD [112] are some examples available. While they all exhibit 
the six-helical bundle fold, there are some variations in the lengths and relative orientations of the 
helices. Moreover, because of the low sequence similarity among DDs, the surface features of 
these DD structures are entirely different, and this may be responsible for their specificity in 
protein-protein interactions [104]. 
 
The adaptor MyD88 and the kinases of the IRAK family, crucial in the downstream 
signaling of the TLR/MyD88/IRAK system and the main subject of the work presented here, 
belong to this DD subfamily. 
 
1.5 DD-Containing Proteins in the TLR/MyD88/IRAK System 
 
1.5.1 Protein Adaptor MyD88 
 
MyD88 was discovered during studies addressing the differentiation of mouse myeloid 
cells in response to growth inhibitory stimuli [113]. Although the role of MyD88 as a signal 
transducer was first shown in the pathways triggered by the engagement of IL-1R [74, 114] and 
TLR4 [30], further studies showed that all TLRs, with the sole exception of TLR3, utilize this 
adaptor protein to initiate their signaling pathway [115]. 
Structurally, MyD88 possesses a C-terminal TIR domain (comprising residues from 
Glu159 to Pro296 in humans) that interacts with other TIR domain-containing molecules such as 
TLRs, and an N-terminal death domain (residues from Thr17 to Gln120) that binds other death 
domain-containing molecules, such as members of the IRAK family [11] (see also section 1.5.2). 
These domains are connected through a long polypeptide with no regular 3D-structure, sometimes 
termed “intermediate domain” (ID) (Figure 1.3a). 
It is known that MyD88 is an essential adaptor for mediating the phosphorylation of 
IRAK-1 by IRAK-4 [79]. The functional importance of this adaptor in innate immune defenses
 
 
Figure 1.3 Schematic representation of human MyD88 structural organization. a) WT 
human MyD88 comprises a DD (residues from Thr17 to Gln120), a long linker sometimes termed 
“intermediate domain”, ID (residues from Gln120 to Glu159, both excluded), and a TIR domain 
(residues from Glu159 to Pro296). b) MyD88s, a splice variant of MyD88, lacks residues from 
Glu110 to Leu154, both included. 
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was recently illustrated by rare MyD88 point mutations identified in individuals that are highly 
susceptible to infection with pyogenic bacteria [116]. Although it is generally accepted that 
MyD88 acts by recruiting kinases IRAK-1 and 4 through interactions between their respective 
DDs, the specific residues involved in such interactions have been only partially characterized. 
Remarkably, an alternatively spliced variant of MyD88 (MyD88s), lacking residues Glu110 to 
Leu154 (Figure 1.3b), failed to interact with IRAK-4, suggesting that residues located in both the 
DD and ID of MyD88 are crucially involved in kinase recruitment [79]. On the other hand, 
studies based on site-directed mutagenesis of MyD88 provided strong evidence that MyD88 DD 
residues 27 to 72 are required for the recruitment of IRAK-1 [117]. These data are indirectly 
supported by the fact that two naturally occurring mutations in the MyD88 DD (S34Y and R98C) 
have recently been shown to be dysfunctional in downstream signaling [118]. 
Most studies on the subcellular localization of MyD88 have shown that the protein is 
present as condensed forms in the cytoplasm, such as discrete foci, fibrillar aggregates, and 
inclusion bodies [119-122]. It has been also found that aggregated structures of MyD88 have 
irregular morphologies and do not reside in known particular organelles. Furthermore, some 
authors report that both DD and ID regions are required to form these structures [121]. However, 
because overexpressed MyD88 automatically induces death domain-dependent activation of 
downstream signaling pathways [30, 121, 123, 124], it is still not known whether such condensed 
distributions are artifacts due to the high protein concentrations achieved during overexpression. 
 
1.5.2 IL-1 Receptor Associated Kinase Family 
 
As explained above, TLR-bound MyD88 rapidly recruits some serine/threonine kinases of 
the Pelle subfamily, termed IRAKs [125-132], in close proximity to the membrane.  The term 
IRAK originally referred to a serine/threonine-specific kinase, currently known as IRAK-1, which 
could be coprecipitated in an IL-1-inducible manner with the IL-1R [133, 134]. Four different 
mammalian IRAK proteins have been identified, with a crucial role in the signaling pathways 
initiated by members of the TLR/IL-1R family [74, 75, 135, 136]. These four IRAKs are termed 
IRAK-1 [80], IRAK-2 [74], IRAK-M (also known as IRAK-3) [137] and IRAK-4 [75, 138]. 
Human IRAK-1, IRAK-2 and IRAK-4 are ubiquitously expressed, whereas human IRAK-M is 
only detectable in monocytes and macrophages in an inducible manner [80, 139]. 
Structurally, IRAK family members share a similar organization (Figure 1.4). They 
contain an N-terminal DD followed by a long linker, a conserved kinase domain, and a C-terminal 
stretch that contains binding sites for TRAF6 (except for IRAK-4) [78, 140]. IRAK-1 contains 
three TRAF6 interaction motifs, whereas IRAK-2 is reported to have two, and IRAK-M contains 
only one TRAF6 interaction motif [141]. IRAK-4 lacks this C-terminal sequence and it is 
therefore unclear whether it could interact with TRAF6. The DD is vital for signaling since it 
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Figure 1.4 Domains of the human receptor-associated kinases (IRAKs). Each member has a 
death domain, a long DD-kinase linker, a conserved kinase domain, and a C-terminal region, with 
the exception of IRAK-4 which lacks the C-terminal region. (Modified from [142]). 
 
interacts with MyD88 [74], further discussed in sections 1.7.2b and c. The DD-kinase linker, of 
lower similarity, is rich in serines, prolines and threonines. The IRAK-1 linker, which has been 
reported to be hyperphosphorylated [78], contains two potential PEST sequences that may 
facilitate its degradation. By contrast, IRAK-2, which does not display these sequences, is not 
degraded [143]. The kinase domain in all IRAK molecules possesses a functional ATP binding 
pocket with an invariant lysine residue, critical for the catalytic activity [144]. In addition, they 
have a tyrosine residue at the centre of the ATP binding site, called the gatekeeper residue, which 
controls access to a pre-existing internal hydrophobic pocket at the back of the ATP-binding site 
[145]. This feature is exclusive to the IRAK family of kinases [146]. Whereas IRAK-1 and 
IRAK-4 contain a functional catalytic site with a critical aspartate residue (D340 in human IRAK-
1 and D311 in human IRAK-4, Figure 1.4), this residue is changed into an asparagine in IRAK-
M, which renders this kinase inactive [137, 147]. Since this critical aspartate residue is also 
changed into a serine in IRAK-2, it was first believed that this kinase was also inactive [137]. 
However, a recent study demonstrated that IRAK-2 is enzymatically active [148]. 
 
a) IRAK-1 
IRAK-1 was the first member of the IRAK family to be discovered, and shown to play a 
role in IL-1 signaling [80]. This kinase, a protein of 712 amino acids in length and a molecular mass 
of ~85 kDa, is ubiquitously expressed in humans, and has been shown to undergo phosphorylation 
upon TLR stimulation. Phosphorylation of IRAK-1 is essential for downstream signaling [82, 114], 
and some residues appear to be of critical importance in this regard (Figure 1.4). Phosphorylation 
of IRAK-1 takes place in a series of steps. It has been shown, in vitro, that IRAK-1 is initially 
phosphorylated at Thr209, a functionally critical residue as its mutation completely disrupts kinase 
activity. Phosphorylation of Thr209 results in a conformational change in the kinase domain of 
IRAK-1 that allows subsequent phosphorylations including Thr387, a critical residue that has been 
suggested to be a potential target for phosphorylation by IRAK-4 (Figure 1.4) [78]. 
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b) IRAK-2 
In 1997, a 65-kDa protein of 590 amino acids sharing sequence and functional similarity 
to IRAK-1 was discovered and named IRAK-2 (Figure 1.4). Initial reports showed that 
overexpressed IRAK-2 activated NF-κB, and that IRAK-2 DD was required for this activity, since 
a truncated IRAK-2 variant lacking the whole DD failed to activate NF-κB [74]. Further evidence 
that IRAK-2 played a role in the TLR pathway emerged when it was shown that IRAK-2 interacts 
with MyD88, TRAF6 and TIRAP (TIR domain-containing adaptor protein)/Mal (MyD88-
adaptor-like), a critical adaptor protein acting as a linker between MyD88 and TLR2/4 [74, 149-
151]. 
It has long been thought that IRAK-1 and IRAK-4 were the only active members of the 
IRAK family. However, some studies revealed the importance of IRAK-2 in TLR-induced NF-κB 
activation. Ten years after its discovery, studies with vaccinia virus showed that A52, an 
important protein for virus virulence [152], interacts with IRAK-2 and TRAF6, but not with 
IRAK-1, inhibiting TLR-mediated NF-κB signaling [153]. Recently, it has been proposed that the 
active-site lysine residue in the protein kinase subdomain, common to all IRAKs, is sufficient for 
IRAK-2 to act as an active enzyme, since an in vitro kinase assay showed that IRAK-2 is 
phosphorylated upon stimulation with a TLR2 ligand [148]. These findings thus revealed a 
potential crucial role for the IRAK-2 kinase activity in TLR-mediated NF-κB activation, although 
its mechanism of action remains uncertain. 
 
c) IRAK-M 
IRAK-M is a protein of 596 amino acids with a molecular mass of 68 kDa (Figure 1.4), 
whose expression is limited to monocytes and macrophages [137]. While the other members of 
the IRAK family share many structural features, IRAK-M is unique, as it is the only member of 
this family that lacks kinase activity, working as a negative regulator of TLR signaling [136]. 
Initial reports on IRAK-M showed that, upon overexpression, it was able to activate NF-κB and to 
restore NF-κB activation when expressed in cells lacking IRAK-1 [137]. It was therefore assumed 
that IRAK-M was a positive regulator of TLR-mediated NF-κB signaling. However, macrophages 
derived from IRAK-M knockout mice display enhanced activation of IL-1/TLR signaling [136, 
154], thus suggesting a negative role for this family member. 
Additionally, it has been shown that IRAK-M is involved in different processes, such as 
osteoclastogenesis control [131, 147] and monocytes/macrophagues tolerance to endotoxins [126, 
132] in patients with acute coronary syndrome [127]. IRAK-M has been also described as an 
essential element for cancer tolerance shown by tumor infiltrated monocytes/macrophagues [125]. 
In terms of its regulation, our group showed that TNF-α plays an important role in this process 
[129]. 
 
 Introduction 
 
42 
 
d) IRAK-4 
Human IRAK-4, the most recently discovered member of the IRAK family, is a 460 
amino acids protein with a molecular weight of 52 kDa [138]. It is the closest human homologue 
of the Drosophila Pelle protein, a kinase involved in signaling downstream of the Toll pathway 
during embryonic development and also essential for insect immunity [80, 155]. The key role of 
IRAK-4 in TLR signaling was revealed through studies with knockout mice. Indeed, Irak4(-/-) 
animals were shown to be fully resistant to LPS-induced septic shock, and lacked a cytokine 
response when challenged with various TLR ligands. Furthermore, IL-1-induced NF-κB was 
severely defective in cells lacking IRAK-4, and LPS-induced NF-κB activation was delayed [75].  
IRAK-4 plays a critical role in meditating NF-κB activation through initially interacting 
with MyD88 [79] (see sections 1.7.2b and c). Activated IRAK-4 presumably phosphorylates 
IRAK-1, leading to the autophosphorylation and activation of IRAK-1 itself. It has been shown 
that IRAK-4 also induces degradation of IRAK-1 [156], which indicates that IRAK-4 acts in a 
negative feedback loop to regulate the MyD88-dependent pathway. It is also noteworthy that, to 
date, IRAK-4 is one of the few IL-1/TLR signaling proteins to be implicated in human disease, as 
a group of patients with recurrent infections and a poor inflammatory response were found to 
have an inherited IRAK4 deficiency [157-160]. 
 
1.6 Negative Regulation of the TLR/MyD88/IRAK Pathway 
 
As discussed above, stimulation of TLRs by microbial components results in the 
upregulation of specific proinflammatory cytokines and chemokines, which ultimately leads to 
pathogen control and clearance. However, when these molecules are produced in excess they 
induce serious systemic disorders leading to severe complications and even death. Bacterial 
sepsis, autoimmune disorders, and chronic inflammatory diseases are examples of hyperimmune 
conditions arising from excessive, dysregulated activity of the innate and adaptive immune 
systems [161]. It is therefore not surprising that mechanisms have evolved for modulating TLR-
mediated responses. Some well-characterized negative regulators of TLR signaling are briefly 
described below (Figure 1.5). 
 
a) IRAK-M 
As discussed above, IRAK-M is expressed only in monocytes and macrophages, and is 
upregulated upon stimulation with TLR agonists [137].  A direct relationship between IRAK-M 
protein levels and induction of a tolerance state to cancer cells in human tumor-infiltrating 
monocytes has been established [125]. Although the inhibitory mechanism of IRAK-M is unclear, 
it appears to block formation of the IRAK-1/TRAF6 complex, but not recruitment of IRAK-1 to 
MyD88 [136]. Therefore, IRAK-M can inhibit dissociation of IRAK-1 and IRAK-4 from TLRs 
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by either blocking their phosphorylation or by stabilizing the TLR/MyD88/IRAK-4 complex, so 
TRAF6 is excluded and signaling to NF-κB and/or MAPKs cannot proceed. However, a novel 
role for IRAK-M as a specific negative regulator of TLR2-induced p38 activation has recently 
been shown [162]. Regardless of the mechanism of action, IRAK-M mediated inhibition is 
stronger in human monocytes previously exposed to TLR ligands or tumor cells [125, 132]. 
 
b) SOCS-1 
SOCS-1 is a member of the SOCS (Suppressor Of Cytokine Signaling) family of proteins 
induced by cytokines, which negatively regulates TLR signaling pathways by an up to date 
unknown mechanism [163]. SOCS-1 might function by blocking IRAK-1 activation, but recent 
data suggest that it negatively regulates signaling via TLR2 and TLR4 through degradation of 
TIRAP [164]. Alternatively, two recent studies indicate that SOCS-1-dependent inhibition of TLR 
signaling is indirect and occurs by blocking or decreasing type I IFN autocrine/paracrine signaling 
after TLR-mediated IFN-α/β secretion [165, 166]. 
 
c) TOLLIP 
Toll interacting protein (TOLLIP) is an adaptor protein that interacts with the cytoplasmic 
TIR domain of several TLRs, including TLR2 and TLR4, blocking their ability to induce NF-κB 
activation [167, 168]. Overexpression of TOLLIP results in formation of a complex with IRAK-1, 
consequently inhibiting IL-1-induced signaling by blocking IRAK-1 phosphorylation [168]. 
 
d) MyD88s 
MyD88s, an alternatively spliced variant of MyD88 that lacks residues from Glu110 to 
Leu154, both included (Figure 1.3b), is overexpressed in monocytes upon stimulation with LPS or 
proinflammatory cytokines [169]. This variant is unable to recruit IRAK-4 and therefore inhibits 
IRAK-4-mediated IRAK-1 phosphorylation. This impairs LPS-induced NF-κB activation, and 
decreases the inflammatory response to several stimuli [79]. 
 
e) SIGIRR/TIR8 and ST2/T1 
In addition to cytoplasmic molecules, membrane-bound proteins such as SIGIRR/TIR8 
and ST2/T1 may also play a role in modulating TLR signaling. The single immunoglobulin IL-
1R-related protein (SIGIRR) is an orphan receptor that does not induce NF-κB activation, as it 
possesses an intracellular TIR domain that lacks two amino acids essential for signaling by IL-1R 
[170, 171]. SIGIRR is expressed in different cell types ranging from epithelial cells to immature 
dendritic cells, but it is not expressed in macrophages, fibroblasts, or endothelial cells. Although 
the exact mechanism by which SIGIRR functions is unclear, it appears to be recruited by TLR4 to 
block signaling by sequestering IRAK-1 and TRAF6 [171, 172]. In a similar manner, ST2/T1, a
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Figure 1.5 Negative regulation of TLR signaling. IRAK-M has been postulated to inhibit 
dissociation of the IRAK-1•IRAK-4 complex from the receptor. MyD88s blocks association of 
IRAK-4 with MyD88. SOCS-1 is likely to associate with IRAK-1 and inhibit its activity. TOLLIP 
inhibits autophosphorylation of IRAK-1. Transmembrane receptors, such as SIGRR and ST2L, 
also downregulate TLR signaling by blocking MyD88/IRAK-1/4 activation or sequestering 
MyD88, respectively. (Modified from [11]). 
 
membrane-bound member of the IL-1 receptor family, may inhibit IL-1R- and TLR4-mediated 
signaling, but not TLR3 signaling, by sequestering the TIR-containing adaptors MyD88 and 
TIRAP [173]. 
 
1.7 Known Three-Dimensional Structures in the Toll/TLR Signaling Pathway: MyD88 
and IRAK-4 
 
The TLR/MyD88/IRAK system has been thoroughly studied in recent years. Despite the 
biological importance of DDs, the crystal structure of the monomeric Pelle DD•Tube DD complex 
in the Drosophila Toll pathway was the only structure available from this system [174]. In 
addition, the NMR solution structure of MyD88 TIR domain [175, 176], and the crystal structures 
of IRAK-4 kinase domain [145, 146] and DD [111] have also been determined. However, studies 
on MyD88–IRAK-4 interactions came out only very recently (2009) [177], and the crystal 
structure of the MyD88•IRAK-4•IRAK-2 complex was just released in 2010 [178]. The main 
features of these structures are discussed in some detail below. 
 
1.7.1 Structure of Individual Domains of MyD88/IRAKs 
 
a) Solution structure of MyD88 TIR domain 
To date, out of the MyD88 domains, only the C-terminal TIR domain has been 
structurally characterized in isolation. The two most recently reported structures of this module,
 Introduction 
 
45 
 
 
Figure 1.6 NMR solution 
structure of human MyD88 
TIR domain. Ribbon drawing of 
the NMR structure of human 
MyD88 TIR domain, residues 
157-296. The notation of the 
secondary structures (βA-βE, 
αA-αC, and αE) is based on that 
of TLR TIR domains [179-181]. 
(From [175]). 
 
 
released in 2009, were determined in solution by NMR spectroscopy [175, 176]. Although these 
structures were solved under different experimental conditions, their overall folding is essentially 
identical. It should be noted that the isolated MyD88-TIR domain exists as a monomer in 
solution, while some TIR domains have been reported to form dimers when crystallized [179, 
180]. In this regard, although full-length MyD88 is known to form aggregates (see above), 
aggregation seems to be mediated via homotypic interactions between death domains [73, 182]. 
The MyD88 TIR domain structure comprises a central 5-stranded parallel β-sheet (βA-
βE) surrounded by 4 α-helices (αA-αC and αE) (Figure 1.6). The global fold is similar to that 
previously observed in the crystal structures of TIR domains of receptors TLR1, TLR2, TLR10, 
and IL-1RAPL [179-181] (PDB codes: 1FYV, 1FYW, 2J67, and 1T3G, respectively); MyD88 
TIR domain exhibits the highest sequence similarity to TLR2 [175]. Previous studies have 
indicated that three short sequence motifs, termed boxes 1-3, are conserved between the TIR 
domains [183]. Of these, the box 2 motif, which resides in the so-called BB loop region (Ser194-
Ala208 of the human MyD88 TIR domain) (Figure 1.6), has been suggested to be important for 
specific TIR–TIR interactions [33, 181]. 
 
b) Crystal structure of IRAK-4 kinase domain 
The crystal structure of the kinase domain of IRAK-4 has been recently reported by two 
separate groups both as the non-liganded, active form and complexed with different inhibitors 
[145, 146]. These structures reveal structural features typical of both Ser/Thr and tyrosine kinases. 
The structural analysis revealed extra ordered residues extending from the N-terminus of the 
kinase domain, found to be important for protein expression as well as for kinase activity, and 
demonstrate that the ATP-binding site in IRAK-4 has not a deep pocket in the back, but does have 
a prominent front pocket [145]. As predicted from sequence analysis, the gatekeeper residue at the 
ATP-binding site is a tyrosine, a unique feature of the IRAK family. 
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Figure 1.7 Schematic representation of 
IRAK-4 DD. The hexahelical bundle 
structure is shown with colored-coded 
helices, and the tail regions and 
interconnecting loops denoted in gray. N- 
and C-termini are represented by the 
letters N and C, respectively. (From 
[111]). 
 
 
 
c) Crystal structure of IRAK-4 DD 
The crystal structure of mouse IRAK-4 DD, solved in 2005, reveals a compact, 
hexahelical domain (helices α1-6, Figure 1.7) [111], similar to other previously characterized 
members of the family such as the FADD DD [109]. 
Several features of the protein are noteworthy. There is a highly structured N-terminal tail 
preceding helix α1, which engages in several hydrogen bonds with the loop connecting helices α4 
and α5. A rigid tail is also observed at the C-terminus, potentially required for orienting the C-
terminal kinase domain so that proper molecular recognition can take place [111]. Furthermore, 
the structure shows an ordered loop between two of the major α-helices (α2 and α3), apparently 
unique to IRAK-4 [111], which could preclude interactions of IRAK-4 similar to those seen in 
Drosophila Tube•Pelle complex (see section 1.7.2a). 
 
1.7.2 Multimeric Structures 
 
a) Crystal structure of Tube DD•Pelle DD 
The Drosophila Toll pathway is conceptually similar to the mammalian TLR/IL-1R 
system (Figure 1.8). In Drosophila, a heterotrimeric complex of MyD88, Tube and Pelle mediates 
the orthologous Toll pathway [184], which is important for immune responses against fungal 
infection [7], as well as for dorsoventral patterning [185]. While Pelle is the functional orthologue 
of IRAK, Tube is an adapter protein that has no counterpart in mammals. MyD88, Tube and Pelle 
all contain a DD, and assemble via DD-mediated interactions. 
In 1999, the crystal structure of the binary complex between DDs of the Drosophila 
kinase Pelle and its adaptor Tube [174] provided the first structural information about homotypic 
DD-mediated complex formation (Figure 1.9). Previously, genetic experiments had demonstrated 
that Tube functions upstream of Pelle [186], suggesting that Tube is the link between the receptor 
and the kinase. Tube acts as a bridge between MyD88, which interacts directly with Toll, and 
Pelle, which signals downstream for the nuclear translocation and activation of the NF-κB 
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orthologue Dorsal, the key event in dorsoventral patterning. On the other hand, sequence 
comparisons indicate that Pelle is most closely related to IRAK-4 among the members of the 
IRAK family [138]. Moreover, it has been proposed that signal-induced Pelle activation leads to 
the phosphorylation of Toll, Tube, and Pelle itself, allowing the dissociation of the 
Toll•Tube•Pelle membrane proximal complex that forms immediately upon receptor activation. 
Dissociation of the receptor complex would allow Pelle, and likely Tube, to disengage from the 
transmembrane receptor after activation, and to move into the cytoplasm where they are required 
to mediate signal transduction [187]. 
The crystal structure of Tube DD•Pelle DD shows that both components of the complex 
exhibit the six-helix bundles characteristic of the DD superfamily (helices α1-α6, Figure 1.9) 
[174]. Regardless of the details of the interaction, the most remarkable aspect is perhaps its 
asymmetry, considering what might have been expected for homotypic interactions. The first 
interface involves the α4 helix and the following loop of Pelle, which contact the helix α6 and the 
loops α1-α2 and α5-α6 in Tube. Most strikingly, the C-terminal tail of Tube sits in a narrow 
groove formed by a cavity between the Pelle α4-α5 and α2-α3 loops to form a second interface 
that contributes significantly to strengthen the interaction [174]. Both loops are rather small and 
lack secondary structure or polar contact pairs within them. However, in this second interface, 
three Tube residues with bulky hydrophobic side chains (Ile169, Leu171, and Leu173) are involved in 
the interaction (Figure 1.9b). Interestingly, it has been shown that Pelle, which lacks
 
Figure 1.8 Conservation and divergence of TLR-mediated innate immune response in 
insects and mammals. Schematic representation of complex formation following ligand binding 
to transmembrane receptors Toll (insects, left) or TLR (mammals, right). A second non-enzymatic 
adaptor in insects, Tube, seems to be replaced by IRAK-4 in mammals. 
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Figure 1.9 Three-dimensional crystal structure of Drosophila Tube DD•Pelle DD complex. a) 
The six-helix bundle fold of both components of the complex is shown with Pelle in magenta and 
Tube in green. Inserted helices αA and αB of Tube-DD are marked with *. b) Electrostatic surface 
representation of the Tube•Pelle dimer. Pelle is displayed with its electrostatic surface potential 
(left) and a magenta ribbon (right), and Tube is represented as a green ribbon (left) or its 
electrostatic surface potential (right). Notice that the C-terminal tail of Tube-DD contributes 
significantly to the interaction interface. Hydrophobic residues of this carboxy-terminal end that 
are in contact with Pelle, as well as charged residues of Pelle surrounding the above region, are 
labeled on the respective surfaces. (Modified from [174]). 
 
the C-terminal sequence of the kinase domain as IRAK-4 does in mammals, seems to interact 
with Drosophila TRAF1 through its DD [188]. 
 
b) Stoichiometry of the MyD88•IRAK-4 complex 
Although the Toll-MyD88-Tube-Pelle cascade is functionally equivalent to that of TLRs-
MyD88-IRAKs (Figure 1.8) [184, 189], there are major differences between mammalian and 
insect immune responses. Most relevant, mammals lack a Tube orthologue, whose role appears to 
be assumed by IRAK-4 [79, 138, 184, 190-192]. Indeed, it has recently been reported that DDs of 
IRAK-4 and MyD88 form a large oligomeric structure termed the Myddosome [177]. The results 
of analytical ultracentrifugation, mass spectrometry, and small angle X-ray scattering studies 
suggest that the DDs of human MyD88 and IRAK-4 assemble into defined structures having 7:4 
or 8:4 stoichiometries, in a two-layer structure with a ring of seven or eight MyD88 subunits and a 
second layer of four IRAK-4 subunits, although resolution was too low to determine the 
arrangement of the subunits in the complex. 
 
c) Crystal structure of the MyD88 DD•IRAK-4 DD•IRAK-2 DD ternary complex 
The recently reported crystal structure of the MyD88•IRAK-4•IRAK-2 DD complex 
[178] represents a milestone in structural immunobiology, and elucidated in particular some of the 
questions regarding the architecture and stoichiometry of this complex. The structure, determined 
at 3.4 Å resolution, revealed a single stranded, left-handed helix of DDs with a tower-shaped 
arrangement of four layers (Figure 1.10). The nature of this helical assembly therefore dictates
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a) b) c)
 
Figure 1.30 Structure of the ternary Myddosome complex. a) Ribbon diagram of the structure, 
with the six MyD88 molecules in cold colors, the four IRAK-4 molecules in earth-tone colors and 
the four IRAK-2 molecules in warm colors. b) Surface diagram of the complex with each subunit 
labeled using the same color coding as in (a). M, MyD88; I4, IRAK-4; I2, IRAK-2. c) Planar 
arrangement of the complex. (From [178]). 
 
that molecules at both ends of the helix are less ordered or perhaps exhibit less occupancy than 
the central molecules. 
The crystal structure of the MyD88•IRAK-4•IRAK-2 DD complex reveals that 
Myddosome assembly is nucleated by oligomerization of six MyD88 DDs, which form the 
“bottom” two layers of the structure (M1-6). Through an unknown mechanism, four IRAK-4 DDs 
are subsequently incorporated into the complex, forming the middle layer (I41-4), and this forms 
a docking site for four IRAK-2 DDs (I21-4) to shape the top layer (Figure 1.10). The hierarchical 
assembly of this “signaling tower” seems to bring the kinase domains of IRAKs into close 
proximity for trans-phosphorylation and activation. This study also showed that the affinity of the 
MyD88 DD oligomer for IRAK-4 DDs exceeds that for IRAK-2 DDs, apparently due to a better 
charge complementarity. 
As a conclusion, it can be stated that Drosophila and mammals use a similar three layer 
system with different stoichiometries in Toll or TLR/IL-1R signaling: unlike the oligomeric 
MyD88•IRAK-4•IRAK-2 complex, the MyD88•Tube•Pelle ternary complex in solution possesses 
a 1:1:1 stoichiometry [193]. 
 
1.8 Involvement of the TLR/MyD88/IRAK System in Disease 
 
Several lines of evidence indicate that TLR-mediated pathways are implicated in 
inflammatory and immune disorders. Production of proinflammatory cytokines such as IL-1β, IL-
6, TNF-α and IL-12 is a major process stimulated upon TLR activation [194]. Secreted cytokines, 
however, induce a positive feedback in the immune system, which could cause severe 
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immunopathology if uncontrolled. We conclude this introduction with a brief outline of some of 
the conditions in which MyD88 or IRAK proteins are involved. 
Several diseases have been associated to MyD88. For example, development of 
atherosclerosis observed in apolipoprotein E-deficient mice is rescued by introduction of MyD88 
deficiency, indicating that the TLR-mediated pathway is responsible for the development of 
atherosclerosis [195, 196]. Also, the MyD88-dependent pathway has been implicated in allograft 
rejection [197], and MyD88-deficiency is shown to increase the risk of diabetes in mice [198]. 
Finally, it has been reported that children with MyD88 mutations that affect either the DD or the 
TIR domain of the protein present recurrent pyogenic infections [116]. 
IRAK family members have also been related to various inflammatory and infectious 
diseases [199]. For example, IRAK-M overexpression has been shown to be involved in several 
conditions such as in sepsis [132], acute coronary syndrome [127, 200], cancer [125, 201], and 
osteoporosis [147]. 
Since aberrant regulation of TLR/MyD88/IRAK pathway is relevant for several 
inflammatory and autoimmune diseases [202, 203], it is likely that specific inhibitors of this 
pathway would constitute valuable tools for novel therapeutic approaches [204, 205]. Given the 
essential and universal role of IRAK family members as signaling molecules in TLR/IL-1R 
responses, interference with IRAK activity is appealing as a therapeutic strategy. For instance, 
synthetic peptides, corresponding to the binding site between IRAK-1 and TRAF6, have been 
successfully used to block NF-κB activation [141]. Moreover, drugs/inhibitors targeting 
individual IRAKs could be used for certain IL-1/TLR pathways in specific contexts, while not 
affecting the entire IL-1/TLR system. 
Therefore, a deep understanding of the structural organization of the complexes formed 
by components of the TLR/MyD88/IRAK system is essential to develop therapeutic drugs in the 
future, which could up- or downregulate this pathway whenever needed. 
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2 Objectives 
 
The main goal of this work is to elucidate the molecular bases of the TLR-MyD88-IRAK 
signaling pathway, as part of the immune system. In particular, we set the following objectives: 
 
1) Establishment of expression and purification protocols for the different functional 
domains of the adaptor MyD88 and the kinases IRAK-1 and IRAK-4, as well as of the 
negative regulator IRAK-M. 
 
2) Setting up protocols for obtaining purified complexes between the death domains of 
MyD88 and the different IRAK recombinant variants. 
 
3) Determination of the regions (globular domain vs linker) necessary for the formation of 
stable complexes between MyD88 and IRAK proteins. 
 
4) Determination of the mechanisms by which IRAK-M plays an inhibitory role in immune 
responses: competition with IRAK-4 for MyD88 binding vs. MyD88•IRAK-1 complex 
stabilization. 
 
5) Crystallization and structure resolution of the MyD88 and IRAK isolated DDs, as well as 
of their complexes. 
 
  
  
 
  
  
3. Materials and Methods 
  
 
  
 Materials & 
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1 The C-terminus of MyD88(S) differs from the previously reported natural form, MyD88s, which lacks 
residues 110 to 157. 
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3.1 Recombinant Protein Expression 
 
To design and produce the MyD88 and IRAK recombinant fragments of interest, several 
aspects needed to be considered such as the length, amino acid composition, presence of 
hydrophobic stretches, and secondary structure of the polypeptides. These factors influence the 
correct assembly, solubility properties and purification possibilities of each peptide, and are the 
main focus of this section. 
 
3.1.1 Sequence Alignments and Secondary Structure Prediction 
 
Before deciding the synthesis of selected recombinant fragments we performed a 
thorough analysis of the amino acid sequences of MyD88, IRAK-1, IRAK-M, IRAK-4, which 
were also compared to the Drosophila melanogaster Tube and Pelle proteins. These sequences 
were retrieved using the sequence retrieval system (SRS) from the Swiss-Prot database [206], 
with the following accession numbers: Q99836 (human MyD88), P51617 (human IRAK-1), 
Q9Y616 (human IRAK-M), Q9NWZ3 (human IRAK-4), Q8R4K2 (mouse IRAK-4), P22812 
(Drosophila melanogaster Tube) and Q05652 (D. melanogaster Pelle). The propensity to form 
globular domains (order/disorder) was analyzed with GlobPlot [207], DISOPRED [208] and 
IUPred [209]. Next, to determine the boundaries of globular domains, amino acid sequences of 
MyD88 and IRAK-4 from various species, together with those of Drosophila Tube and Pelle, 
were aligned according to the structural information available at the moment [111, 174], using 
ClustalW [210]. Finally, to disfavor gaps or insertions within the secondary structure elements, 
the secondary structure was predicted with the programs JPred [211] and PSIPRED [212]. The 
results of these combined analyses are summarized in Appendix II. Putative interactions sites in 
MyD88 and IRAK-4 death domains, predicted with PPI-Pred, are given in Appendices III and IV, 
respectively. 
 
3.1.2 Cloning of Death Domains 
 
Synthetic genes coding for the fragments of interest were designed to maximize the odds 
of heterologous expression in Escherichia coli, and all sequences were optimized in terms of 
codon usage and mRNA secondary structure. Selected fragments included six to eight amino acid 
residues N-terminally from the start of the first predicted α-helix of each death domain, and C-
terminally from the end of the last helix. They were termed MyD88(S)1, IRAK-1(S), IRAK-M(S) 
and IRAK-4(S), respectively (see Table 4.2 in Results). In addition, similar constructs coding for 
both the globular death domains and the DD-TIR (MyD88) or DD-kinase linkers (IRAK proteins) 
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were generated. These fragments were termed MyD88(L), IRAK-1(L), IRAK-M(L), and IRAK-
4(L), respectively. To help protein detection and purification, N-terminal 6xHis, c-MYC 
(EQKLISEED) and FLAG® M2 (DYKDDDDK) tags were included in MyD88, IRAK-M and 
IRAK-4 variants, respectively. The main physico-chemical parameters of the resulting 
recombinant fragments are summarized in Table 4.2 (Results). 
All eight synthetic genes coding for the different variants of death domains were 
generated via oligonucleotide assembly. The resulting fragments were digested with restriction 
enzymes Nde I and BamH I, and ligated into the corresponding sites of the T7 promoter region of 
the expression plasmid pET-3a (Novagen, Schwalbach, Germany). This plasmid contains a bla 
coding sequence, which confers resistance to ampicillin (see Appendix V for the full pET-3a 
restriction map). Oligonucleotide synthesis and assembly, as well as cloning in the expression 
vector, were performed at Entelechon GmbH (Heidelberg, Germany). The DNA sequences of 
these artificial genes are shown in Appendix VI. 
 
3.2 Site-Directed Mutagenesis 
 
Site-directed mutagenesis is a technique for generating changes over a double-stranded 
nucleotide sequence. The methods used in this investigation basically involve a polymerase chain 
reaction (PCR) using a supercoiled plasmid vector as template and two synthetic oligonucleotide 
primers containing the desired mutation. During PCR, thousands to millions of copies of the 
mutated DNA sequence are generated. The template (wild-type) plasmid, which is methylated in 
almost all E. coli strains, is then removed by digestion with Dpn I, a DNase specific for 
methylated DNA. The new (mutant) DNA is not methylated and remains intact in the reaction. 
 
3.2.1 Primer Design 
 
Mis- or nonsense mutants were designed based on the nucleotide sequences of expression 
plasmids coding for either MyD88(L) or IRAK-4(L), and according to the codons most frequently 
used by E. coli.  The mutants generated are given in Figure 3.1, and they were termed MyD88 
R81E, MyD88 I109X, MyD88 Y116C, MyD88 E143X, IRAK-4 E92R, IRAK-4 V105X, IRAK-4 
N110X, and IRAK-4 K115X (see Table 4.2 in Results for the main physicochemical parameters 
of these constructs). 
The mutagenic oligonucleotides were designed considering that both mutagenic primers 
(sense and antisense) must contain the desired mutation and anneal to the same sequence on 
opposite strands of the plasmid (sequences shown in Table 3.1). In addition, we had to consider 
that primers should be between 25 and 45 bases long, since shorter primers could bind DNA
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Figure 3.1 Generated mutations over the MyD88(L) and IRAK-4(L) nucleotide sequences. 
a) Nucleotide sequence of MyD88(L) highlighting generated mutations. Triplets modified by site-
directed mutagenesis (corresponding to Arg81, Ile109, Tyr116 and Glu143) are colored as the mutants 
generated from their replacement, shown next to them. b) Nucleotide sequence of IRAK-4(L) 
highlighting generated mutations. Triplets modified by site-directed mutagenesis (corresponding 
to Glu92, Val105, Asn110 and Lys115) are colored as the mutants generated from their replacement, 
shown next to them. 
 
nonspecifically, and longer primers increase the likelihood of secondary structure formation, 
lowering the efficiency of the mutagenesis reaction. Secondly, the desired mutation should be in 
the middle of the primer with ~10-15 bases of correct sequence on both sides, and should 
preferably end in one or more C or G bases. Finally, the primer melting temperature (Tm) should 
be ≥ 78°C. The value of Tm, the temperature at which 50% of the DNA duplex dissociates into 
single-stranded, can be estimated by Equation 3.1, where N is the primer length in bases, %GC is 
the number of G's and C's in the primer as a percentage of the total number of bases (optimally ≥ 
40%), and % mismatch is the number of bases in the primer that do not match the dsDNA 
template as a percentage of the total number of bases. 
 
Tm 81.5 0.41(%GC) 675N % mismatch  Equation 3.1 
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Table 3.1 Designed MyD88 and IRAK-4 primer sequences for site-directed mutagenesis. 
Mutated triplets are shown in capital letters and underlined. The specific nucleotides replaced 
within the codons are shown in bold and underlined. (The original sequences of MyD88(L) and 
IRAK-4(L) are given in Figure 3.1). 
Mutation Primer Sequence Tm (°C) 
MyD88 
R81E 
Sense 5’-cgatgcatggcagggtGAAccaggtgcatctgttgg-3’ 
78.33 
Antisense 3’-gctacgtaccgtcccaCTTggtccacgtagacaacc-5’ 
MyD88 
I109X 
Sense 5’-cctggaactgggtccgtctTAAtaggaagactgccag-3’ 
78.40 
Antisense 3’-ggaccttgacccaggcagaATTatccttctgacggtc-5’ 
MyD88 
Y116C 
Sense 5’-ggaagactgccagaaaTGCatcctgaaacagcag-3’ 
79.20 
Antisense 3’-ccttctgacggtctttACGtaggactttgtcgtc-5’ 
MyD88 
E143X 
Sense 5’-ctgtaccacgtacggctTAActggctggtatcacc-3’ 
81.60 
Antisense 3’-gacatggtgcatgccgaATTgaccgaccatagtgg-5’ 
IRAK-4 
E92R 
Sense 5’-ctgctcatccagaacCGTttctttgctccagcttctctcc-3’ 
78.65 
Antisense 3’-gacgagtaggtcttgGCAaagaaacgaggtcgaagagagg-5’ 
IRAK-4 
V105X 
Sense 5’-ctcctgctgccagatgcaTAAccgaaaactgcgaacactc-3’ 
78.65 
Antisense 3’-gaggacgacggtctacgtATTggcttttgacgcttgtgag-5’ 
IRAK-4 
N110X 
Sense 5’-gcagttccgaaaactgcgTAAactctgccgtctaaagag-3’ 
79.00 
Antisense 3’-cgtcaaggcttttgacgcATTtgagacggcagatttctc-5’ 
IRAK-4 
K115X 
Sense 5’-cgaacactctgccgtctTAAgaggcgattactgtg-3’ 
80.44 
Antisense 3’-gcttgtgagacggcagaATTctccgctaatgacac-5’ 
 
Primers (50 nmol each, purified by HPLC) were synthesized at Invitrogen 
(www.invitrogen.com). The resulting lyophilized product was dissolved in bidistilled water to a 
final concentration of 200 ng/µL, from which working dilutions at 100 ng/µL were prepared. 
 
3.2.2 PCR Conditions 
 
PCR site-directed mutagenesis was performed using the QuikChangeTM II Site-directed 
Mutagenesis kit (Stratagene), following manufacturer's instructions. Two reactions were prepared 
for each mutant, using from 10 to 50 ng of template DNA. The volumes and reagents used for the 
mutagenesis of 50 ng of DNA template were as follows: 
 
5 µL 10X reaction buffer (supplied by the manufacturer) 
5 µL (50 ng) dsDNA template (pMyD88(L) or pIRAK-4(L)) 
6.25 µL (125 ng) sense primer (20 ng/µL) 
6.25 µL (125 ng) antisense primer (20 ng/µL) 
1 µL dNTP mix 
ddH2O to a final volume of 50 µL 
1 µL PfuUltra HF DNA polymerase (2.5 U/µL) (added just before the 
start of the PCR reaction) 
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PCR reactions were carried out using the GeneAmp® PCR System 9700 (Applied 
Biosystems) or the MultiGene Mini (Labnet) thermal cycler, with the following parameters: 
 
Segment # of cycles T (°C) Time 
1 1 95 30 s 
2 16 
95 30 s 
55 1 min 
68 5 min 
3 - 4 ∞ 
 
To digest the parental (non-mutated) supercoiled dsDNA, each amplification reaction was 
mixed thoroughly with 1 µL of the Dpn I restriction enzyme (10 U/µL), and incubated at 37°C for 
1 h.  
The reaction products were then transformed into XL1-Blue supercompetent cells 
(Stratagene) according to the transformation protocol detailed in section 3.3.2, with some 
modifications: 5 µL of Dpn I-treated DNA were used for transformation, and transformed cells 
were spread onto an LB/agar plate (see Appendix VII for composition) with 100 µg/mL 
ampicillin, 80 µg/mL X-gal and 20 mM IPTG, in order to perform the blue-white color screening 
test. This color screening for recombinant plasmids is available when transforming host cells 
containing the lacIqZDM15 gene on the F’ episome (such as the XL1-Blue strain) with a plasmid 
providing α-complementation (such as the pET-3a plasmid used here). When lacZ expression is 
induced by IPTG in the presence of the chromogenic substrate X-gal, colonies without the desired 
insert are stained blue while those containing plasmids with the insert of interest remain white. 
 
3.2.3 DNA Extraction and Sequencing 
 
To verify the mutant DNA sequence, single white colonies from the transformed XL1-
blue cells plate (see section 3.2.2) are inoculated into 5 mL LB (see Appendix VII for 
composition) containing 100 µg/mL ampicillin. The culture was grown overnight at 37ºC, and 
cells were collected by centrifugation at 3,000g for 10 min. The mutated DNA was then extracted 
with the Wizard® Plus SV Minipreps purification kit (Promega), following the manufacturer’s 
protocol. 
Mutated DNA sequences were verified using a T7 primer compatible with the T7 
promoter of pET-3a (see Appendix V) (reactions performed by Dr. Mercè Miquel, DNA 
Sequencing platform of the CID-CSIC, Barcelona, Spain). 
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3.3 Heterologous Expression of MyD88, IRAK-1, IRAK-4 and IRAK-M Variants 
 
3.3.1 Escherichia coli Strains 
 
Heterologous expression of the recombinant proteins was performed in different strains of 
One Shot® E. coli competent cells, from Invitrogen: BL21(DE3), BL21(DE3)pLysS and BL21 
Star™(DE3)pLysS. These E. coli strains contain a λ prophage (DE3), carrying the T7 RNA 
polymerase gene and the T7lac promoter. In the transformed pET vector constructs, the cloned 
genes are under control of the T7lac promoter and expression is repressed until IPTG induction of 
T7 RNA polymerase from the lac promoter. The pLysS plasmid codes for T7 lysozyme, a natural 
inhibitor of the T7 polymerase, which is constitutively expressed. Therefore, the E. coli 
BL21(DE3)pLysS and BL21Star™(DE3)pLysS strains are used to minimize low-level expression 
of potentially toxic gene products before IPTG induction. The BL21Star™(DE3)pLysS strain also 
carries a mutated rne gene (rne131), which encodes a truncated RNase E variant. This modified 
enzyme lacks the ability to degrade mRNA, resulting in an increase in mRNA stability. 
In terms of antibiotic resistance, all these E. coli strains are resistant to ampicillin. 
BL21(DE3)pLysS and BL21 Star™(DE3)pLysS strains are also resistant to chloramphenicol, 
since they contain a CamR marker. 
 
3.3.2 Transformation of Competent Cells 
 
Transformation of competent cells was performed using the heat shock method, as 
follows:  
1. Competent cells were allowed to thaw on ice. 
2. Ten ng of plasmid DNA were added to the cells in a laminar-flow hood or on a 
cleaned bench surface next to a Bunsen burner, and mixed gently. 
3. The tubes were incubated on ice for 30 min, then heat-shocked at 42°C for 45 seconds, 
and incubated on ice for at least 2 additional min. 
4. Two hundred and fifty µl SOC medium (see Appendix VII for composition) were 
warmed to 37°C and then added to the cells.  
5. The cells were incubated at 37°C for 1 h with constant agitation at 225 rpm. 
6. Afterwards, the samples were centrifuged at 3500 rpm for 1 min, the supernatant was 
discarded, and the pellet was slowly resuspended in 50 µl SOC medium. 
7. The entire transformation was spread onto a pre-warmed LB/agar plate with the 
appropriate antibiotics, which was incubated overnight, upside down, at 37°C. 
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The antibiotic concentrations used in all media throughout this work were 100 µg/mL 
ampicillin (for all strains) and 34 µg/mL chloramphenicol (additionally, for BL21(DE3)pLysS 
and BL21 Star™(DE3)pLysS strains). 
 
3.3.3 Preparation of Starter Cultures 
 
Bacterial starter cultures for protein overexpression were prepared as follows: 
1. A single colony was picked from a freshly grown transformation plate with a sterile 
pipet tip, and inoculated into 50 mL LB medium containing the appropriate antibiotics. 
2. The culture was grown overnight at 20°C with constant agitation at 225 rpm. 
3. Next morning, either larger cultures or glycerol stocks were prepared as explained in 
the following sections. 
 
3.3.4 Preparation of Glycerol Stocks  
 
E. coli strains can be stored for years at -80°C in a medium containing 15% glycerol. 
These glycerol stocks of bacterial cells containing the plasmid of interest were generally prepared 
as follows: 
1. Five-hundred-microliter aliquots were taken from the starter culture (section 3.2.3) and 
added to 0.5 mL of a 30% glycerol solution in LB, previously sterilized. 
2. The tubes were gently mixed, quickly frozen in liquid nitrogen, and stored at -80°C 
until needed. 
3. To prepare a starter culture from a glycerol stock, a glycerol stock vial was allowed to 
thaw and inoculated into 50 mL LB medium (previously autoclaved), with the 
appropriate antibiotics. The culture was then treated as explained in section 3.2.3, for 
preparing starting cultures. 
 
3.3.5 Preparation of Larger Cultures 
 
After preparing a starter culture either by inoculating a single colony or from a glycerol 
stock preparation, larger cultures were obtained by the following procedure: 
1. The starter culture was diluted into 500 mL LB medium with the appropriate 
antibiotics, in a 2-L flask. 
2. The culture was grown at 37°C with constant shaking at 225 rpm until the optical 
density at 600 nm (A600) was 0.4-0.8 (indicating the beginning of the exponential 
growth phase). LB medium was used as a blank for all A600 measurements. 
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3. Protein expression was then induced by adding 0.8 mM IPTG. The culture was 
incubated at 20°C for 6 h with constant agitation at 225 rpm, to ensure sufficient 
aeration. 
4. Cells were harvested by centrifugation at 4,500g for 15 min at 4°C. The supernatant 
was removed and cell pellets were either stored at -80°C or lysed as explained in 
section 3.4.1. 
 
3.4 Extraction and Renaturation of Recombinant Fragments 
 
Proteins overexpressed in E. coli were always extracted by chemical cell lysis, and 
unfolded proteins were then renatured using different solutions, as explained below. 
 
3.4.1 Extraction of MyD88 and IRAK Recombinant Fragments 
 
Both MyD88 and IRAK proteins were extracted by cell lysis. Cell membranes were 
disrupted with detergents, as follows: 
1. Frozen cell pellets were resuspended in B-PER® reagent (Thermo Scientific) 
supplemented with 10 mM MgCl2, 20 mM 2-mercaptoethanol (2-ME), 1 mM EDTA, 
200 mM NaCl and 10 mM imidazole. From now on, B-PER® reagent with these 
additives will be referred to as B-PER (see Appendix VII, approximately 100 µL B-
PER were used per 1 mL culture).  
2. Once resuspended, 1 unit/mL DNase I was added to the mixture, which was incubated 
at room temperature for 30 min under agitation. 
3. Mixtures were then centrifuged at 13,000g for 15 min at 4°C, the supernatant extracted, 
and the resulting pellet resuspended again in the same volume of B-PER as in step 2. 
4. The pellet from the 2nd B-PER extraction was then resuspended in extraction buffer 
(see Appendix VII), supplemented with increasing quantities of urea (from 2 to 8 M). 
Samples were taken after each extraction step for further analysis by gel electrophoresis. 
See Table 4.1 (Results) for the expression and extraction conditions used for each protein.  
 
3.4.2 Renaturation of Recombinant Proteins 
 
In many cases, expression of recombinant proteins in E. coli leads to formation of 
insoluble inclusion bodies (IBs). In general, folding insoluble proteins into a biologically native 
conformation, although technically challenging, has the advantage of working with large 
quantities of essentially pure protein. To refold insoluble proteins, some features regarding the 
tested renaturing solutions must be taken into account. The folding solution should favor 
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formation of the native state while minimizing aggregation of folding intermediates. Polar 
additives such as arginine, osmolytes, detergents, and chaotropes can minimize aggregation and 
increase the yield of biologically active material [213]. Other factors affecting formation and 
stability of the folded state are pH, redox environment, ionic strength, protein concentration, and 
the presence or absence of specific ligands. 
Here, in order to search for the proper folding conditions, 50 µL of recombinant proteins 
fully unfolded in an 8-M urea solution were added to 950 µL of each of the 16 unique folding 
solutions of the fractional factorial protein-folding screen prepared in house essentially following 
the work of N. Armstrong and co-workers [214] with minor modifications, such as the use of 
lauryldimethylamine-N-oxide (LDAO) as detergent, at a concentration of 1.4 mM, instead of 
lauryl maltoside. The final protein concentration in these solutions was of 0.1 mg/mL (see 
Appendix VIII for the formulation of these buffers). Mixtures were incubated overnight at 4°C on 
a rocker, then centrifuged at 13000 rpm for 10 min to remove precipitated material, and 
supernatants were analyzed by SDS-PAGE. Suitable FoldIt conditions were noted and renatured 
proteins were buffer-exchanged and purified by either affinity or ion-exchange chromatography 
(sections 3.5.1 and 3.5.2, respectively). Once the most significant factors had been identified, the 
folding conditions were optimized for larger scale renaturation experiments. These were 
performed essentially as for the initial screens but protein solutions were added drop-wise to the 
most suitable FoldIt solution(s) under continuous stirring. IRAK-4(S) was alternatively renatured 
by overnight dialysis against 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM 2-ME, 1 mM 
LDAO. The specific renaturing conditions used in each case are shown in Table 4.1 (Results). 
 
3.5 Purification of Recombinant Fragments of MyD88 and IRAK Proteins 
 
Recombinant fragments of MyD88 and IRAK proteins were purified by a combination of 
one or several of the following purification techniques: metal affinity chromatography in batch or 
by HPLC using prepacked columns (MyD88 variants and its complexes), ion-exchange 
chromatography (for IRAK proteins), and size-exclusion chromatography (to separate MyD88 
aggregates from non-aggregated forms and the MyD88•IRAK-4 complex(es) from its 
components). 
 
3.5.1 Purification of MyD88 and its Complexes by Affinity Chromatography 
 
This purification step is based on the interaction of nickel ions, bound to a specific resin, 
with the 6xHis tags present at the NH2-terminal ends of MyD88 recombinant fragments. The 
matrix used in this investigation was Ni-NTA agarose, from Qiagen. Nitrilotriacetic acid (NTA) is 
a tetradentate chelating agent that occupies four of the six ligand binding sites in the coordination
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Figure 3.2 Schematic representation of the interaction between neighboring residues in the 
6xHis tag and the Ni-NTA matrix. Nitrilotriacetic acid (NTA) is a tetradentate chelating 
adsorbent that occupies four of the six ligand binding sites in the coordination sphere of the nickel 
ion, leaving two sites free to interact with the 6xHis tag. (From [215]). 
 
sphere of the nickel ion, leaving two sites free to interact with the 6xHis tag of the recombinant 
MyD88 variants (Figure 3.2). The matrix is then washed and bound proteins are eluted with 
increasing concentrations of imidazole, which can bind to Ni2+ and therefore disrupt protein to 
matrix interactions. Affinity chromatography was performed either in batch or by FPLC using 
prepacked columns mounted on an ÄKTA Explorer System (GE Healthcare). 
 
Purification procedure with Ni-NTA agarose 
The batch procedure entails binding the protein to the Ni-NTA resin in solution. This 
strategy is fast and promotes efficient binding of the 6xHis-tagged protein, especially when the 
6xHis tag is not fully accessible or when the protein in the lysate is present at a very low 
concentration. The batch purification procedure used for MyD88 purification is described below 
(see Appendix VII for buffers compositions): 
1. The extracted protein mixture (section 3.4) was diluted in binding buffer to a final 
concentration of 0.2 mg/mL and added to the Ni-NTA agarose matrix, previously 
equilibrated with binding buffer, and gently mixed by shaking (200 rpm on a rotary 
shaker) for 3-4 h, at 4ºC. 1 mL of Ni-NTA agarose was used for every 5 mg protein, 
corresponding to 25 mL of the initial bacterial culture. 
• For Ni-NTA agarose matrix equilibration, 2 mL of the Ni-NTA agarose slurry (for 
every mL of Ni-NTA agarose matrix to be used) were pipetted into an empty 
Eppendorf tube and centrifuged at 800g for 2 min. The supernatant was removed 
and binding buffer was added to the matrix. The mixture was gently mixed by 
inverting, centrifuged, and the supernatant discarded. 
2. The protein mixture was centrifuged at 800g for 2 min, and the supernatant was 
collected (non-bound fraction). 
3. The matrix was washed with 10 volumes of wash buffer, centrifuged for 2 min at 
800g, and the supernatant collected (wash fraction). 
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4. Specifically bound proteins were finally eluted from the affinity matrix with 5 volumes 
of elution buffer (containing 500 mM imidazole). The mixture was centrifuged for 2 
min at 800g and the supernatant was collected in different fractions (elution fractions). 
Samples were taken after each extraction step for further analysis by gel electrophoresis. 
Alternatively, the Ni-NTA matrix was first settled at the bottom of an empty PD-10 
column, and the procedure continued as described above. 
 
3.5.2 Ion-Exchange Chromatography of IRAK Proteins 
 
Ion chromatography is based on the ionic (Coulombic) interactions of analyte ions with a 
stationary phase displaying oppositely charged functional groups. Retention of the analyte is 
related to its affinity to the ion exchanger inside the column. Cation exchange matrices retain 
positively charged cations using a negatively charged stationary phase, while anion exchange 
resins hold anions using a positively charged stationary one. Usually, samples are loaded under 
low ionic strength conditions and bound proteins are then eluted using a buffer with higher ionic 
strength. 
In this work, IRAK-4(S), IRAK-1(S) and IRAK-M(S) proteins were purified, when 
necessary, by anion exchange chromatography on Q (quaternary ammonium)-SepharoseTM Fast 
Flow matrix (GE Healthcare). The followed procedure was similar as for batch and column 
purification on Ni-NTA agarose (section 3.5.1), but with the following specificities (see Appendix 
VII for buffers compositions): 
1. The Q-Sepharose matrix was equilibrated with equilibration buffer. One mL of Q-
Sepharose matrix was used for every 5 mg protein to be purified. 
2. The protein fraction to be purified was diluted to ~0.2 mg/mL in equilibration buffer. 
3. The matrix was washed and proteins eluted with equilibration buffer, supplemented 
with increasing concentrations of NaCl (from 100 to 500 mM). 
Samples were taken after each extraction step for further analysis by gel electrophoresis. 
 
3.5.3 Size-Exclusion Chromatography 
 
Size-exclusion chromatography is a purification method in which particles of different 
sizes pass through a stationary phase at different rates. As a result, particles of a solution are 
separated by size rather than by molecular weight. As the solution travels down a column filled 
with a porous matrix, small particles enter into the pores, while larger particles cannot. 
Consequently, larger molecules elute faster from the column than smaller particles. Typically, 
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when an aqueous solution is used to transport the sample through the column, the technique is 
known as gel filtration chromatography. 
In this work, gel filtration chromatography was used to separate MyD88(L) and MyD88 
E143X monomers from other multimeric forms, as well as MyD88(L)•IRAK-4(L) and MyD88 
E143X•IRAK-4(L) complexes from non-complexed forms. Gel filtration chromatography was 
performed using a HiPrep 16/60 Sephacryl S-200 High Resolution column (GE Healthcare) 
connected to an FPLC system. The column was always washed first with distilled water, and then 
equilibrated with gel filtration buffer (see Appendix VII for composition) before use. The column 
was calibrated with six standard samples of known molecular weight: Blue Dextran (to determine 
the void volume (Vo) of the column; Mr 2000 kDa), β-amylase (Mr 200 kDa), alcohol 
dehydrogenase (Mr 150 kDa), albumin (Mr 66 kDa), carbonic anhydrase (Mr 29 kDa) and 
cytochrome C (Mr 12.4 kDa). 
The quotients between elution volumes of standard proteins (Ve) and Vo were plotted 
against the logarithm of the molecular weights of standard proteins. All samples (standards and 
newly characterized MyD88/IRAK fragments and complexes thereof) were dissolved in gel 
filtration buffer. In this manner, the Mr of the different eluted fractions of a sample could be 
calculated with the calibration curve created for this buffer, as a reference. The initial sample 
volume to be injected into the column was kept to 1-2 mL at an initial concentration of 1-3 
mg/mL, and gel filtration was performed at a constant flow of 0.5-2 mL/min. Samples were 
examined by absorbance readings at 280 nm throughout the process, and elution fractions were 
collected manually. 
 
3.6 Ultrafiltration of Protein Solutions and Determination of Protein Concentration 
 
Knowledge of the protein concentration is important for most biochemical and 
biophysical studies. In this work, protein concentrations were either determined with the BCATM 
protein assay kit (Pierce) following manufacturer’s instructions, or in most cases, by the 
absorbance of aqueous protein solutions at 280 nm (A280), a faster and cleaner technique. When a 
higher concentration of a protein was needed, ultrafiltration devices were used to reduce sample 
volumes by separating larger solutes from other molecules of lower molecular weight. These 
ultrafiltration devices were used not only for protein concentration but also for protein dialysis 
and separation. These techniques constitute the main topic of this section. 
 
3.6.1 Determination of Protein Concentration from the Absorbance at 280 nm 
 
Absorbance assays are fast and convenient, since no additional reagents or incubations are 
required, and no protein standard needs to be prepared. This method is mostly used to monitor 
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fractions from pure proteins, since any non-protein component of the solution that absorbs 
ultraviolet (UV) radiation will interfere with the assay. Proteins in solution absorb UV radiation 
with absorbance maxima at about 280 and 200 nm. Peptide bonds are primarily responsible for 
the peak at around 200 nm, and amino acids with aromatic rings are the primary reason for the 
absorbance peak at about 280 nm. The relationship of absorbance to protein concentration is 
linear over a large concentration range, and is determined by Lambert-Beer’s Law (given in 
Equation 3.2), where A is the absorbance, at a given wavelength of light, c is the molar 
concentration of solute in the solution being measured, ε is the molar extinction coefficient, 
expressed in M-1cm-1, and l is the path length of the sample (distance that light travels through the 
sample contained in an analytical cell), expressed in cm. 
 
A εcl  Equation 3.2 
 
Absorbance was measured at 280 nm with either the UV-Vis Cary 100 Bio dual beam 
spectrophotometer (Varian), using 100-µL quartz micro cuvettes with a 1-cm path length 
(Hellma), or the Nanodrop ND-1000 spectrophotometer (Thermo). As blank buffer we used the 
one in which the protein to be measured was dissolved. From the A280 value obtained, protein 
concentration was calculated using the theoretical absorption coefficients and molecular weights 
given in Tables 3.1 and 3.2, and applying Equation 3.2. Although protein concentration can be 
monitored by collecting data at a single wavelength (usually 280 nm), a complete UV spectrum 
(e.g. in the range of 240-320 nm) was usually recorded so that information about protein quality 
could be gathered, and distortions due to the presence of contaminating substances absorbing at 
close wavelengths (for example, DNA or RNA, absorbing at 260 nm) could be excluded. 
 
3.6.2 Ultrafiltration of Protein Solutions 
 
Protein solutions are often required to be concentrated and/or buffer-exchanged for 
further use. This can be done by ultrafiltration, which is far gentler to labile macromolecules than 
other techniques such as precipitation. This technique is very efficient because it can 
simultaneously be used for protein buffer-exchange, desalting, concentration, or removal of 
materials of low molecular weight from a solution of macromolecules. When using commercially 
available ultrafiltration devices, a centrifugal force is applied to force the passage of small 
molecules through a membrane that contains pores of a definite size. Retention and product 
recovery are a function of a variety of other factors, including the molecular shape and size of the 
molecule, electrical characteristics, sample concentration and composition, operating conditions, 
and device or system configuration. Nevertheless, the nominal molecular weight limit of a 
membrane has proven to be an effective general indicator of membrane performance for globular 
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proteins. This limit indicates that most dissolved molecules with lower molecular weights will pass 
through the membrane while proteins of higher molecular weight will be retained. 
Here, in order to separate MyD88 and IRAK proteins (or their complexes) from other 
buffer components, three different ultrafiltration devices were used: 
1. Centricon devices (Millipore): for initial protein solution volumes of up to 2 mL and 
desired final volumes of 40 µL or higher (Figure 3.3a).  
2. Amicon Ultra-15 devices (Millipore): for initial volumes of up to 15 mL and final 
recovery volumes of 200 µL or higher (Figure 3.3b). 
3. Microcon devices (Millipore): for initial protein solution volumes of up to 500 µL and 
final recovery volumes of 10 µL or higher (Figure 3.3c). 
The above mentioned devices contain a low-adhesion cellulose membrane with a specific 
nominal weight limit according to its pore size. Depending on the protein or complex to be 
retained, the most frequently used membranes had nominal molecular weight limits of 3, 10 or 30 
kDa. For safety margin, the cut-off of the selected membrane was usually well below the 
molecular weight of the macromolecule to be concentrated/desalted. Since these membranes 
contain trace amounts of glycerin, they were always pre-rinsed with distilled water prior to use. 
Ultrafiltration was always performed at 4ºC following manufacturer’s instructions.  
 
 
Figure 3.3 Ultrafiltration devices used for protein concentration and dialysis. Ultrafiltration 
of protein solutions was performed with devices containing a low adhesion cellulose membrane 
with a specific pore size. The protein solution to be concentrated or buffer-exchanged is loaded 
into the upper part of the device. When centrifuged, macromolecules larger than the membrane 
pore size will be retained on top of the device, while smaller molecules will pass through the 
membrane to the bottom part of the device. Depending on the initial volume of protein solution 
and on the final concentration desired, three different devices where used (all from Millipore): a) 
Centricon devices, for initial protein solution volumes of up to 2 mL and desired final volumes of 
40 µL or higher; b) Amicon devices, for initial volumes of up to 15 mL and final recovery 
volumes of 200 µL or higher; or c) Microcon devices, for initial protein solution volumes of up to 
500 µL and final recovery volumes of 10 µL or higher. (Modified from [216]). 
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3.7 Protein Detection 
 
3.7.1 Protein Separation by SDS-PAGE 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a common 
technique used to separate proteins according to their electrophoretic mobility, which is a function 
of molecular mass if they are previously denatured and homogeneously charged using the 
detergent sodium dodecyl sulfate (SDS), a strong ionic detergent. Thus, this relatively simple 
technique allows for the estimation of the molecular mass of a protein and/or its domains. Further, 
SDS-PAGE is routinely used to assess the purity of protein samples and the progress of a 
fractionation or purification procedure. In this study, SDS-PAGE was performed as follows (see 
Appendix VII for buffers compositions): 
Proteins to be analyzed were previously denatured and evenly negatively charged so they 
could be separated primarily by mass. This was accomplished by treating the proteins with sample 
buffer (which contains 2% (w/v) SDS) and heating them at 95°C for 10 min in a heating block. 
The sample buffer includes the bromophenol blue dye as well, which facilitates supervision of the 
electrophoresis process. In some cases, the sample buffer additionally contained a reducing agent, 
usually 200 mM DTT, in order to reduce disulfide bonds and ensure disruption of tertiary and 
quaternary protein structures.  
To obtain optimal resolution, the gels were prepared with a “stacking” gel cast over the 
top of the “separating” gel. The separating gel, responsible for the separation of polypeptides by 
size, was approximately 5 cm in length. The stacking is prepared with a lower concentration of 
acrylamide, lower pH and different ionic content than the separating gel. It included the sample 
wells, and allowed the loaded protein samples to be concentrated into a thin layer before they 
reached the separating gel. Gels were mounted on a Mini Protean 3 electrophoresis system 
(BioRad), and electrophoresis was performed with adequate buffers. (Please note that different 
buffers are used as cathode and anode in Tris-Tricine systems). Generally, 5-10 µg  protein were 
loaded in each well, with equal sample volumes typically of 30 µL. Novex Sharp (Invitrogen) 
molecular weight marker was loaded in one well, in order to determine the molecular weight of 
the proteins being analyzed. Once samples were loaded into the wells, the proteins were forced to 
move through the gel matrix by applying a difference potential (80 V at first, and 100-120 V once 
the front end had reached the separating gel). Electrophoresis was usually performed until the 
front end reached the end of the gel (2 h approximately). 
In some occasions, in particular to verify complex formation, samples were run under 
native conditions, using the gel, buffer and sample compositions specified in Appendix VII. 
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Once separated by electrophoresis, proteins were either detected directly in the gel using 
Coomassie blue or Silver staining methods, or transferred to nitrocellulose or PVDF membranes 
for analysis by Western blotting. These detection methods are described in the following sections. 
 
3.7.2 Protein Gel Staining 
 
To visualize protein bands in a gel, two different protein staining techniques were used, 
depending on the sensitivity needed: Coomassie blue staining, usually sensitive enough for 
regular purposes; and silver staining, of higher sensitivity. 
 
a) Coomassie Blue Staining 
Coomassie dye is the most popular reagent for staining protein bands after gel 
electrophoresis. In acidic solutions, Coomassie dye binds to basic and hydrophobic residues of 
proteins being able to detect, for most proteins, as few as 50-100 ng per band in a mini-gel [217]. 
Coomassie blue staining was performed as follows (see Appendix VII for the composition of 
solutions used): 
1. The polyacrylamide gel was rinsed once with ddH2O in a suitable container, not much 
larger than the gel itself. 
2. Enough Coomassie stain solution was added to cover the gel, which was incubated on 
a rocking table for 30-60 min at room temperature.  
3. After discarding the Coomassie stain solution, the gel was rinsed twice with ddH2O 
and incubated in destaining solution I on a rocking table. The incubation took place for 
30 min, at room temperature, and the solution was then discarded. This step was 
repeated twice. 
4. Destaining solution I was then removed and replaced with destaining solution II. The 
gel was incubated in this solution at room temperature, on a rocking table, until the 
blue protein bands stood out against a clear background. The solution was changed as 
many times as necessary. 
 
b) Silver Staining 
Silver staining is a highly sensitive method for detecting proteins in polyacrylamide gels. 
With this technique, metallic silver is deposited onto the surface of a gel at the location of the 
protein bands. Proteins bind silver ions and, when these are reduced under appropriate conditions, 
a visible image of protein bands is achieved. This method is 100-fold more sensitive than 
Coomassie blue staining [218], although it requires a considerably more tedious procedure, 
described below (see Appendix VII for the compositi
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1. The polyacrylamide gel was rinsed once with ddH2O in a suitable container, not much 
larger than the gel itself. 
2. The proteins were fixed in the gel by incubating in fixative solution for at least 1 h. 
3. After this time, the fixative solution was discarded and the gel was washed three times 
in 30% (v/v) ethanol (about 20 min each). 
4. The gel was then reduced by incubation in a 0.02% (w/v) sodium thiosulfate 
(Na2S2O3) solution for 1 min. 
5. The Na2S2O3 solution was discarded and the gel was washed three times with ddH2O 
(about 1 min each). 
6. The gel was then incubated with silver staining solution for 1 h. 
7. After this time, the staining solution was removed and the gel was washed three times 
with ddH2O (about 1 min each). 
8. The gel was then incubated in developer solution until the protein bands became 
visible and, at this point, the reaction was stopped with fixative solution. 
 
3.7.3 Protein Immunodetection by Western Blot 
 
The Western blot (WB) is a technique used to detect specific proteins after separation by 
gel electrophoresis. After SDS-PAGE, proteins are electrophoretically transferred to an 
appropriate nitrocellulose or PVDF membrane, and probed with an antibody specific to the target 
protein (the primary antibody). The membrane is then incubated with another antibody (secondary 
antibody), directed at a species-specific portion of the primary antibody. The secondary antibody 
is usually linked to a reporter enzyme such as horseradish peroxidase (HRP), which in turn reacts 
with a chemiluminescent agent, and the reaction product produces luminescence in proportion to 
the amount of protein. An image of the antibodies bound to the blot can then be created by 
chemiluminescent detection methods. 
In this work, mouse anti-His monoclonal antibody (GE Healthcare) was used for the 
detection of recombinant MyD88 fragments, which contain an N-terminal 6xHis tag. IRAK-4 
fragments, containing an N-terminal FLAG® M2 tag (DYKDDDDK), were detected with mouse 
anti-FLAG® M2 monoclonal antibody (Sigma-Aldrich). Natural IRAK-4 from monocyte extracts 
(see section 3.8) was detected with anti-human IRAK-4 polyclonal antibody (R&D Systems). 
Lastly, mouse anti-MYC monoclonal antibody (Sigma-Aldrich) was used for detecting IRAK-M 
proteins, which have an N-terminal c-MYC (EQKLISEED) tag. Rabbit HRP-linked anti-mouse 
polyclonal antibody (Dako) was used, in all cases, as the secondary antibody. Protein 
immunodetection was performed following the procedure described below (see Appendix VII for 
the composition of used buffers): 
 
 Materials & 
Methods 
 
74 
 
1. Proteins were separated by SDS-PAGE (section 3.7.1). 
2. When using a PVDF membrane, this was soaked in 100% methanol for a few seconds 
until its appearance changed from opaque to semi-transparent. 
3. A transfer “sandwich” was prepared using the Mini Trans-blot cell system (BioRad): 
• For each gel to be transferred, four pieces of Whatman paper (about the size of the 
gel), one piece of nitrocellulose or PVDF membrane and two sponges were pre-wet 
in transfer buffer.  
• The gel and pre-wet materials were stacked as shown in Figure 3.4 and air bubbles 
were removed by carefully rolling a clean glass pipette over the surface of each 
layer in the stack. 
4. The transfer tank is filled with transfer buffer and the sandwich is placed inside the 
tank with the membrane oriented to the anode and the gel to the cathode, so that 
proteins would migrate from the gel to the membrane, in the presence of an applied 
electric field. 
5. An ice block and a stirring magnet are added into the transfer tank, which is placed on 
a magnetic stirrer at 4ºC. The electrodes are then coupled and the electrophoretic 
transfer is performed at 400 mA for 2 h, with constant stirring. 
6. When the transfer is finished, the apparatus is disassembled and the membrane is 
incubated with blocking solution containing no BSA on a rocking table, either for 1 h 
at room temperature or overnight at 4°C. In this manner, the non-specific binding of 
the antibody to the membrane is prevented. 
 
 
Figure 3.4 Schematic representation of the “sandwich” assembly for transferring 
proteins to a synthetic membrane. The polyacrylamide gel containing the proteins 
separated by SDS-PAGE is in contact with the nitrocellulose or PVDF membrane, which 
is located facing the anode. The membrane and gel are placed between two filter papers, 
and these in turn are located between two sponges. The whole system is immersed in a 
tank filled with Transfer Buffer (Appendix VII). Proteins, which are negatively charged 
because of the bound SDS, migrate towards the anode when an electric field is applied, 
being retained in the membrane. 
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7. The membrane is then incubated with the primary antibody for 1 h at room 
temperature on a rocking table. 
• For MyD88 detection, mouse anti-His monoclonal antibody (GE Healthcare) was 
diluted 1:3000 in blocking solution. 
• For recombinant IRAK-4 detection, mouse anti-FLAG® M2 monoclonal antibody 
(Sigma-Aldrich) was diluted 1:3000 in blocking solution. 
• For IRAK-M detection, mouse anti-MYC monoclonal antibody (Sigma-Aldrich) 
was diluted 1:5000 in blocking solution. 
8. The blocking solution is removed and the membrane is washed six times (about 5 min 
each) with Tris-buffered saline solution (TBS). 
9. The membrane is incubated on a rocking table, for 1 h, with Polyclonal Rabbit Anti-
Mouse Immunoglobulin/HRP (Dako), at room temperature. The antibody was diluted 
1:10000 in blocking solution. 
10. The antibody-containing solution is removed and the membrane is washed six times 
with TBS (about 5 min each). 
To develop the WB, a chemiluminescence reaction is carried out using the Immobilon 
Western Chemiluminescent HRP Substrate (Millipore), following the manufacturer’s instructions. 
During the chemiluminescence reaction, horseradish peroxidase covalently coupled to the 
secondary antibody, and therefore indirectly to the membrane-bound target proteins, catalyzes the 
oxidation of luminol, a light-emitting reaction. Emitted photons are usually captured on a Curix 
RP 2 Plus photographic film (AGFA) placed over the membrane, in a dark room, and using G334 
and G139 (AGFA) as fixating and developing reagents, respectively. Different films were 
exposed to the membrane for increasing periods of time. Alternatively, the emitted light was 
detected using the KODAK Image Station 4000MM Pro (Carestream Molecular Imaging), 
equipped with a CCD camera, to capture digital images of the Western blot. 
 
3.8 Monocyte Isolation and Culture 
 
Peripheral blood mononuclear cells were isolated from blood of healthy donors by 
centrifugation on Ficoll-Hypaque Plus (Amersham Biosciences), as previously reported [125, 
132]. Cells were initially cultured for 2 h to a density of 106 cells/mL in Dulbecco’s Modified 
Eagle Medium (D-MEM, Gibco/Invitrogen) supplemented with antibiotics (100 IU/mL penicillin 
and 100 µg/mL streptomycin). The supernatant was then removed and adherent cells (2×106 per 
well) were cultured in the same medium supplemented with 10% of heat-inactivated fetal bovine 
serum. Purity of all cultures was verified by CD14 staining. 
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To prepare monocyte lysates, cells were resuspended in cold phosphate-buffered saline 
(PBS) at a concentration of about 106 cells/mL, washed, and finally incubated at 4ºC for 30 min 
with ice-cold cell lysis buffer (see Appendix VII for buffers compositions) with gentle rotation. 
Cellular debris was then removed by centrifugation at 15,000g for 30 min, and the supernatant 
was aliquoted and stored at -20ºC until further use. 
 
3.9 Heterocomplex Formation of MyD88 and IRAK Proteins in Solution 
 
To evaluate MyD88 affinity for the different IRAK proteins, several experiments were 
performed. In some cases, proteins were directly incubated in binding buffer and then purified 
with Ni-NTA agarose. In other cases, protein were first denatured in 8 M urea and then incubated 
in a proper renaturing solution, prior to Ni-NTA agarose purification. The specific procedures 
followed in each case are described below (see Appendix VII for the composition of buffers 
used). 
 
3.9.1 Binding Assays Performed with Soluble MyD88/IRAK-4 Recombinant 
Fragments 
 
To qualitatively assess IRAK-4 affinity for death domain-containing fragments of 
MyD88, equimolar amounts of the purified recombinant proteins of interest were mixed in 
binding buffer at 37°C for 2 h. After this time, the mixtures were incubated for 15 min with 
excess Ni-NTA agarose matrix previously equilibrated in the same buffer, and then centrifuged at 
800g. The matrix was then thoroughly washed with wash buffer and specifically bound proteins 
were finally eluted with the same buffer supplemented with up to 500 mM imidazole (see section 
3.5.1). The same binding assays and purification procedures were performed simultaneously with 
IRAK-4 recombinant fragments alone to exclude non-specific binding of IRAK-4 fragments to 
the Ni-NTA agarose matrix. To verify complex formation, samples of IRAK-4 only and 
MyD88+IRAK-4 were subjected to SDS-PAGE and analyzed either by protein staining or WB 
methods (sections 3.7.2 and 3.7.3). In some experiments, samples were alternatively separated 
using anti-His tag monoclonal antibody coupled to magnetic microbeds (Miltenyi Biotec), 
following the manufacturer’s instructions. 
Alternatively, various amounts of IRAK-4(L) were incubated in binding buffer with 1 µg 
of purified MyD88(L) for 2 h, at 37°C. Equal volumes of Ni-NTA agarose matrix were then 
added to these mixtures and further incubated for 15 min. Mixtures were centrifuged to recover 
the affinity matrix, which was thoroughly washed with wash buffer, containing 10 mM imidazole, 
before eluting specifically bound proteins with reducing sample buffer. Protein fractions were 
analyzed by WB using anti-FLAG or anti-6xHis monoclonal antibodies. 
 Materials & 
Methods 
 
77 
 
3.9.2 Demonstration of Recombinant MyD88 Interaction with Natural Full-
Lenght IRAK-4 Kinase 
 
Fixed amounts (2 µg) of purified MyD88(S) or MyD88(L) were incubated with 
increasing quantities of cytosolic extracts from cultured human monocytes (from 1 to 100 µg of 
total monocyte proteins). After incubation at room temperature for 30 min, Ni-NTA agarose 
matrix was added to the mixtures, and samples were centrifuged at 800g for 2 min. The 
supernatants were precipitated with 5 volumes of cold acetone, and specifically bound proteins 
were recovered with reducing sample buffer after thoroughly washing the affinity matrix with cell 
lysis buffer. Samples were subjected to SDS-PAGE and analyzed by WB, using a human IRAK-4 
affinity-purified polyclonal antibody (R&D Systems). 
 
3.9.3 Detergent Screening to Enhance MyD88(L)-IRAK-4(L) Complex Formation 
 
Clusters of hydrophobic residues on the protein surface can promote non-specific 
aggregation and interfere with complex formation with physiologically relevant partners, even if 
they are present in molar excess. The addition of mild, biological detergents can enhance protein 
solubility and promote complex formation by disturbing these non-specific hydrophobic 
interactions. To explore whether non-ionic detergents could enhance MyD88•IRAK-4 complex 
formation in vitro, 24 different detergents from Detergent Screen 1 (Hampton Research) were 
added to equimolar mixtures of recombinant MyD88(L) and IRAK-4(L) variants (see Appendix 
IX for a detailed formulation of the used detergents). Ten µL of each detergent were used per 100-
µL aliquot of the MyD88(L)/IRAK-4(L) mixture. Each sample was incubated for 3-4 h with equal 
amounts of Ni-NTA matrix on a rotary shaker, at 37°C, and treated as described above (section 
3.5.1).  
 
3.9.4 Co-renaturation of MyD88 and IRAK Recombinant Domains 
 
As another approach for demonstrating complex formation, equimolar amounts of 
MyD88 and IRAK variants were separately denatured in 8 M urea, mixed in various proportions, 
and subjected to the fractional factorial folding screen, essentially as described in section 3.4.2. 
After overnight incubation at 4°C, the pH was adjusted to 7.0 with concentrated sodium 
phosphate and excess Ni-NTA matrix equilibrated in the appropriate renaturing condition was 
added. Samples were incubated for 30 min at room temperature, and then the affinity matrix was 
treated as described in section 3.5.1 to recover specifically bound proteins. For larger-scale 
experiments, protein mixtures were added drop-wise to the most suitable renaturing condition 
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found in the factorial screen, and treated as above. Samples of all eluted fractions were analyzed 
by WB (see section 3.7.3). 
Alternatively, a fixed amount of MyD88(S) (10 µg) was incubated with increasing 
quantities of IRAK-4(L) (from 1 to 20 µg) in 8 M urea, and mixtures were co-renatured by rapid 
dilution in FoldIt condition 5 (with sodium phosphate pH 7.0 instead of MES). Soluble proteins 
were pulled down with Ni-NTA matrix, and treated as described above. A similar experiment was 
conducted with approximately molar equivalent amounts of IRAK-4(S) (from 0.58 to 11.63 µg). 
Samples of all eluted fractions were analyzed by Western blot. 
 
3.10 Protein Characterization 
 
3.10.1 Dynamic Light Scattering 
 
Dynamic light scattering (DLS) is a non-invasive technique for measuring the size of 
macromolecules and small particles typically in the submicron size range. Particles and molecules 
in suspension undergo Brownian motion, which is caused by the large number of solvent 
molecules continuously colliding with the much larger particles, which consequently move in a 
random manner. If the particles or molecules are illuminated with a laser, the intensity of the 
scattered light fluctuates at a rate that is dependent upon the size of the particles (smaller particles 
move faster). The particle diameter that is measured in DLS experiments is called the 
hydrodynamic diameter, and refers to how a particle diffuses within a fluid. The diameter 
obtained by this technique is that of a sphere that has the same translational diffusion coefficient 
as the particle being measured.  The translational diffusion coefficient depends not only on the 
size of the particle core, but also on any surface structure, as well as on the concentration and 
nature of ions in the solution [219]. 
In this work, purified proteins to be analyzed were first centrifuged and filtered to remove 
dust particles from the solution, and then subjected to DLS. Twenty µL of each protein at 0.1 
mg/mL were measured in a 100-µl quartz micro cuvette using a Zetasizer Nano S instrument 
(Malvern Instruments Ltd), equipped with a He-Ne ion laser (633 nm). The results were evaluated 
with built-in software. 
 
3.10.2 Limited Proteolysis 
 
Purified recombinant proteins or their complexes were incubated at 25°C with 
endoproteinases Glu-C or chymotrypsin at a 1:100 enzyme to protein ratio. Additionally, free 
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MyD88(L) was digested at 37ºC with endoproteinase Arg-C at a 1:200 enzyme to protein ratio. 
The procedures followed for each enzyme digestion are described below. 
 
a) Glu-C digestion 
Approximately 50 µg of the proteins of interest were buffer-exchanged into 100 mM 
ammonium bicarbonate, pH 7.9, and concentrated to a final volume of 350 µL using ultrafiltration 
devices (see section 3.6.2). A 40-µL aliquot was taken from each sample before adding 
endoproteinase Glu-C, and incubated with 8 µL of reducing sample buffer (see Appendix VII) at 
95ºC for 10 min. Five hundred ng of sequencing grade endoproteinase Glu-C (Roche) were added 
to the remaining protein samples, and mixtures were incubated at 25ºC in a heating block for up 
to 8 h. Forty-µL aliquots were taken during the digestion process, usually from 5 min to 8 h. The 
reactions were stopped by immediately adding 8 µL of 6X reducing sample buffer to each aliquot 
and heating the tubes at 95ºC for 10 min. All samples were subjected to SDS-PAGE and WB 
analysis, using appropriate antibodies (see section 3.7.3). The same protocol was followed for 
MyD88(S)•IRAK-4(L) Glu-C digestion. Prior to the experiment, the complex was prepared using 
50 µg of IRAK-4(L) and an equimolar amount of MyD88(S), and purified with Ni-NTA agarose 
(see section 3.5.1). 
 
b) Chymotrypsin digestion 
Fifty µg of the proteins to be digested were buffer-exchanged into chymotrypsin digestion 
buffer (100 mM ammonium bicarbonate, pH 7.9, 10 mM CaCl2) and concentrated to a final 
volume of 350 µL, using ultrafiltration devices (see section 3.6.2). Aliquots were taken from each 
sample before adding the protease, and incubated for 10 min with 8 µL of 6X reducing sample 
buffer, at 95ºC. Five-hundred ng of chymotrypsin sequencing-grade (Roche) were then added to 
the remaining samples and incubated for up to 8 h in a heating block, at 25°C. Forty-µL aliquots 
were taken during the digestion process at various times (from 5 min to 8 h). The reactions were 
stopped by immediately adding 8 µL of reducing sample buffer to each aliquot and heating the 
tubes at 95ºC for 10 min. All samples were subjected to SDS-PAGE and WB analysis, using 
appropriate antibodies (see section 3.7.3). 
 
c) Arg-C digestion 
Proteins of interest were buffer-exchanged into Arg-C digestion buffer (100 mM Tris-HCl 
pH 7.6, 10 mM CaCl2) and concentrated to a final volume of 260 µL, using ultrafiltration devices 
(see section 3.6.2). Thirty µL activation solution (50 mM DTT, 5 mM EDTA) were added to the 
concentrated sample, and a 30-µL aliquot was taken from this mixture and mixed with 3 µL of 0.5 
M EDTA. Sequencing-grade endoproteinase Arg-C (Roche) was resuspended in a solution 
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containing 50 mM Tris-HCl pH 8.0, 10 mM CaCl2, 5 mM EDTA, at a final concentration of 0.1 
µg/mL. Eight µL of this Arg-C aliquot were added to the protein sample at a final enzyme to 
protein ratio of 1:200. Arg-C digestion was allowed to proceed at 37ºC for up to 8 h in a heating 
block, and 30-µL aliquots were taken at various times (from 5 min to 8 h). All aliquots were 
immediately mixed with 3 µL of 0.5 M EDTA, in order to stop proteolysis. Alternatively, the 
digestion was stopped by adding 6 µL of 6X reducing sample buffer to all aliquots, instead of 
EDTA, and the mixtures were heated for 10 min in a heating block, at 95ºC. All samples were 
subjected to SDS-PAGE (see section 3.7.1) and the gels were stained with Coomassie Brilliant 
Blue (see section 3.7.2). 
 
3.10.3 Surface Plasmon Resonance Studies 
 
For surface plasmon resonance (SPR) studies, one interacting partner (the ligand) is 
attached to the surface of a sensor chip, and then a solution containing the other interaction 
partners (the analytes) is allowed to pass over the coated surface. Binding of molecules to the 
sensor surface generates a response that is proportional to the bound mass, and changes in the 
amount of bound protein can be detected on the sensor surface. The response is measured in 
resonance units (RU) and is directly proportional to the concentration of biomolecules bound to 
the surface. 
One approach for attaching biomolecules to the surface of the sensor chip is the high 
affinity capture, where the molecule of interest is attached by non-covalent interaction with 
another molecule, which is in turn covalently immobilized to the chip surface. In this work, all 
SPR studies were performed at 25ºC, using Sensor Chip NTA (GE Healthcare). 
a) Sensor Chip NTA 
This sensor chip has a glass surface covered with a uniform thin layer of gold, and a 
covalently bound layer of carboxymethylated dextran molecules to protect samples from contact 
with the metal layer. This dextran surface also contains immobilized NTA (manufactured by 
 
 
 
 
 
 
Figure 3.5 Ni2+-NTA interaction 
with polyhistidine-tagged ligands. 
Nickel ions form a chelation bond 
between NTA immobilized on the 
surface and polyhistidine tags on the 
ligand. (From [220]). 
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Qiagen), which chelates metal ions such as Ni2+, creating coordination sites that bind to 
polyhistidine-tagged ligands (Figure 3.5). 
b) Protein immobilization procedure 
All SPR studies were carried out at the Institut de Biologie Structurale (Grenoble, 
France), under the supervision of Dr. Nicole Thielens. All experiments were performed on a 
Biacore® X system (GE Healthcare), which contains two flow cells (Fc1 and Fc2), using the 
built-in BIAevaluation software. First, before immobilization, proteins of interest were diluted in 
SPR running buffer (see Appendix VII), previously filtered through a 0.45 µm pore-size 
membrane, and all protein solutions were centrifuged at 13,000 rpm for 10 min. The chip was 
washed by passing 20 µL of 350 mM EDTA through Fc1 and Fc2, at a flow of 20 µL/min. Then, 
to allow capture of histidine-tagged proteins, the surface of the sensor chip NTA was activated 
with Ni2+ by passing 20 µL of 500 µM NiCl2 through both flow cells. Then, 40 µL His-tagged 
protein solution were passed over the surface of the chip (through Fc2 only) in SPR running 
buffer, at a constant flow of 20 µL/min. After stabilization of the signal, 40 µL of analytes were 
injected through both flow cells, in SPR running buffer, at a constant flow of 20 µL/min. Binding 
was detected and registered during the experimental procedure and sensorgrams were analyzed 
with the provided software. To remove any nickel ions and bound proteins remaining on the NTA 
surface, the chip was regenerated after each analysis cycle with 60 µL of 350 mM EDTA along 
with other different solutions. See Table 4.3 (Results) for a summary of all experimental set-up 
steps used for SPR analysis. 
 
3.10.4 Analytical Ultracentrifugation 
 
Analytical ultracentrifugation (AUC) is a technique used to analyze biological molecules 
in solution, in specially designed centrifuges, which can, for instance, separate the different 
multimeric states of a given biological molecule. The sedimentation rate of the molecule is 
monitored continuously to obtain the molecular weight profile of the species observed, from 
which the multimeric state(s) of this molecule can be determined. This technique is also very 
helpful for studying protein-protein interactions in solution. In AUC analysis, sedimentation 
velocity is much more frequently used than sedimentation equilibrium, since it can be applied to a 
wider range of biological systems. Sedimentation velocity is a method that measures the rate at 
which molecules move towards the bottom of the cell in response to a high speed centrifugal force 
generated in a centrifuge. This sedimentation rate provides information about both the molecular 
mass and shape of the molecule(s) under study. 
Sedimentation velocity experiments were performed on a ProteomeLab™ XL-I 
Analytical Ultracentrifuge, equipped with an 8-place An-50 Ti Rotor and cells with double-sector 
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centerpieces of 12 mm optical path length and sapphire windows (Beckman-Coulter Instruments). 
For the first measurements, a wavelength and radial scan at 280 nm was acquired at 20°C at a 
rotor speed of 3000 rpm. Afterwards, sedimentation velocity was performed at 20°C at a rotor 
speed of 42000 rpm, overnight, at 280 nm. The duration of the scan was ~1.5 min per radial scan 
at a given wavelength per cell, and samples were analyzed with SEDFIT [221]. Each sample was 
dissolved in a different solution, which was used as optical reference for that sample (see 
Appendix VII for the composition of each buffer used). The loading volume (~450 µL) was 
identical for the reference and sample chambers of the double-sector centerpiece, and a 
counterbalance was used in one cell to provide a reference for calibrating radial distances and to 
balance the opposing cell. Major sample and buffer characteristics are summarized in Table 4.4 
(Results). The density and viscosity of the ultracentrifugation buffers were calculated from their 
respective compositions, and the partial specific volume and molecular weights of the proteins 
were calculated based on the amino acid composition, using the software SEDNTERP [222]. 
 
3.11 Crystallization of MyD88 DD Recombinant Fragments and Their Complexes with 
IRAK-4(L) 
 
3.11.1 Protein and Complex Preparation for Crystallization 
 
Crystallization tests were performed with protein samples that were previously dialyzed 
against HEPES or Tris-based buffers (see Appendix X) using Amicon Ultra-15 ultrafiltration 
devices (Millipore), and concentrated to final concentrations of 1-10 mg/mL using these and 
Microcon ultrafiltration devices (Millipore), for further concentration (section 3.6.2). Samples 
were either dialyzed directly after Ni-NTA purification (section 3.5.1), or separated into 
monomers, dimers and multimers by FPLC procedures (section 3.5.3), prior to dialysis. 
 
3.11.2 Finding Optimal Crystallization Conditions for Crystal Growth 
 
Screenings to find optimal crystallization conditions for crystal growth were performed 
by hanging-drop and sitting-drop vapor-diffusion methods (see Figure 3.6). Hanging-drop vapor-
diffusion trials were set up in 24-well ComboPlates™ (Greiner), using siliconized glass coverslips 
(18 mm diameter) to cover each well, and silicone grease (Bayer) to seal the plates. Alternatively, 
EasyXtal 15-Well (formerly 24-Well) Tool plates with standard X-Seal crystallization supports 
(both from Qiagen), which minimize evaporation and prolongs the reuse of reservoir solutions, 
were used for hanging-drop experiments. Sitting-drop vapor-diffusion trials were set up in 24-
well Linbro Plates (Hampton Research), using Crystal Clear sealing tape (Hampton Research) to 
seal the plates. 
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Figure 3.6 Hanging- and sitting-drop vapor diffusion crystallization methods. Hanging- and 
sitting-drop vapor diffusion methods entail a droplet containing purified protein, buffer and 
precipitants, which is allowed to equilibrate against a larger reservoir containing the same buffer 
and precipitants. Initially, the droplet of protein solution contains an insufficient concentration of 
precipitant for crystallization, but as water vaporizes from the drop and transfers to the reservoir, 
the precipitant concentration increases to a level optimal for crystallization. Both methods require 
a closed system, and differ in the vertical orientation of the protein solution drop within the 
system. a) Diagram of the hanging-drop method, in which the drop hangs from a cover slice 
placed on top of the reservoir. b) Diagram of the sitting-drop method, in which the protein drop 
sits on a pedestal above the reservoir solution. Drop volumes varied from 1 to 3 µL and could 
have different volume ratios between the protein and crystallization solutions. (Modified from [223]). 
 
Initial screenings were performed using reagents from Crystal Screens 1 and 2 (Hampton 
Research) and Morpheus™ MD1-46 (Molecular Dimensions). Crystallization reagents from 
ProPlex™ MD1-38 were also used for some crystallization assays (see Appendix X for a detailed 
list of used crystallization solutions). Protein solutions were centrifuged at 13,000g for 2-5 min to 
remove all suspended particles before setting up the crystallization experiments. Regardless of the 
used system, one drop of concentrated protein solution (1-2 µl) was mixed with one drop of 
crystallization solution, of equal volume. Manipulation of the drop volume ratio is one of the 
commonly used strategies for optimizing the crystallization conditions. In this study, initial 
screenings were performed using 1 µL of protein solution and 1 µL of crystallization solution for 
a final drop volume of 2 µL. In all cases, this final drop was allowed to equilibrate over a 
reservoir containing 0.5-1 mL crystallization solution in a Rumed 3201 incubator (Rumed), at a 
constant temperature of 20°C. Drops were periodically observed under a Nikon SMZ800 zoom 
stereomicroscope equipped with a digital camera. 
 
3.11.3 Crystal-quality Optimization Methods 
 
Crystallization is a phase transition phenomenon that can be illustrated by a phase 
diagram showing which state (soluble, crystalline or amorphous) is stable under a variety of 
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Figure 3.7 Schematic illustration of a protein solubility phase diagram. Adjustable parameters 
include precipitant or additive concentration, pH and temperature. The four most commonly used 
crystallization methods are represented: (i) microbatch, (ii) vapor diffusion, (iii) dialysis and (iv) 
free interface diffusion. Each involves a different route to reach the nucleation and metastable 
zones, assuming the adjustable parameter is precipitant concentration. The filled black circles 
represent the starting conditions. Two alternative starting points are shown for (iii) and (iv) 
because the undersaturated protein solution can contain either protein alone or protein mixed with 
a low concentration of the precipitating agents. The solubility curve is defined by the 
concentration of protein in the solution that is in equilibrium with that in crystals. The 
supersolubility curve separates conditions under which the crystallization solution remains clear 
from those under which spontaneous nucleation, phase separation or amorphous precipitation 
occurs. (From [224]). 
 
physico-chemical parameters. The phase diagram is obtained experimentally by varying two 
parameters at a time. In a typical crystallization phase diagram (Figure 3.7), four regions can be 
distinguished: an area of very high supersaturation, where the protein will precipitate; an zone of 
moderate supersaturation, where spontaneous nucleation will take place; an region of lower 
supersaturation just below the nucleation zone, where crystals are stable and may grow, but no 
further nucleation will take place (referred to as the metastable zone, this region is usually best for 
growth of large, well-ordered crystals); and an undersaturated area, where the protein is fully 
stable in solution and will never crystallize [225-227]. 
Crystallization proceeds in two phases: nucleation (a prerequisite) and growth. The 
optimal conditions for nucleation may not be the same as for crystal growth: nucleation occurs 
when the solution is supersaturated, whereas ordered growth of crystals is optimal in a state of 
lower supersaturation, corresponding to the metastable zone (Figure 3.7). Once a critical nucleus 
has formed, growth follows spontaneously [227-229]. By examining the crystallization phase 
diagram and solubility properties of a protein, an understanding may be gained to optimize the 
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process of crystal growth. The four commonly used crystallization methods (microbatch, vapor 
diffusion, dialysis and free interface diffusion) proceed through the phase diagram following 
different routes. In the vapor diffusion method, the protein solution is initially undersaturated and 
gradually reaches supersaturation by equilibration with a solution containing the crystallization 
agents (see Figure 3.7). 
 
a)  Pre-growth optimization techniques 
Sometimes in a crystallization test, the system is far from the nucleation zone and no 
crystals are allowed to form. However, very often, excess nucleation occurs, resulting in the 
formation of numerous low-quality crystals [230]. Excess nucleation can be bypassed by inserting 
formed nuclei directly into the metastable zone, which ensures the presence of only one or a 
limited number of nuclei that can then grow into large single crystals. The best way to achieve 
this is by seeding the metastable zone with already-grown small crystals (macro-seeding), 
microcrystals or an ordered precipitate (micro-seeding), of the same protein [229, 231, 232]. 
In this study both macro- and micro-seeding techniques were employed. For macro-
seeding procedures, which involve seeding with visible single crystals, a loop was used to move 
the crystal form the drop it grew in, to a new metastable drop. For micro-seeding, in which the 
seeds are too small to be viewed directly, a hair or fiber was used to touch a crystal and pick some 
microcrystals from the contact. The hair was then streaked through the new drops, dispensing the 
seeds as a dilution series (see Figure 3.8). 
Other parameters that can be varied to influence the crystallization process are the 
concentration of the precipitant agent, the volume of the reservoir, the ratio between the volumes 
of protein and crystallization solutions in the drop, the pH of the crystallization solution, the use 
of additives such as detergents, and the size of the crystallization drop. In this study, 1:2, 1:1, 
1.5:1, 2:1 and 3:1 protein to crystallization solution ratios were tested, in final drop volumes of 1-
3 µL, and the reservoir volume was varied from 0.5 to 1 mL. 
 
 
Figure 3.8 Micro-seeding technique for growing protein crystals. A hair or fiber is used to 
pick some microseeds from a drop, and dispense them through a new drop. a) Seeding tool used 
to pick up the seeds. b) Microseeds are first collected from the original drop by contact. c) 
Microseeds are spread on a new drop by passing the fiber through it. (From [233]). 
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b) Post-growth optimization techniques 
The crystal harvesting and data collection techniques described in sections 3.11.4 and 
3.11.5 below can distort the crystal lattice and increase the mosaicity of the crystal, ultimately 
resulting in a lower data resolution. To overcome this problem, frequently associated with an 
incorrect manipulation of the crystal and ice formation on its surface, the crystal can be submitted 
to an annealing procedure before data collection. In this study, crystals were sometimes annealed 
by the flash-annealing technique [234], in which the cold nitrogen stream that is directed to the 
crystal during data collection (Figure 3.9, section 3.11.5) is blocked for a few seconds. In this 
manner, the cryoprotectant is allowed to homogeneously distribute through the crystal before 
cooling it down again to the temperature of liquid nitrogen. 
 
3.11.4 Crystal Harvesting and Cryopreservation 
 
To overcome the radiation damage associated with room-temperature data collection, 
cryogenic conditions are nowadays almost always used. In this method, crystals are flash-cooled 
to cryogenic temperatures, usually near 110 K [235], and maintained at this temperature during 
data collection. It is essential to cool the crystal while preventing ice formation on its surface, 
which may produce high backgrounds due to water scattering, and without distorting the crystal 
lattice or increasing its mosaic spread. This is achieved by modifying the liquid layer with 
reagents known as cryoprotectants, which effectively prevent ice formation when added at an 
appropriate concentration. The most frequently used cryoprotectants are 10-30% (v/v) glycerol, 
10-30% (v/v) ethylene glycol, and 25-35% (v/v) polyethylene glycol (PEG) 400. The use of 
glucose, 2-methyl-2,4-pentanediol (MPD), or xylitol has also been reported [236]. In this study, 
cryoprotectants were selected by comparing the condition in which a particular crystal was grown 
to the conditions of the Crystal Screen Cryo kit (Hampton Research); the selected cryoprotectant 
was the one used in the most similar condition of this kit. Crystals were collected directly from 
the drop with either nylon loops (Hampton Research) or LithoLoopsTM (Molecular Dimensions) 
of the appropriate size. After a brief immersion in the cryoprotectant solution, the crystal was 
quickly placed in liquid N2, where the loop containing the crystal was inserted into a magnetic 
vial. Crystals grown in Morpheus™ crystallization conditions (Molecular Dimensions) were 
directly frozen in liquid N2, since their formulations include cryoprotectant agents. All crystals 
were maintained in liquid N2 until data collection. 
 
3.11.5 X-Ray Diffraction Data Collection 
 
To obtain the diffraction patterns, the loop containing the crystal was mounted on a 
goniometer head under a steady stream of liquid N2 to prevent crystal decay during data 
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Figure 3.9 Typical X-ray diffraction unit. Example taken from ID14-4 (ESRF). The X-ray 
source consists of a tube having a filament, which acts as a cathode opposite to a water cooled 
anode.  A high voltage is passed through the filament and high energy electrons are produced. The 
sample holder is a needle that holds the crystal in place while the X-ray diffractometer takes 
readings. The detector is a transducer that counts the number of photons that collide into it.  This 
photon counter gives a digital readout in number of photons per unit time. The crystal can be 
rotated during measurements, and a liquid N2 stream is directed to it at all times to keep it cold. 
 
collection. The crystal was aligned in a beam of X-rays and diffraction data was collected with a 
coupled X-ray detector as the crystal was rotated with the goniometer (see Fig. 3.9). An image 
was taken at each angle of rotation, usually between 0.5-1 degrees, depending on the cell 
constants and crystal quality (mosaicity), as discussed below. 
In this study, all diffraction measurements were performed at the European Synchrotron 
Radiation Facility (ESRF), in Grenoble (France), using the ID-29, ID-23, BM-16 or ID-14 
beamlines, equipped with different detectors (see details in Table 3.2). 
 
Table 3.2 Main characteristics of the ESRF beamlines used for X-ray diffraction analysis of 
protein crystals. 
Beamline Energy (keV) Minimum beam size (µm2) 
Maximum 
beam size (µm2) Detector 
ID14-1 13.27 (fixed) 50x50 300x300 ADSC Q210 CCD 
ID14-2 13.294 (fixed) 50x50 200x200 ADSC Q4 CCD 
ID23-1 5-20 (tunable) 10x10 30x45 ADSC Q315R CCD 
ID23-2 14.2 (fixed) 8x5 8x5 MarMosaic225 CCD 
ID29 6-20 (tunable) 10x10 75x30 Pilatus 6M 
BM16 6.5-17 (tunable) 100x100 200x200 ADSC Q210r CCD 
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Collecting a full data set from a single crystal requires previous knowledge of its space 
group, unit cell parameters, and it orientation with respect to the X-ray beam. With this 
information, an adequate strategy for data collection can be established, determining the optimal 
rotation angle(s) for data collection (the lower the symmetry, the greater the rotation angle). In 
this study, a small number of diffraction data was initially collected for each crystal (usually two 
images, at perpendicular angles). These initial images were useful for evaluating the crystal 
quality and anisotropy, in the first place, and determining basic crystallographic information 
(possible space group and cell constants) for a full data collection. Data collection was controlled 
with the beam-line control computer using the MxCuBe software [237]. 
  
3.11.6 Diffraction Data Processing: Integration and Data Reduction 
 
For the mathematic analysis of crystal diffraction data, it is useful to consider the 
diffracted beams as resulting from reflections on crystal planes. Each reflection can be labeled 
with a value (hkl) corresponding to the Miller indices of the lattice planes [238]. In this work, the 
intensities corresponding to each reflection were determined with MOSFLM [239], following the 
steps briefly summarized below. 
First, the space group, crystal orientation and unit cell dimensions were determined with 
the autoindexing option and initial data (usually one or two images). This unit cell was then 
refined with data from at least two images or groups of images separated by 90º, and all frames 
were integrated to obtain the whole set of I(hkl) intensities. Finally, these intensities were reduced 
to the corresponding structure factor modules F(hkl), which contain information from all atoms 
within the asymmetric unit of the crystal. The structure factor F(hkl) is a mathematical function 
describing the amplitude and phase of a wave diffracted from crystal lattice planes, characterized 
by Miller indices (hkl). This function is defined by Equation 3.3, where (x,y,z) are the coordinates 
of the individual atoms of the unit cell, fj is the scattering factor of the atom j, and N is the total 
number of atoms contained in the crystal unit cell In this study, structure factors were calculated 
using the CCP4i program suite [240] and, in particular, the SCALA program [241]. 
F(hkl) fj 2πi hxj kyj lzjNj=1   Equation 3.3 
 
The three-dimensional electron density map determined from an X-ray diffraction 
experiment, is the Fourier transform of the structure factors. This function is defined by Equation 
3.4, where p(xyz) is the electron density function in a point of the unit cell given by the 
coordinates (x,y,z), corresponding to a diffracted beam with Miller indices (hkl), and Φ(hkl) 
represent the phases of the structure factors F(hkl). 
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Φ   Equation 3.4 
 
The electron density map describes the contents of the unit cells averaged over the whole 
crystal. However, to calculate an electron density map, both amplitudes and phases of the 
diffracted X-rays are needed, and the phases cannot be experimentally measured. This is known 
as the phase problem, and the resolution of a crystal structure necessarily starts with the 
calculation of an appropriate set of phases Φ(hkl). 
 
3.11.7 Crystal Structure Determination 
 
As mentioned above, solving the phase problem is a crucial step for crystal structure 
determination. In this study, we attempted to solve the phase problem by molecular replacement, 
a method in which a similar known structure is used to derive initial phase values (Φcalc). This 
method is also known as Patterson search. The Patterson function P(u,v,w) is essentially the 
Fourier transform of the intensities rather than the structure factors, and it is defined by Equation 
3.5, where coordinates (u,v,w) represent the differences between the coordinates (x,y,z) of each 
pair of atoms in the crystal: u=x1-x2, v=y1-y2, w=z1-z2. 
P u,v,w F(hkl) 2 2πi(hu kv lw)lkh   Equation 3.5 
 
The Patterson function simplifies the information contained in the electron density 
function (Equation 3.4), since the term containing the phases is removed and the amplitudes of the 
structure factors are replaced by their squares. The Patterson function can be calculated 
immediately from the available experimental data (intensities), and the information provided by 
the maxima of this function corresponds to the relative positions between each pair of atoms in 
the structure. If Patterson maps are generated for the data derived from both the unknown and the 
similar, known structures, the correct orientation and position of the unknown molecule within its 
unit cell can be inferred, since both maps should be closely correlated. Fortunately, the molecular 
replacement search in a six-dimensional space can be usually divided into two independent three-
dimensional searches: a rotation and a translation search. 
In the rotation function, the unknown Patterson map is compared to Patterson maps 
derived from the known similar structure in different orientations. The R-factor (R) is a measure 
of the agreement between the crystallographic model (Fcalc) and the experimental X-ray 
diffraction data (Fobs), and it is used to score the rotation function. The R-factor can be calculated 
from Equation 3.6, where F is the structure factor, and the sums extend over all the reflections 
measured and their calculated counterparts. The highest correlation is obtained when the two 
structures (known and unknown) are in similar orientations. 
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R Fobs Fcalc
Fobs
  Equation 3.6 
 
The second step of the molecular replacement search is the translation function, in which 
the oriented model is correctly positioned by translating it to the correct coordinates within the 
asymmetric unit. This is accomplished by moving the model, calculating a new Patterson map, 
and comparing it to the unknown-derived Patterson map. 
Once the phasing models are correctly oriented and translated, the phases derived from 
them can be used to calculate electron density maps, used to build and refine an atomic model of 
the unknown structure. The quality of an electron density map depends on the quality of the 
diffraction data collected, especially on the obtained resolution. 
 
3.12 Three-Dimensional Modeling of MyD88 and IRAK-4 Death Domains 
 
Three-dimensional models were generated with SWISS-MODEL server [242] and 
depicted with the MIFit 8 program (http://code.google.com/p/mifit). Model quality was assessed 
with PROCHECK [243], and structure figures were generated with PyMOL [244]. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
4. Results 
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4.1 Preliminary Studies on MyD88 and IRAK Recombinant Proteins 
 
4.1.1 Sequence Comparisons Indicate the Presence of a Seventh C-Terminal Helix in 
the Death Domain of MyD88, in Addition to the Conserved Six-Helix Bundle 
 
Despite notable similarities in immune responses in insects and mammals, there also exist 
important differences. To study complex formation between human MyD88 and IRAK proteins, 
and to analyze the contributions of the corresponding globular/unstructured regions to this 
process, we cloned and overexpressed the death domains of these proteins, both alone and 
extended by the full-length linkers to their C-terminal TIR or kinase domains (see Figure 4.1 for a 
schematic representation of domain organization and structure of generated variants). To 
determine the boundaries of the globular domains, the amino acid sequences of MyD88 and 
IRAK-4 from different vertebrate species were aligned with the help of available structural 
information on murine IRAK-4 death domain [111] and the Tube•Pelle complex [174]. The results 
of the combined analysis are summarized in Appendix II. Of particular note, residues Ile109 to Lys119
 
Figure 4.1 Schematic representation of domain organization in human MyD88 and IRAK 
proteins. Numbers indicate approximate domain boundaries; those of MyD88 death domain 
correspond to the structure-based alignment given in Appendix II. The structure of truncated 
variants generated in the current study is shown below their corresponding native proteins; 
encircled letters H, M and F point to the N-terminal tags attached to these recombinant forms 
(6xHis, c-MYC and FLAG, respectively). Also represented is the natural truncated variant 
MyD88s, which lacks the last helix of the death domain from the adaptor along with most of the 
DD-TIR linker (see text for details). 
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in human MyD88 are highly similar to those of Drosophila Pelle, in striking contrast to the rather 
low sequence conservation throughout the DD superfamily. This observation and the results of 
secondary structure predictions allow us to predict with high confidence that MyD88 possesses a 
seventh, C-terminal helix, in addition to the conserved framework of six antiparallel helices 
observed in Pelle [174], as well as in death domains from murine IRAK-4 [111], Drosophila Tube 
[174], Fas [103] and FADD [109, 245]. 
 
4.1.2 Expression and Characterization of MyD88 and IRAK Death Domains 
 
 “Short” and “long” variants of MyD88 and IRAK-death domains were expressed in E. 
coli cells and purified as described in Materials and Methods. A summary of protein expression, 
renaturation and purification conditions is given in Table 4.1, and an SDS-polyacrylamide gel of 
the eight purified recombinant proteins is shown in Figure 4.2 (see also Table 4.2 for the main 
physicochemical parameters of these recombinant fragments). 
In our preliminary expression experiments we noticed that preparations of the linker-
extended forms of the studied proteins underwent limited proteolysis upon longer incubation at 4 
°C. Analysis of these fractions revealed molecular masses ranging between those of the “L” and 
 
Table 4.1 Summary of expression, renaturation and purification conditions for MyD88 and 
IRAK recombinant fragments generated in the current investigation. The most frequently 
used E. coli strains and conditions for the expression of MyD88 and IRAK recombinant 
fragments are indicated, as well as the preferred renaturation and purification conditions for each 
variant (see text for further details). IB, inclusion bodies. 
Construct Host Localization Renaturation and purification conditions 
MyD88(S) BL21(DE3) or BL21 Star™(DE3)pLysS Insoluble (IB) 
FoldIt condition 13(a) /Affinity 
chromatography on Ni-NTA 
MyD88(L) BL21 Star™(DE3)pLysS 
Soluble 
(cytosol) - /Affinity chromatography on Ni-NTA 
IRAK-1(S) BL21 Star™(DE3)pLysS 
Soluble 
(cytosol) 
-/Anion-exchange chromatography on Q-
Sepharose 
IRAK-1(L) BL21 Star™(DE3)pLysS Insoluble (IB) 
FoldIt condition 8(b)/Anion-exchange 
chromatography on Q-Sepharose 
IRAK-M(S) BL21(DE3) Soluble (cytosol) 
-/Anion-exchange chromatography on Q-
Sepharose 
IRAK-M(L) BL21(DE3) Insoluble (IB) FoldIt condition 8
(c)/Anion-exchange 
chromatography on Q-Sepharose 
IRAK-4(S) BL21(DE3) Insoluble (IB) Dialysis against low-salt buffer*/Anion-
exchange chromatography on Q-Sepharose 
IRAK-4(L) BL21(DE3) Insoluble (IB) FoldIt condition 8
(d)/Anion-exchange 
chromatography on Q-Sepharose 
 (a)Similar results were obtained in FoldIt condition 6. (b)Similar results were obtained in FoldIt condition 16. 
(c)Similar results were obtained in FoldIt conditions 3, 7, 9, 13 and 14. (d)Similar results were obtained in 
FoldIt conditions 3, 6, 9, 10, 11 and 12. *Dialysis buffer: 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM 2-
ME, 1 mM LDAO. 
 
 Results 
 
95 
 
 
Figure 4.2 Overexpression of human death domains from MyD88 and IRAK proteins. 
Approximately 5 µg of each of the recombinant proteins used in this investigation were resolved 
in a 12% SDS-Tris-Tricine polyacrylamide gel and stained with Coomassie Brilliant Blue. 
Samples were applied as follows: lane 2, MyD88(L); lane 3, MyD88(S); lane 4, IRAK-1(L); lane 
5, IRAK-1(S); lane 5, IRAK-M(L), lane 6, IRAK-M(S), lane 7, IRAK-4(L), lane 8, IRAK-4(S). 
All samples were incubated with reducing Laemmli buffer. Lane 1 contains the Novex® Sharp 
Pre-stained Protein Molecular Weight Standard (Invitrogen); the corresponding molecular masses 
are given in kDa. Notice that all proteins migrate approximately as expected from their theoretical 
masses (see Table 4.2). 
 
“S” variants, and degraded forms of MyD88(L) and IRAK-4(L) were recognized by the 
corresponding anti-tag monoclonal antibody (data not shown). These findings suggested that the 
linker regions are notably more accessible to proteolytic attack than the N-terminal globular 
domains, and indirectly confirm correct folding of the recombinant proteins. 
 
Table 4.2 Major physicochemical parameters of recombinant proteins generated for the 
current study. Protein parameters were calculated using the ProtParam tool from the proteomic 
server ExPASy [246]. All MyD88 and IRAK proteins were recombinantly expressed in E. coli. 
Mr (Da), calculated relative mass expressed in Daltons. pI, theoretical isoelectric point. ε, 
extinction coefficient at 280 nm, measured in water and expressed in g/mol/cm. A280 (0.1%), 
theoretical absorbance of a 1-g/L solution of pure protein at 280 nm. 
Construct N-residue C-residue Tag Mr (Da) pI ε (g/mol/cm) A280 (0.1%) 
MyD88(S) 1 Thr17 Gln120 6xHis 12,621 6.05 13,980 1.108 
MyD88(L) Thr17 Met157 6xHis 16,521 5.29 13,980 0.846 
IRAK-1(S) Gly14 Ala106 None 10,894 7.98 30,480 2.798 
IRAK-1(L) Gly14 Asn211 None 21,661 8.40 46,980 2.169 
IRAK-4(S) Thr6 Lys107 FLAG 12,446 5.03 15,470 1.243 
IRAK-4(L) Thr6 Ile185 FLAG 21,429 4.98 18,450 0.861 
IRAK-M(S) Thr15 Leu109 c-MYC 11,701 5.26 24,980 2.135 
IRAK-M(L) Thr15 Asn164 c-MYC 17,788 5.21 26,470 1.488 
MyD88 R81E Thr17 Met157 6xHis 16,495 5.05 13,980 0.848 
MyD88 I109X Thr17 Ser108 6xHis 11,130 6.30 12,490 1.122 
MyD88 Y116C Thr17 Met157 6xHis 16,462 5.29 12,490 0.759 
MyD88 E143X Thr17 Ala142 6xHis 14,957 5.65 13,980 0.935 
IRAK-4 E92R Thr6 Ile185 FLAG 21,456 5.25 18,450 0.860 
IRAK-4 V105X Thr6 Ala104 FLAG 12,122 4.83 15,470 1.276 
IRAK-4 N110X Thr6 Ala109 FLAG 12,618 5.03 15,470 1.226 
IRAK-4 K115X Thr6 Ser114 FLAG 13,131 5.03 15,470 1.178 
1 The C-terminus of MyD88(S) differs from the previously reported form, MyD88s, which lacks residues 110 to 157. 
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Figure 4.3 Preferential cleavage of interdomain linkers in recombinant proteins suggests 
correct folding of MyD88 and IRAK variants. Approximately 50 µg of IRAK-1(L) (a), IRAK-
M(L) (b), IRAK-4(L) (c) and MyD88(L) (d), were digested with 500 ng endoproteinase Glu-C in 
100 mM ammonium bicarbonate buffer, pH 7.9. Purified samples of IRAK-4(S) andMyD88(S) 
were loaded along samples of panels c and d, respectively. Additionally, the same amount of 
MyD88(L) was digested with endoproteinase Arg-C at a 1:200 enzyme to protein ratio (e), as 
described in Materials and Methods. Samples were taken at the indicated times and subjected to 
SDS-PAGE for Coomassie Blue Staining (CBB). MyD88(L) and IRAK-4(L) samples were also 
immunoblotted with anti-FLAG (c, lower panel) or anti-His (d, lower panel) antibodies, 
respectively. The sequences of C-terminal linkers to the TIR (MyD88) and kinase domains (IRAK 
variants) are given on top of each panel; putative Glu-C (a-d) and Arg-C (e) cleavage sites are 
indicated with black arrowheads. The sequence of the Tube tail is also shown along with the 
linker residues of IRAK-4 (d), and the polypeptide stretch from Tube that engages in major 
contacts with the death domain of the kinase Pelle is boxed. Additionally, the C-terminal end of 
the sequence missing in MyD88s is indicated in panels d and e. Notice that, in all cases, a stable 
fragment of an apparent molecular mass slightly higher than the corresponding linker-less variant 
is generated. Based on the distances migrated by these stable proteolytic fragments, their most 
likely C-terminal residues are Glu126 or Glu128 (IRAK-1, panel a), Glu113 or Glu118 (IRAK-M, 
panel b), Glu116 (IRAK-4, panel c), Glu143 (MyD88, panel d) and Arg140 (MyD88, panel e). Notice 
that dimers of intact and proteolytically modified forms of IRAK-4(L), but not MyD88(L), are 
detected by immunoblotting (compare panels c and d). 
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To directly verify that residues from the C-terminal tails of the “long” variants are 
unstructured and thus more prone to proteolysis, we treated samples of MyD88(L), IRAK-4(L), 
IRAK-1(L) and IRAK-M(L) with endoproteinase Glu-C for several times. The results of this 
analysis confirmed preferential cleavage of Glu-Xxx scissile peptide bonds within the irregular 
linker peptides (Figure 4.3a-d; potential cleavage sites within the tails are marked with black 
arrowheads). According to the distances migrated by the cleavage products in SDS-
polyacrylamide gels, the C-terminal residues of the stable fragments formed upon limited 
proteolysis appear to be Glu143 (MyD88), Glu126 and/or Glu128 (IRAK-1), Glu113 and/or Glu118 
(IRAK-M) and Glu116 (IRAK-4). We note, however, that upon prolonged incubation (> 6 h) a 
shorter form of MyD88 started to accumulate, indicating cleavage of the Glu110-Glu111 and/or 
Glu111-Asp112 peptide bonds. Additionally, and in order to obtain a truncated variant of MyD88 
containing only a few residues of the DD-TIR linker, free MyD88(L) was digested at 37ºC with 
endoproteinase Arg-C at a 1:200 enzyme to protein ratio, as described in Materials and Methods 
(see Fig. 4.3e). Only the Arg140-Thr141 peptide bond of the DD-TIR linker, but none of the Arg-
Xxx linkages of MyD88(L) DD, was cleaved after 8 h of incubation, indirectly confirming correct 
folding of MyD88(L). 
 
4.1.3 Purified Death Domains of MyD88 and IRAK-4 Form Large Aggregates in 
the Absence of Detergents 
 
In preliminary experiments we noticed that preparations of MyD88 and IRAK-4 variants 
undergo unspecific aggregation even in the presence of reducing agents (Figure 4.4). To further 
assess the size and polydispersity properties of MyD88 and IRAK-4 recombinant fragments, 
dynamic light scattering (DLS) was performed on these purified samples. The results of this 
 
 
Figure 4.4 Human MyD88 and IRAK-4 death domains have a strong tendency to form 
aggregates. Fifty ng of the recombinant proteins were separated by SDS-PAGE and transferred to 
a PVDF membrane for WB analysis. Samples in lanes 1-2 of both panels were incubated with 
non-reducing Laemmli buffer, and samples in lanes 4-5 of both panels were incubated with 
reducing Laemmli buffer. Molecular masses are given on the left, in kDa. a) MyD88 samples 
probed with anti-6xHis antibody. Lanes 1 and 4, MyD88(L). Lanes 2 and 5, MyD88(S). b) IRAK-
4 samples probed with anti-FLAG antibody. Lanes 1 and 4, IRAK-2(L). Lanes 2 and 5, IRAK-
4(S). Notice that dimers are formed even in reduced samples, pointing to an exacerbated tendency 
to homodimerization. 
 Results 
 
98 
 
analysis also revealed that these recombinant forms of death domains form large aggregates in 
solution (up to one-hundred monomers), even in the presence of relatively large urea 
concentrations (see Figure 4.5). 
Gel filtration studies also showed that MyD88(L) has a strong tendency to form large 
aggregates in solution (see Figure 4.6). In these studies, the void volume (Vo) and elution 
volumes (Ve) of known globular proteins were used to plot a standard curve of Ve/Vo against 
MW, as explained in Materials and Methods (section 3.5.3), and the theoretical Ve of an 
MyD88(L) monomer was estimated to be ~ 78.5 mL (see Figure 4.6a). When analyzing 
MyD88(L) samples, however, most of the protein was found to elute around 40 mL, 
corresponding to MW of ~ 330 kDa (19 to 20 monomers), even though the running buffer 
contained 0.1% β-OG. These results confirm that MyD88(L) is mostly found in aggregated forms 
(see upper panels in Figure 4.6b). This strong tendency of MyD88(L) to self-aggregate seems to 
be reduced only when using low protein concentrations (≤ 0.5 mg/mL, see lower panel in Fig. 4.6b). 
When performing gel filtration analysis on the adaptor variant truncated at Glu143, MyD88 
E143X, (see Supplemental Figure 1, Appendix XI), a strong tendency to form large aggregates in 
solution was observed as well. As seen in Supplemental Figure 2 (Appendix XI), the Ve of 
MyD88 E143X monomers was estimated to be ~ 80.7 mL, and most of the protein eluted at 
around 44 mL (corresponding to a MW of ~ 240 kDa, about 17 protein monomers). MyD88 
E143X was also found to form large aggregates at higher concentrations (3.3 mg/mL), since part 
of the protein was eluted at ~ 39 mL, corresponding to a MW of 350 kDa (~ 25 monomers). 
Generally, the poor solubility of these variants resulting from their tendency to form large 
aggregates in solution was overcome with the addition of mild detergents, as seen later on in 
Figure 4.8 for MyD88(L)•IRAK-4(L) complex studies. 
 
 
Figure 4.5 DLS analysis of purified recombinant proteins. The results of MyD88(L) (a), 
MyD88(S) (b), IRAK-4(L) (c) and IRAK-4(S) (d) DLS analysis are given as intensity (%) against 
particle size (diameter, given in nm). Notice that all four recombinant proteins form large 
aggregates of molecular diameter ranging between 100 and 700 nm, which would correspond to 
particles containing up to several hundred-thousand molecules each. 
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Figure 4.6 Gel filtration analysis of recombinant MyD88(L) samples. a) Standard curve for 
MW determination. The ratios of the elution volumes (Ve) of  β-amylase, alcohol dehydrogenase, 
albumin, carbonic anhydrase and cytochrome C over the Ve of blue dextran (void volume, Vo) 
were plotted against their known MW, and the Ve of MyD88(L) was calculated from its MW 
(table cells in red). b) Different examples of MyD88(L) FPLC analysis run at a flow of 2 mL/min. 
MyD88(L) is normally eluted at ~ 40 mL corresponding to a MW of ~ 330 kDa (19 to 20 
monomers) at concentrations of 2 and 6 mg/mL (upper and middle panels). As expected, 
MyD88(L) aggregates are reduced when using lower protein concentrations (≤ 0.5 mg/mL, lower 
panel), as indicated by a major elution peak at ~ 70 mL, corresponding to a MW of 31.86 kDa 
(MyD88(L) dimers). 
 
4.2 Interactions Between MyD88 and IRAK-4 Recombinant Variants 
 
4.2.1 The Isolated Death Domains of MyD88 and IRAK-4 Form a Stable Complex 
in Solution 
 
Although the bipartite adaptor, MyD88, is known to recruit IRAK proteins in vivo, it has 
not been unambiguously established whether additional cofactors are necessary for kinase 
binding. To verify that the death domain of MyD88 suffices to recruit IRAK-4, we took 
advantage of the presence of an N-terminal polyhistidine tag in our recombinant constructs of the 
adaptor. MyD88(L) was incubated with an equimolar amount of purified IRAK-4(L), purified 
with Ni-NTA agarose matrix, and purification fractions were analyzed by SDS-PAGE and 
Western blotting, as explained in Materials and Methods. As a control, the same amount of 
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Figure 4.7 Formation of MyD88(L)•IRAK-4(L) heterodimer in solution. Equimolar amounts 
of purified MyD88(L) and IRAK-4(L) were incubated in binding buffer and purified with Ni-
NTA agarose as explained in Materials and Methods. Non-bound (NB), wash (W) and elution (El) 
fractions were collected and separated by SDS-PAGE. Proteins on the gel were either stained with 
Coomassie Brilliant Blue (CBB) (upper panel) or transferred onto a nitrocellulose membrane for 
Western blot analysis using anti-FLAG monoclonal antibody (lower panel). 
 
IRAK-4(L) was treated in a similar manner. IRAK-4(L) was pulled down by the affinity matrix in 
the presence but not in the absence of MyD88(L), indicating death domain-mediated formation of 
the MyD88(L)•IRAK-4(L) complex (Figure 4.7). However, we observed only partial complex 
formation, apparently because forces holding together aggregates of individual components were 
strong enough to effectively interfere with heterodimer formation in vitro. 
To identify conditions that could enhance complex formation in vitro we analyzed the 
influence of several experimental variables (e.g., incubation time and temperature, as well as ionic 
strength) on MyD88(L)-IRAK-4(L) complex formation. As expected, and in line with the 
negative effect of aggregation discussed above, low protein concentrations had the highest 
positive impact on heterodimer formation. We also studied the effects of 24 unique non-ionic 
detergents on MyD88(L) and IRAK-4(L) complexation, and the results of this screen showed that 
several detergents notably enhance complex formation (see Figure 4.8). Thus, combining low 
protein concentrations with the use of detergents β-OG and C12E9 in binding, wash and elution 
buffers resulted in quantitative formation and purification of a stable MyD88(L)•IRAK-4(L) 
complex in solution. 
In other experiments, we incubated increasing amounts of IRAK-4(L) with a fixed 
quantity of MyD88(L), and fractions purified with Ni-NTA agarose were analyzed by Western 
blotting with anti-His and anti-FLAG antibodies (Figure 4.10a). The results of this experiment 
confirmed specific binding of the kinase death domain to the adaptor, MyD88. Interestingly, at 
low IRAK-4 concentrations no heterocomplex was detected, and the MyD88(L) DD-TIR linker 
was partially cleaved by a contaminating protease. Degradation was prevented at higher IRAK-
4(L) concentrations that support complex formation, suggesting protection of the linkers in the 
heterodimer. These findings were verified with the help of an anti-His tag monoclonal antibody 
coupled to magnetic microbeds. Again, the death domain of the kinase was pulled down in the 
presence but not in the absence of MyD88(L) (data not shown). 
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Figure 4.8 Several non-ionic detergents support formation of stoichiometric 
MyD88(L)•IRAK-4(L) complex. Aliquots containing equimolar amounts of purified MyD88(L) 
and IRAK-4(L) were incubated with detergents from Detergent Screen 1 (Hampton Research) and 
purified with Ni-NTA agarose, as described in Materials and Methods. Elution fractions were 
analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue. The used detergents (see 
Appendix IX) and their critical micellar concentrations are as follows: Lane 1, C12E9 (0.08 mM); 
2, C12E8 (0.11 mM); 3, n-dodecyl-β-D-maltoside (0.17 mM); 4, sucrose monolaurate (0.20 mM); 
5, CYMAL-6 (0.56 mM); 6, TRITON X-100 (0.90 mM); 7, CTAB (1.00 mM); 8, deoxy BigChap 
(1.40 mM); 9, n-decyl-β-D-maltoside (1.80 mM); 10, LDAO (2.00 mM); 11, CYMAL-5 (2.40 
mM); 12, ZWITTERGENT 3-12 (4.00 mM); 13, nonyl-β-D-glucoside (6.50 mM); 14, 1-s-octyl-
β-D-thioglucoside (9.00 mM); 15, DDAO (10.4 mM); 16, HECAMEG (19.5 mM); 17, n-
ocytanylsucrose (24.4 mM); 18, Heptyl-β-D-thioglucoside (30.0 mM); 19, n-octyl-β-D-glucoside 
(24.5 mM); 20, CYMAL-3 (34.5 mM); 21, CHEGA- 10 (35.0 mM); 22, ZWITTERGENT 3-10 
(40.0 mM); 23, MEGA-8 (79.0 mM); 24, n-hexyl-β-D-glucoside (250.0 mM). 
 
4.2.2 The Death-Domains of MyD88 and IRAK-4 Can Be Co-renatured to Form a 
Stoichiometric Complex 
 
To confirm heterodimer formation while minimizing interference of aggregation effects, 
we subjected mixtures of MyD88(L) and IRAK-4(L) previously denatured in 8 M urea to 
renaturation trials by rapid dilution in refolding solutions of the FoldIt Screen shown in Appendix 
VIII. Following this procedure, we found several conditions in which apparently equimolar 
amounts of MyD88(L) and IRAK-4(L) remained in solution after removal of chaotropic agents, 
and which could be quantitatively recovered by metal affinity chromatography. Best results were 
obtained in FoldIt solution 5 (Figure 4.9, see Appendix VIII), which was employed for larger-
scale experiments (using sodium phosphate pH 7.0 instead of MES). In these experiments, a 
protein mixture containing a slight molar excess of MyD88(L) was incubated in the presence of 
reduced and oxidized glutathione, and soluble material was recovered with Ni-NTA agarose, as 
detailed in Materials and Methods (Figure 4.10b). The results of this experiment demonstrated 
formation of MyD88(L)•IRAK-4(L) heterodimer by co-renaturation of its components, providing 
a simple means for analysis of death domain-mediated complex formation. 
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Figure 4.9 MyD88(L) and IRAK-4(L) co-renaturation trial by rapid dilution in refolding 
solutions. Aliquots containing equimolar amounts of purified MyD88(L) and IRAK-4(L), 
previously denatured in 8 M urea, were diluted in each of the 16 folding solutions of the FoldIt 
Screen and incubated overnight at 4 °C on a rocker. Samples were then centrifuged to remove 
precipitated material, supernatants were analyzed by SDS-PAGE and stained with Coomassie 
Brilliant Blue. Best results were obtained in solutions 2, 5 and 9, in which a significant fraction of 
IRAK-4(L) remained in solution after centrifugation, apparently complexed with MyD88(L). 
FoldIt solution 5 was chosen for larger-scale experiments. The composition of each renaturing 
condition tested can be found in Appendix VIII. 
 
 
Figure 4.10 The isolated death domains of MyD88(L) and IRAK-4(L) form a stable complex 
in solution. a) Increasing amounts of IRAK-4(L) were incubated with 1 µg purified MyD88(L) in 
binding buffer supplemented with 80 mM C12E9 and 0.7% β-OG, as explained in Materials and 
Methods. Equal volumes of Ni-NTA agarose matrix were added to these mixtures and specifically 
bound proteins were eluted with Laemmli sample buffer. Protein fractions were separated by 
SDS-PAGE, blotted onto PVDF membranes, and analyzed by Western blot using anti-FLAG 
(upper panel) or anti-6xHis (lower panel) monoclonal antibodies. Notice that increasing amounts 
of IRAK-4(L) are retained in the matrix, indicating formation of MyD88(L)•IRAK-4(L) 
heterodimers. b) IRAK-4(L) and MyD88(L) were denatured in 8 M urea, mixed in an equimolar 
proportion, and refolded by rapid dilution in renaturation solution, as detailed in Materials and 
Methods. Insoluble material was removed and soluble proteins were purified with Ni-NTA 
agarose using increasing imidazole concentrations. Samples were analyzed by SDS-PAGE and 
stained with Coomassie Brilliant Blue (CBB). 
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4.2.3 The Unstructured Death Domain-TIR Linker of MyD88 Is Not Required for 
IRAK-4 Recruitment 
 
After having demonstrated the formation of stable, death domain-mediated complexes of 
MyD88 and IRAK-4, we wished to determine whether the unstructured interdomain connectors of 
these proteins are required for complex formation. To this end, we performed experiments 
essentially as described above, but replacing the “long” forms of the recombinant proteins by their 
linker-less counterparts. First, we analyzed whether MyD88(S) was able to form a stable complex 
with IRAK-4(L). This was indeed the case, as IRAK-4(L) could be pulled down with Ni-NTA 
matrix in the presence of the death domain-only form of the bipartite adaptor (Figure 4.11a). 
 
 
Figure 4.11 The death domain-TIR linker of MyD88 is not required for kinase recruitment, 
but the DD-kinase linker of IRAK-4 is important for heterodimer formation. a) A fixed 
amount of MyD88(S) (10 µg), was incubated with increasing quantities of IRAK-4(L) (from 1 to 
20 µg) in 8 M urea, and mixtures were co-renatured by rapid dilution in the same solution used for 
MyD88(L) / IRAK-4(L) co-renaturation (see Figure 4.10b). After centrifugation to remove 
insoluble material, Ni-NTA agarose was added to the supernatant. The affinity matrix was 
thoroughly washed and specifically bound proteins were recovered with elution buffer. Samples 
of the eluted fractions were analyzed by SDS-PAGE and immunoblotted with anti-FLAG (upper 
panel) or anti-6xHis (lower panel) monoclonal antibodies. Notice saturable binding of IRAK-4(L) 
to the death domain-only variant of the adaptor, indicating that MyD88 linker residues Gln121-
Met157 do not contribute significantly to heterodimer formation. b) A similar experiment was 
conducted with approximately molar equivalent amounts of IRAK-4(S) (from 0.58 to 11.63 µg). 
Notice that, by contrast to the linker-containing form of the kinase, much lower quantities of 
IRAK-4(S) are pulled down by MyD88(S), indicating that residues from the DD-kinase linker of 
IRAK-4 are important for heterodimer formation. 
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4.2.3.1 The Isolated Death-Domain of MyD88 Interacts with Native IRAK-4 
To verify the ability of recombinant death domain-only variants of MyD88 to pull down 
the natural full-length kinase, IRAK-4, we mixed purified MyD88(L) or MyD88(S) with 
increasing amounts of human monocyte extracts obtained as described in Materials and Methods 
(section 3.8). After incubation of these mixtures with Ni-NTA matrix, specifically bound proteins 
were separated on SDS-polyacrylamide gels, transferred to PDVF membranes, and subjected to 
immunoblotting with an anti-human IRAK-4 polyclonal antibody. The results of this experiment 
demonstrate quantitative, saturable binding of natural IRAK-4 by the recombinantly expressed 
death domain of the adaptor (Figure 4.12). 
Of particular note, the fact that both recombinant variants of MyD88 death domain 
interact with natural IRAK-4, corroborates that the DD-TIR linker of the adaptor is not required 
for kinase recruitment. Incomplete pull-down of IRAK-4 by MyD88(S) (compare left panels in 
Fig. 4.12a and Fig. 4.12b) probably results from the higher tendency to self-aggregation of this 
recombinant variant. Further, the apparent contradiction with the reported inability of MyD88s to 
interact with IRAK-4 [79] suggests involvement of MyD88 helix α7 in kinase recruitment. 
 
 
Figure 4.12 The death domain of MyD88 pulls down natural IRAK-4 from monocyte 
extracts. Human monocytes were cultured in DMEM, and cytosolic proteins were extracted by 
incubation in ice-cold Cell Lysis Buffer with gentle rotation at 4ºC for 30 min. Fixed amounts (2 
µg) of MyD88(L) (a) or MyD88(S) (b) were added to increasing quantities of these extracts (from 
1 to 100 µg total monocyte proteins). After incubation at room temperature for 30 min, Ni-NTA 
agarose matrix was added to this mixture and samples were centrifuged. The supernatants (labeled 
“S”) were precipitated with 5 volumes of cold acetone, while specifically bound proteins (labeled 
“B”) were recovered with Laemmli buffer after thoroughly washing the affinity matrix with Cell 
Lysis Buffer. Samples were resolved on 12% Tris-Glycine-SDS polyacrylamide gels, 
electroblotted into PVDF membranes, and analyzed by Western blotting with an anti-IRAK-4 
polyclonal antibody. Notice that left and right panels are derived from separately loaded SDS-
polyacrylamide gels to avoid running-over of samples. 
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4.2.3.2 SPR Analysis of DD-Mediated MyD88–IRAK-4 Interactions 
In an attempt to quantitate the strength of DD-mediated IRAK-4–MyD88 interactions, we 
performed a surface plasmon resonance (SPR) analysis, using Sensor Chip NTA and the 
recombinant variants expressed and purified as described above. A total of four SPR tests were 
performed with MyD88(S) as the ligand, immobilized to the sensor chip surface via its N-terminal 
polyhistidine tag, and IRAK-4(L) as the analyte, as described in Materials and Methods (Section 
3.10.3). Different concentrations of MyD88(S) and IRAK-4(L) were used, as seen in Table 4.3 
(see also Figure 4.13a-d and legend for details). To exclude any responses due to non-specific 
interactions between IRAK-4(L) and the surface of the sensor chip, MyD88(S) was injected only 
to Fc2, at concentrations of either 187 nM (tests 1 to 3) or 837 nM (test 4), and IRAK-4(L) was 
then injected to both Fc1 and Fc2 at concentrations ranging from 1.33 µM (Test 1) to 55.2 nM 
(Test 4). However, and as seen in Figure 4.13e, the relative responses obtained for MyD88(S) 
were not in agreement with the input protein concentrations, being equal in tests 1-3 (panels a-c) 
and higher in test 4 (panel d). Moreover, IRAK-4 (L) presented higher affinity for the reference 
channel, with no MyD88(S) attatched to it (Fc1, shown in red in all panels of Figure 4.13), than
 
 
Figure 4.13 Surface plasmon resonance studies of MyD88(S)–IRAK-4(L) interactions. Four 
different SPR tests were performed, using Sensor Chip NTA (GE Healthcare), previously 
activated with Ni2+. All experiments were performed at 25 ºC in SPR running buffer (see 
Appendix VII), as described in Materials and Methods. a-d) Response over time plots, obtained 
for tests 1- 4, respectively. MyD88(S) injections (purple triangles) proceeded only through Fc2 at 
the following concentrations: 187 nM (a-c), 837 nM (d). IRAK-4(L) injections (yellow triangles) 
proceeded through both Fc1 and Fc2, at the following concentrations: 1.33 µM (a), 276 nM (b), 
138 nm (c), 55.2 nM (d). e) Comparison of the responses obtained with MyD88(S) in tests 1- 4 
(only Fc2 shown). Note that the obtained responses were not in agreement to the used MyD88(S) 
concentrations. f) Comparison of the responses obtained with IRAK-4(L) in both flow cells of 
each test. Note that higher responses were obtained through Fc1 (without MyD88) than through 
Fc2 (containing the adaptor). Y-axes in all panels indicate the obtained response, in Resonance 
Units (RU), as shown in (a) and (d). 
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Table 4.3 Summary of experimental set-up and solutions used for SPR analysis of 
MyD88(S)–IRAK-4(L) interactions. A total of four tests were performed using MyD88(S) and 
IRAK-4(L), in running buffer (see text). All proteins and solutions were passed at a flow rate of 
20 µL/min. MyD88(S) was passed through Fc2 only, while IRAK-4(L) was injected through both 
Fc1 and Fc2. The following reagents were used at the following concentrations: EDTA, 350 mM; 
NiCl2, 500 mM; MgCl2, 3 M; GdnHCl (Guanidine hydrochloride), 6 M. 
Protocol steps Test 1 Test 2 Test 3 Test 4 
(1) Wash 20 µL EDTA 20 µL EDTA 20 µL EDTA 20 µL EDTA 
(2) Surface activation 20 µL NiCl2 20 µL NiCl2 20 µL NiCl2 20 µL NiCl2 
(3) Ligand 
immobilization 
40 µL MyD88(S) 
(187 nM) 
40 µL MyD88(S) 
(187 nM) 
40 µL MyD88(S) 
(187 nM) 
40 µL MyD88(S) 
(837 nM) 
(4) Analyte injection 40 µL IRAK-4(L) (1.33 µM) 
40 µL IRAK-4(L) 
(276 nM) 
40 µL IRAK-4(L) 
(138 nM) 
40 µL IRAK-4(L) 
(55.2 nM) 
(5) Regeneration 
60 µL EDTA, 
40 µL MgCl2, 
20 µL GdnHCl 
60 µL EDTA, 
20 µL GdnHCl 
60 µL EDTA, 
20 µL GdnHCl, 
10 µL GdnHCl 
60 µL EDTA, 
20 µL GdnHCl 
 
for the MyD88(S)-coated channel of the chip (Fc2, in green, in the same figure), even when 
extensively coating the sensor chip with high concentrations of MyD88(S), as in test 4. This lack 
of detectable MyD88–IRAK-4 interactions probably results from the high tendency of the 
proteins to self-aggregate, and the absence of reducing agents in the SPR running buffer (see 
Appendix VII for composition). Further, MyD88(S) residues important for interactions with 
IRAK-4(L) may not be accessible due to the adaptor orientation on the surface of the chip. 
 
4.2.4 Residues up to Ser114 in IRAK-4 DD-Kinase Linker Are Required for MyD88 
Binding 
 
We have prevoiusly shown that IRAK-4(S) bound only weakly to the DD-only form of 
MyD88 (compare intensity of bands in the anti-FLAG panels of Fig. 4.11a and Fig. 4.11b), and 
similar results were obtained with MyD88(L) (data not shown), indicating that the DD-kinase 
connector of IRAK-4 is important for complex formation. To verify whether the DD-TIR linker 
of kinase IRAK-4 was required for complex formation with MyD88, and encouraged by our 
previous findings (Figure 4.10a), we compared accessibility of this polypeptide stretch to 
proteolytic attack in the presence or absence of MyD88(S). Similar to the experiments described 
above for protein characterization (Figure 4.3), we incubated Ni-NTA-bound MyD88(S)•IRAK-
4(L) complex with Glu-C for various times. Presence of the adaptor completely abolished 
proteolysis of the Glu116-Ala117 peptide bond, while the more C-terminal Glu143-Leu144 site was 
hydrolyzed as in free IRAK-4(L), although with slower kinetics (Figure 4.14, compare with 
Figure 4.3c). In line with our previous observations, linker residues were in general protected to a 
greater extent in the complex, and substantial amounts of uncleaved IRAK-4(L) remained after 8 
h incubation with the protease. 
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Figure 4.14 Residues up to Glu116 in IRAK-4 linker are protected from proteolytic attack in 
the complex with MyD88. The equimolar MyD88(S)•IRAK-4(L) complex, obtained as described 
in the legend for Figure 4.11, was immobilized in Ni-NTA agarose, buffer-exchanged into 100 
mM ammonium bicarbonate buffer, pH 7.9, and incubated with endoproteinase Glu-C at 25 °C 
for the indicated times. Samples were centrifuged to separate soluble from matrix-bound material, 
and the latter was analyzed by SDS-PAGE and Western blotting with anti-FLAG (upper panel) or 
anti-His (lower panel) antibodies. Lane 9 in the upper panel contains free IRAK-4(L) treated with 
the same amount of Glu-C for up to 8 hours; the corresponding lane in the lower panel contains 
0.8 µg free MyD88(S). Notice that the Glu116-Ala117 peptide bond is not cleaved in MyD88-bound 
IRAK-4(L), indicating protection of these residues in the complex. 
 
 
Figure 4.15 Similar kinetics of chymotrypsin cleavage of free and complexed IRAK-4(L). 
Samples of free IRAK-4(L) (a) and MyD88(S)•IRAK-4(L) complex (b) containing the same 
amount of the kinase domain were buffer-exchanged into 100 mM ammonium bicarbonate buffer, 
pH 7.9, with 10 mM CaCl2, and incubated with sequencing-grade chymotrypsin at 25 °C (enzyme 
to protein ratio, 1:100) for the indicated times. Samples were analyzed by Western blotting with 
anti-FLAG antibody. Lane 10 in both panels contains untreated IRAK-4(S). 
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Figure 4.16 Residues beyond Ser114 in IRAK-4 linker do not contribute to complex 
formation with MyD88. Equimolar amounts of MyD88(S) and the kinase variant IRAK-4 
K115X, were denatured in 8 M urea and co-renatured in FoldIt solution 5 (see Appendix VII). Ni-
NTA matrix was added to the mixture and processed as described in Materials and Methods. Non-
bound (NB), wash (W) and elution (El) fractions were analyzed by SDS-PAGE and 
immunoblotted with anti-FLAG (upper panel) or anti-His (lower panel) monoclonal antibodies.  
Unimpaired complex formation of these two proteins indicates that IRAK-4 residues C-terminally 
of Ser114 are dispensable for binding to the adaptor. 
 
In other experiments, we incubated aliquots of IRAK-4(L) alone and of 
MyD88(S)•IRAK-4(L) complex with chymotrypsin. In this case, however, cleavage patterns of 
free and adaptor-bound IRAK-4(L) were essentially identical (Figure 4.15), indicating that the 
scissile peptide bond Phe127-Glu128 is not protected in the MyD88•IRAK-4 complex. 
Next, with the aim of verifying the kinase residues involved in complex formation with 
MyD88, we expressed and purified the IRAK-4 K115X mutant, truncated at Lys115 (Supplemental 
Figure 1, Appendix XI), and studied its ability to complex with MyD88(S). Equimolar amounts of 
MyD88(S) and IRAK-4 K115X were denatured in 8 M urea and co-renatured in FoldIt solution 5 
(see Materials and Methods and Appendix VII). Ni-NTA matrix was then added to the mixture 
and specifically bound proteins were eluted with increasing imidazole concentrations. All samples  
were analyzed by SDS-PAGE and immunoblotted with anti-FLAG (Figure 4.16, upper panel) or 
anti-His (lower panel) monoclonal antibodies. The obtained results showed that MyD88(S) and 
IRAK-4 K115X can form a stable complex in solution, indicating that IRAK-4 residues C-
terminally of Ser114 are dispensable for binding to the adaptor. 
 
4.2.5 MyD88•IRAK-4 Complexes Form Large Aggregates in Solution 
 
In previous expression and characterization experiments, we have repeatedly noticed that 
recombinant MyD88 and IRAK-4 variants undergo unspecific aggregation even in the presence of 
reducing agents (see Figures 4.7 and 4.8). To assess the size and aggregation properties of these 
proteins and their complexes, AUC analysis was further employed. Different conditions and 
protein concentrations (with A280 values ranging from 0.1 to 1) were used for the study of 
MyD88(S), MyD88(L) and IRAK-4(L) individual proteins, as well as MyD88(S)•IRAK-4(L), 
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MyD88(L)•IRAK-4 K115X and MyD88(L)•IRAK-4(L) (Figure 4.17). A summary of the 
conditions used for each sample, as well as the obtained results can be seen in Table 4.4. 
Complexes were obtained by mixing individual components directly into the cell or by 
renaturation in FoldIt condition 5, and were previously verified by SDS-PAGE. In addition, the 
results of an electrophoretic analysis of MyD88(L)•IRAK-4(L) and MyD88(L)•IRAK-4 K115X 
samples under native conditions are shown in Supplemental Figure 3, Appendix XI. Interpretation 
of the results was complicated by very weak signals (in some cases, no data analysis could be 
performed), with typical signal-to-noise ratios of 2-3. (Notice that, for a proper analysis, signal-to-
noise ratios above 20 are usually required). Probably also related to this issue, the results of these 
experiments were difficult to reproduce accurately (compare results obtained for identical samples 
in Figure 4.17b). In spite of these technical problems, which seem to be inherent to the nature of 
the analyzed samples, the obtained results showed that these MyD88 recombinant forms of death 
domains not only form large aggregates individually but also when in complex with IRAK-4. 
 
 
Figure 4.17 AUC analysis of MyD88 and IRAK-4 recombinant fragments and their 
complexes. AUC tests were performed using sedimentation velocity, as detailed in Materials and 
Methods. a) Analysis of MyD88(S)•IRAK-4(L) obtained either by mixing the individual 
components directly into the cell (Complex 1), or after previous co-renaturation in FoldIt 
condition 5 (Complex 2). The individual components of the complex were also analyzed. b) 
Analysis of MyD88(L)•IRAK-4 K115X (Complex 3) at different concentrations and including 
some replicates. c and f) Identical aliquots of MyD88(L) analyzed in different runs. d and e) 
MyD88(L)•IRAK-4(L) (Complex 4) analysis. e) Analysis of MyD88(L)•IRAK-4(L) (Complex 4) 
at different concentrations. All analyses were performed at 10ºC except for (a), run at 20ºC. See 
Table 4.4 for a list of all species found in each sample. 
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Table 4.4 Main characteristics of samples and buffers used for AUC analysis. Buffer density 
and viscosity were calculated from their respective compositions. Protein partial specific volumes 
were calculated using SEDNTERP [222] (see Table 4.2 for other protein parameters). Two identical 
aliquots (al.) of MyD88(L) and complexes 1 and 2 samples were used. C1, MyD88(S)•IRAK-4(L) 
Complex 1, obtained by mixing individual components; C2, MyD88(S)•IRAK-4(L) Complex 2, 
obtained by renaturation; C3, MyD88(L)•IRAK-4 K115X Complex 3; C4, MyD88(L)•IRAK-4(L) 
Complex 4; AUC buffer, buffer in which proteins to be analyzed are dissolved (see Appendix VII).  
Sample Sample A280 
V bar 
(mL/mg) 
AUC 
buffer 
Density 
(g/mL) 
Viscosity 
(cp) Results (found species) 
MyD88 
(S) 0.94 0.733 
Buffer 
1 1.0762 1.501 
0.6 S (33%), 3.0 S (4%), 6.2 S (11%), 9.7 S 
(8%), 15.4 S (8%), 20.3 S (9%), 39.2 (27%) 
(Fig. 4.17a) 
MyD88 
(L) 
0.464 
(al. 1) 0.729 
Buffer 
2 1.0121 1.034 
0.8 S (35%), 2.7 S (18%), 4.0 S (9%), 5.5 S 
(8%), 7.5 S (8%), 13.0 S (7%), 24.9 S (3%), 
36.2 S (3%), 60.6 S (8%) (Fig. 4.17c) 
0.464 
(al. 2) 0.729 
Buffer 
2 1.0121 1.034 
0.3 S (23%), 1.9 S (48%), 4.1 S (13%), 9.9 
S (5%) (Fig. 4.17f) 
IRAK-4 
(L) 0.788 0.726 
Buffer 
3 1.0407 1.44 
0.5-S (25%), 2.2 S (24%), 3.7 S  (33%), 8.7 
S (18%) (Fig. 4.17a) 
C1 
0.9 0.729 Buffer 4 1.0762 1.501 
0.1 S (67%), 1.1 S (2%), 1.9 S (10%), 2.9 S (7%), 
3.6 S (8%), 4.7 S (3%), 6.7 S (3%) (Fig. 4.17a) 
0.4 0.729 Buffer 4 1.0762 1.501 
0.7 S (13%), 2.1 S (24%), 3.4 S (37%), 4.8 S 
(13%), 7.7 S (7%), 14.9 S (4%) (Fig. 4.17a) 
C2 
0.22 0.729 Buffer 5 1.0723 2.064 Not analyzed 
0.354 0.729 Buffer 5 1.0723 2.064 
0.6 S (24%), 11.7 S (27%), 27.7 S (7%), 
39.4 S (8%), 83.1 S (34%) 
0.44 0.729 Buffer 5 1.0723 2.064 
0.1 S (93%), 1.1 S (5%), 3.9 S (1%), 15.2 
S (1(%) (Fig. 4.17a) 
C3 
0.247 
(al. 1) 0.729 
Buffer 
2 1.0120 1.034 Not processed (Fig. 4.17b) 
0.247 
(al. 2) 0.729 
Buffer 
2 1.0120 1.034 
1.2 S (35%), 2.7 S (10%), 5.2 S (8%), 9.0 S 
(8%), 15.8 S (8%), 22.0 S (5%), 30.0 S 
(5%), 53.5 S (19%) (Fig. 4.17b) 
0.356 
(al. 1) 0.729 
Buffer 
2 1.0120 1.034 
1.3 S (62%), 3.2 S (14%), 8.8 S (20%), 20.6 
(3%) (Fig. 4.17b) 
0.356 
(al. 2) 0.729 
Buffer 
2 1.0120 1.034 
0.7 S (22%), 2.2 S (29%), 3.4 S (6%), 5.2 S 
(8%), 8.4 S (8%), 13.4 S (8%), 23.9 S (5%), 
29.3 S (2%), 47.1 S (9%) (Fig. 4.17b) 
0.642 
(al. 1) 0.729 
Buffer 
2 1.0120 1.034 0.2 S (50%), 1.2 S (43%), 3.6 S (6%) (Fig. 4.17b) 
0.642 
(al. 2) 0.729 
Buffer 
2 1.0120 1.034 Not analyzed 
C4 
0.315 
(al. 1) 0.729 
Buffer 
2 1.0121 1.034 
1.7 S (41%), 3.6 S (14%), 7.2 S (13%), 11.7 
S (4%), 16.4 S (7%), 28.3 S (6%), 52.6 S 
(11%) (Fig. 4.17d) 
0.315 
(al. 2) 0.729 
Buffer 
2 1.0121 1.034 
0.5 S (5%), 1.7 S (46%), 3.8 S (11%), 6.3 
(9%), 10.1 S (8%), 17.2 (6%) (Fig. 4.17d) 
0.425 
(al. 1) 0.729 
Buffer 
2 1.0121 1.034 
1.8 S (55%), 4.2 S (18%), 8.2 S (11%) (Fig. 
4.17d) 
0.425 
(al. 2) 0.729 
Buffer 
2 1.0121 1.034 Not analyzed 
0.692 
(al. 1) 0.729 
Buffer 
2 1.0121 1.034 0.4 S (4%), 1.2 S (87%), 4.5 S (4%) (Fig. 4.17e) 
0.692 
(al. 2) 0.729 
Buffer 
2 1.0121 1.034 0.4 S (1%), 1.4 S (96%), 6.3 S (1%) (Fig. 4.17e) 
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Indeed, and in line with our previous results (see Figures 4.7-4.9), AUC analysis revealed 
a high tendency of the individual proteins to form large aggregates in solution. MyD88(S) 
analysis revealed several species, the most relevant ones at 39.2 S (indicating the presence of 
aggregates with up to 40 monomers), although the sample was very polydisperse (Figure 4.17a). 
Several oligomeric states were found as well when analyzing MyD88(L). Although they could not 
be analyzed individually due to the large number of species observed in aliquot 1 (Figure 4.17c), 
most protein in aliquot 2 was found as 1.9 S, corresponding to an 18-kDa globular protein, most 
likely the MyD88(L) monomer (Figure 4.17f). Finally, IRAK-4(L) analysis also revealed several 
different species, which could be interpreted as monomers (0.5 S), dimers (2.2 S), tetramers (3.7 
S) and higher aggregates (8.7 S) (Figure 4.17a). 
AUC analysis of MyD88(S)•IRAK-4(L) samples (complexes 1 and 2) revealed several 
different species (Figure 4.17a). Most protein, however, was found as large aggregates (11.7 S 
and 83.1 S). Aggregation was also detected in MyD88(L)•IRAK-4(L) (Complex 4). Although the 
majority of the protein sediments at ~1.7 S, corresponding to a 16-kDa globular protein (probably 
not complexed protein), other peaks are observed at ~3.8 S (53-kDa globular protein, probably 
corresponding to an elongated heterodimer) and higher sedimentation coefficients (Figure 4.17d 
and e). Importantly, diminished aggregation was detected when performing AUC analysis on 
MyD88(L)•IRAK-4 K115X (Complex 3), as seen in Figure 4.17b. 
The strong tendency of MyD88 and IRAK-4 recombinant fragments to form large 
aggregates when in complex was also demonstrated by FPLC analysis of MyD88(L)•IRAK-4(L) 
and MyD88 E143X•IRAK-4(L) (MyD88 E143X•IRAK-4(L) complex formation had been 
previously demonstrated, as shown in Supplemental Figure 4, Appendix XI). Samples were 
injected at relatively low concentrations of 0.5 and 0.9 mg/mL, respectively, and analyzed as 
explained in Materials and Methods. Using the data obtained from the standard curve given in
 
 
Figure 4.18 FPLC analysis on MyD88(L)•IRAK-4(L) and MyD88 E143X•IRAK-4(L) 
complexes.  MyD88(L)•IRAK-4(L) (in red, injected at 0.5 mg/mL) and MyD88 E143X•IRAK-
4(L) (in blue, injected at 0.9 mg/mL) eluted mostly at ~ 40 mL, corresponding to a MW of ~ 323 
kDa (8 to 9 monomeric complexes). Expected elution volumes for 1:1 complexes were calculated 
from the standard curve given in Figure 4.6a. 
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Figure 4.6a, the elution volumes were estimated to be 67.7 mL for MyD88(L)•IRAK-4(L) and 
68.3 mL for MyD88 E143X•IRAK-4(L) monomeric complexes. As seen in Figure 4.18, both 
complexes were found to elute at around 40 mL, corresponding to a MW of ~ 325 kDa (8 to 9 
monomeric complexes, assuming a globular arrangement). 
 
4.2.6 Recombinant Death Domain-Only Variants of MyD88 Can Be Crystallized 
 
To unveil the structural basis of MyD88-IRAK complex formation, we performed 
crystallization trials on MyD88(L), MyD88 E143X and IRAK-4(L) recombinant fragments, as 
well as on their complexes, with the aim of growing crystals that are large and ordered enough for 
X-ray crystal analysis. Individual proteins were expressed, extracted and purified as described in 
sections 3.3-3.5, and their complexes were usually obtained by co-renaturation (section 3.9.3). 
Crystallization experiments were conducted manually using the hanging-drop method, as 
explained in Materials and Methods (see Appendix X for a detailed list of all used conditions). 
Drops were allowed to stand at 20ºC in a Rumed 3201 incubator, and observed periodically under 
a Nikon SMZ800 zoom stereomicroscope. Although a large number of trials were performed, 
diffracting protein crystals were only obtained for uncomplexed MyD88(L) and MyD88 E143X. 
These crystals were grown in different conditions, shown in Table 4.5, although only the best hits 
are described here.  
 
Table 4.5 Summary of crystallization conditions used on MyD88 recombinant fragments. All 
crystals were grown at 20ºC using the hanging-drop method. Monomers, dimers and aggregates 
refer to gel-filtration samples (see Figure 4.6 and Supplemental Figure 2). Crystallization solutions 
are shown by the name of the used screen and tube number, using the following abbreviations: SS1, 
Structure Screen Box 1; SS2, Structure Screen Box 2; M1, MorpheusTM Box 1; M2, MorpheusTM 
Box 2. The detailed compositions of these solutions, as well as of HEPES and Tris-based buffers, 
can be found in Appendix X. 
Protein Crystallization 
solution 
Protein 
concentration 
(mg/mL) 
Protein/Solution 
Volume (µL) Crystals 
MyD88(L) M2-2 5 0.75/0.75 
 
MyD88 E143X 
(Monomers) SS2-28 4.3 1/0.5 
 
MyD88 E143X 
(Dimers) SS1-36 4.2 0.5/1 
 
MyD88 E143X 
(Aggregates) SS2-28 4.8 0.5/1 
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Unfortunately, crystals were only poorly reproducible, and no clear common patterns 
were found in terms of preferred precipitant agents and pH values. Selected crystals were 
analyzed using synchrotron radiation at the ESRF facilities (Grenoble, France), using 20%
glycerol as cryoprotectant, when necessary. Although crystals were generally small (0.05-0.1 
mm) and, in most cases, diffracted X-rays only poorly, they were established to be protein crystals 
as they presented typical protein diffraction patterns (see Supplemental Figure 5, Appendix XI). 
No complete diffraction sets of these crystals could be collected due to their small sizes and/or 
their extreme anisotropy. 
 
 
Figure 4.19 Orthogonal images of diffraction patterns obtained from MyD88 E143X 
crystals. All crystals were grown as described in text and Table 4.5. a) Diffraction patterns of 
MyD88 E143X (crystal 1), obtained at orthogonal positions. This crystal presents ordered 
diffraction patterns and a full data set at a resolution of 1.8 Å was collected. b) Diffraction 
patterns of MyD88 E143X (crystal 2), obtained at orthogonal positions.  This crystal also presents 
ordered diffraction patterns and a full data set at a resolution of 2 Å was collected. Diffraction 
patterns were measured at the ESRF beamline ID23-2, equiped with a MarMosaic225 CCD 
detector. 
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MyD88 E143X crystals grown from apparently monomeric (crystal 1) or aggregated 
fractions (crystal 2), respectively, were obtained in solution 28 of the Structure Screen 2 
crystallization kit. Since they presented ordered diffraction patterns (see Figure 4.19), a full data 
set of each crystal was collected at ESRF beamline ID23-2 (at resolutions of 1.8 and 2 Å, 
respectively) using the parameters given in Table 4.6. 
Indexing of crystals 1 and 2 allowed us to establish that they are orthorhombic and both 
pertain to the C222 or related space groups. The determined cell constants (see Table 4.6) suggest 
that asymmetric units of these crystals contain, with about 80-90% probability, 3 protein 
molecules and 42% of solvent content. These structures were tried to be solved by molecular 
replacement, using the recently reported crystal structures of MyD88 DD in complex with the 
death domains of IRAK-4 and IRAK-2 [178], and also using truncated models derived from other 
reported DDs structures, such as the Fas/FADD death domain assembly [247] and the 
uncomplexed RAIDD DD [112] and Pelle DD [248] (PDB codes: 3OQ9, 3MOP, 2O71 and 1IK7, 
respectively). Unfortunately, no solution has been obtained so far, suggesting a major 
rearrangement of the six-helix bundle during the long time needed for crystallization, perhaps 
similar to the more compact Pelle structure previously reported by Xiao and co-workers [248]. 
 
Table 4.6 Summary of used and calculated parameters during data collection of MyD88 
E143X crystals. Crystals obtained from monomeric (crystal 1) and aggregated (crystal 2) forms 
of MyD88 E143X, were analyzed using X-ray diffraction at ESRF beamline ID-23-2. Complete 
data sets were collected at maximum resolutions of 1.8 and 2 Å, respectively. The main 
parameters used for data collection are shown. Determined cell constants are defined by vectors a, 
b and c (forming the edges of the parallelepiped), and the angles between these vectors α, 
(between b and c), β (between a and c), and γ (between a and b). 
Crystal 1 Crystal 2 
Wavelength 0.8726 Å Wavelength 0.8726 Å 
Transmission 100% Transmission 100% 
Exposure Time 10 s Exposure Time 10 s 
# Collected images 360 # Collected images 120 
Oscillation range (∆ϕ) 1º Oscillation range (∆ϕ) 1º 
Sample to detector distance 210 cm Sample to detector distance 238 cm 
Space group C222 Space group C222 
Unit cell constants 
a = 87.26 Å 
b = 97.19 Å 
c = 89.99 Å 
α = 90º 
β = 90º 
γ = 90º 
Unit cell constants 
a = 87.23 Å 
b = 96.99 Å 
c = 90.27 Å 
α = 90º 
β = 90º 
γ = 90º 
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4.3 Interactions Between MyD88 and IRAK-M Recombinant Variants 
 
4.3.1 The Linker-Extended Versions of MyD88 and IRAK-M Form a Stable 
Complex in Solution 
 
To verify that MyD88 is able to recruit IRAK-M, similar to what we have previously 
shown for IRAK-4, we took advantage of the N-terminal 6xHis tag present in our MyD88 
recombinant fragments. MyD88(L) was firstly incubated with an equimolar amount of purified 
IRAK-M(L). Excess Ni-NTA agarose matrix was then added to this mixture, and treated as 
described in Materials and Methods (section 3.5.1). All fractions of the purification procedure 
were recovered and analyzed by SDS-PAGE and Coomassie Brilliant Blue staining. As a control, 
the same amount of IRAK-M(L) was treated in a similar manner. IRAK-M(L) was pulled down 
by the affinity matrix in the presence but not in the absence of MyD88(L) (except for some 
unspecific interaction), indicating formation of the MyD88(L)•IRAK-M(L) complex (Figure 
4.20). As with IRAK-4(L), we observed only partial complex formation, probably because a 
fraction of the individual components form aggregates that do not dissociate in the presence of the 
binding partner, thus effectively interfering with heterodimer formation in vitro. 
In other experiments, to confirm heterodimer formation while minimizing interference of 
aggregation effects, we subjected mixtures of MyD88(L) and IRAK-M(L) previously denatured in 
8 M urea to renaturation trials by rapid dilution in refolding solutions of the FoldIt Screen (see 
Appendix VIII). Following this procedure, we found several conditions in which apparently 
equimolar amounts of MyD88(L) and IRAK-M(L) remained in solution after removal of 
chaotropic agents, and which could be quantitatively recovered by metal affinity chromatography. 
 
 
Figure 4.20 Formation of MyD88(L)•IRAK-M(L) heterodimer in solution. Equimolar 
amounts of purified MyD88(L) and IRAK-M(L) were incubated for 2 hours at room temperature 
in binding buffer (see Appendix VII) and then Ni-NTA agarose matrix was added to this mixture. 
After centrifugation to remove non-bound material (NB), the matrix was washed several times 
with binding buffer (W) and specifically bound proteins were finally recovered with elution 
buffer (El). Samples were separated by SDS-PAGE and stained with Coomassie Brilliant Blue 
(MWs given in kDa, on the left). Notice that, despite some unspecific interaction between IRAK-
M(L) and the Ni-NTA agarose matrix, much larger quantities of IRAK-M are bound to the matrix 
in the presence of MyD88(L) indicating MyD88(L)•IRAK-M(L) complex formation. 
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Figure 4.21 MyD88 and IRAK-M(L) co-renaturation trials by rapid dilution in refolding 
solutions. Aliquots containing equimolar amounts of purified IRAK-M(L) and either MyD88(L) 
or MyD88(S), previously denatured in 8 M urea, were incubated overnight at 4 °C on a rocker 
with each of the 16 folding solutions of the FoldIt Screen (Appendix VIII). Samples were then 
centrifuged to remove precipitated material, and supernatants were analyzed by SDS-PAGE and 
stained with Coomassie Brilliant Blue. a) MyD88(L) and IRAK-M(L) co-renaturation trials. b) 
MyD88(S) and IRAK-M(L) co-renaturation trials. Notice that, in both cases, best results were 
obtained in FoldIt solutions 2, 5, 9, 10 and 14, in which apparently equimolar amounts of 
MyD88(L)/(S) and IRAK-M(L) remained in solution after centrifugation. Molecular weights, 
determined with Novex® Sharp Pre-stained Protein Molecular Weight Standard, are given on the 
left of each gel, in kDa. 
 
Best results were obtained with FoldIt solutions 2, 5, 9, 10 and 14 (see Appendix VIII), as seen in 
Figure 4.21a. When the same procedures were repeated using MyD88(S) instead of the linker-
extended version of the adaptor, similar results were obtained (Figure 4.21b). Using a slightly 
modified FoldIt solution 9 (containing sodium phosphate pH 7.0 instead of MES), we performed a 
larger-scale refolding experiment by incubating a protein mixture containing a slight molar excess 
of MyD88(L) in the presence of reduced and oxidized glutathione (see Materials and Methods). 
The supernatant was incubated with excess Ni-NTA agarose and bound proteins were recovered 
with elution buffer. The results of this experiment (shown in Figure 4.22) demonstrate 
MyD88(L)•IRAK-M(L) heterodimer formation by co-renaturation of its components.
 
 
Figure 4.22 The linker-extended variants of MyD88 and IRAK-M form a stable complex. 
Equimolar amounts of IRAK-M(L) and MyD88(L) were denatured in 8 M urea, and refolded 
together by rapid dilution in FoldIt condition 9 (see Appendix VIII). After centrifugation to 
remove insoluble material, Ni-NTA agarose was added to the supernatant and specifically bound 
proteins were recovered with elution buffer (see Appendix VII), as explained in Materials and 
Methods. Non-bound (NB), wash (W), and elution (El) fractions were analyzed by SDS-PAGE 
and stained with Coomassie Brilliant Blue (MWs given in kDa, on the left). As in Figure 4.20, 
much larger quantities of IRAK-M(L) are bound to the matrix in the presence of MyD88(L) 
indicating MyD88(L)•IRAK-M(L) complex formation. 
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4.3.2 Residues Beyond Glu143 in the DD-TIR Linker of MyD88 Are Not Required 
for IRAK-M Recruitment 
 
After having demonstrated the formation of a stable MyD88(L)•IRAK-M(L) complex, we 
wished to analyze the importance of the unstructured DD-TIR linker of the adaptor protein in 
complex formation. With this aim, we performed experiments essentially as described above, but 
replacing MyD88(L) by the variant with a shorter linker, MyD88 E143X, which had been 
previously shown to be fully functional in terms of IRAK-4 binding (see Supplemental Figure 4, 
Appendix XI). First, we analyzed whether MyD88 E143X was able to form a stable complex with 
IRAK-M(L) in binding buffer (see Appendix VII for composition). This was indeed the case, as 
IRAK-M(L) could be pulled down with Ni-NTA matrix in the presence of the truncated form of 
the bipartite adaptor (Figure 4.23a). The same results were obtained when repeating the same 
experiments in FoldIt condition 9 (see Appendix VIII for composition), indicating that residues 
beyond Glu143 in the DD-TIR linker of MyD88 are not required for heterodimer formation (Figure 
4.23b). 
 
 
Figure 4.23 Residues beyond Glu143 in the DD-TIR linker of MyD88 are not required 
for IRAK-M recruitment. Equimolar amounts of purified MyD88 E143X and IRAK-M(L) 
were incubated for 2 hours at room temperature in binding buffer (see Appendix VII) (a) or 
denatured in 8 M urea and refolded by rapid dilution in FoldIt condition 9 (see Appendix VIII) 
(b). Ni-NTA agarose matrix was added to both mixtures and non-bound (NB), wash (W) and 
elution (El) fractions were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue 
(MWs given in kDa, on the left). Despite some unspecific interaction between IRAK-M(L) and 
the Ni-NTA agarose matrix, much more quantities of the kinase are bound to the matrix in the 
presence of MyD88 E143X, indicating MyD88 E143X•IRAK-M(L) complex formation. Notice 
that unspecific interactions are diminished when proteins are allowed to co-renature, as compared 
to simple mixing of the two components in binding buffer. 
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5.1 Overexpression and Characterization of Death Domains of MyD88 and IRAK 
Proteins 
 
Although the innate immune responses in insects and mammals share many similarities, 
and for instance the Toll-MyD88-Tube-Pelle cascade is functionally equivalent to that of TLRs-
MyD88-IRAKs [184, 189], they also present important differences. Most notably, mammals on 
the one hand possess several relatives of the kinase Pelle, termed IRAK proteins, but on the other 
lack a true Tube ortholog. In fact, the role that this adaptor plays in insects appears to be assumed 
in mammals by one of the IRAK members, IRAK-4 (refs. [79, 138, 184, 190-192] and Figure 
1.8). 
Previous investigations on the interface between the death domains (DD) of Drosophila 
Pelle and its adaptor, Tube, indicated that two major regions of the latter are critical for complex 
formation: (i) exposed DD residues mostly donated by helices α4 and α5 and their connecting 
loop, and (ii) a short polypeptide stretch within the non-structured C-terminal extension to this 
globular domain, which inserts between helix α5 and the N-terminus of Pelle DD [174]. Similar 
interactions have been observed in other complexes between members of the death domain 
superfamily. For example, (i) both the α-helical DED module and the irregular C-terminal tail of 
PEA-15, an important modulator of the ERK/MAP kinase pathway, are required for ERK binding 
[96], and (ii) a short stretch preceding the Fas death domain is required for recruiting the bipartite 
adaptor of the extrinsic apoptotic pathway, FADD [249]. Altogether, these findings suggest that 
several members of the DD superfamily combine interactions mediated by globular domains and 
unstructured linkers for specific heterodimer formation. 
In line with these findings, and in particular highlighting the connection between the 
death domains of the Toll and TLR pathways, we have observed a previously unrecognized 
similarity between mammalian MyD88 and Drosophila Pelle. Indeed, a detailed inspection of the 
sequence alignments of MyD88 and IRAK-4 death domains from various species (Appendix II), 
prepared considering the results of secondary structure prediction methods (see Appendices III-
IV), revealed that MyD88 possesses a seventh, C-terminal 310 helix, in addition to the conserved 
framework of six antiparallel helices previously observed in death domains from murine IRAK-4 
[111] and Drosophila Tube [174], as well as in Fas [103] and in FADD [109, 245]. It is 
particularly striking that residues C-terminally of helix α6 in MyD88 (Ile109 to Lys119 in the human 
adaptor) are highly similar to those of Drosophila Pelle, in contrast to the rather low sequence 
conservation throughout the DD superfamily.  
In turn, this observation suggested an arrangement of the mammalian MyD88 DD•IRAK-
4 DD heterodimer similar to that observed in the crystal structure of the Pelle•Tube complex 
[174], and prompted us to study complex formation between human MyD88 and IRAK proteins, 
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and to analyze the contributions of the corresponding globular and unstructured regions to this 
process. To this end, we cloned, overexpressed, and purified the death domains of MyD88 and of 
all known IRAK proteins (with the exception of IRAK-2), both alone and extended by the full-
length linkers to their C-terminal TIR or kinase domains (see Figure 4.1 and Appendix XI). 
Although all eight initial constructs used in this study had been similarly optimized, we 
observed significant differences in expression yields and solubility of recombinant proteins, even 
between “long” and “short” variants of the same protein. For instance, MyD88(L) but not 
MyD88(S) could be recovered from the cytosolic fraction of BL21(DE3)pLysS cells (see Table 
4.1), most probably because of the stronger tendency of the DD-containing only recombinant 
variant to self-aggregate, as indicated by analytical ultracentrifugation, gel filtration and dynamic 
light scattering analyses of these MyD88 recombinant fragments (see Figures 4.4, 4.6 and 4.17, 
and Appendix XI). The higher solubility of MyD88(L) suggests that the DD-TIR linker is largely 
responsible for adaptor solubility in the cytosol, in the absence of activating stimuli and receptor 
engagement. How would inclusion of this unstructured interdomain/linker enhance solubility of 
the adaptor DD? It is tempting to speculate that this relatively long peptide covers, at least 
transiently, a hydrophobic patch on the globular death domain that mediates unspecific 
aggregation. Residues with aliphatic side chains within the MyD88 linker, and in particular the 
well-conserved Leu129, Val131, Val134 and Val138, are likely candidates for interacting with an 
apolar surface on the N-terminal DD. It is particularly noteworthy that residue Leu129 is strictly 
conserved in mammals, and conserved or conservatively replaced by Ile/Val in other vertebrates. 
Further, position 134 is always occupied by valine or isoleucine. This high degree of conservation 
within an otherwise flexibly disordered region points to an important functional role. In line with 
these observations, the designed recombinant variant MyD88 E143X, truncated at Glu143 and thus 
containing the hydrophobic residues mentioned above, was recovered from the cytosolic fraction 
of BL21(DE3)pLysS cells, similar to the linker extended variant MyD88(L) (data not shown). In 
turn, interactions of the DD-TIR linker of the adaptor with the DD module would locate these two 
globular domains in close proximity, forming a somewhat "closed" structure and thus avoiding its 
untimely recruitment by the TIR domains of IL-1R / TLRs, and concomitant activation of 
downstream IRAK kinases (see below). 
The strong tendency of the studied MyD88 recombinant variants to form large aggregates 
in solution is consistent with previous findings of massive aggregation observed in other 
overexpression experiments of the bipartite adaptor. Most notably, studies on the subcellular 
localization of MyD88 have shown that the protein is present as condensed forms in the 
cytoplasm, such as discrete foci, fibrillar aggregates, and inclusion bodies [119-122] (see Figure 
5.1). Although most of the reported work suggests that aggregation of full-length MyD88 is 
essentially mediated by homotypic interactions between its death domains [73, 182], a recent 
work presents evidence indicating that the entire non-TIR region (i.e., DD and linker) is required 
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to form these aggregate structures [121]. Our in vitro results, however, support a more important 
role of the DD module in this regard. 
Interestingly, the situation is exactly opposite in the case of IRAK proteins, as the DD-
only recombinant variants IRAK-1(S) and IRAK-M(S), but not their linker-extended counterparts, 
were expressed as soluble proteins in E. coli (see Table 4.1). It would seem that the unstructured 
DD-(pseudo)kinase linkers are prone to aggregate formation per se. Along these lines, most 
reported aggregation-prone motifs are rich in β-branched aliphatic and aromatic residues as well 
as in hydroxyl-containing Ser/Thr residues, but show a lower-than-expected proportion of charged 
residues [250]. These features are observed in the DD-kinase linker of human IRAK-1. In 
particular, the Ser138-Ser144 stretch is predicted as an aggregation "hot spot" by Aggrescan [251] 
(http://bioinf.uab.es/aggrescan/), which almost exactly matches the region of maximum 
aggregation propensity within the linker identified by ProA (http://www.abl.ku.edu/ProA/), 
Ser137-Phe142. 
 
 
Figure 5.1 Overexpressed MyD88 is localized in the cytoplasm as large condensed forms. a) 
Micrographs of mouse embryonic fibroblasts expressing hemagglutinin-tagged MyD88. MyD88 
was found in discrete foci scattered throughout the cytosol, as identified with FITC-cholera toxin 
B (CTB) (extracted from [119]). b) HEK293 cells were transfected with yellow fluorescent protein 
(YFP)-tagged MyD88 and visualized by inverted fluorescence microscopy. Notice that MyD88-
YFP is expressed as a condensed form in the cytoplasm (extracted from [120]). c) Confocal image 
of HEK293T-MyD88-YFP cells stained with Alexa Fluor 594-conjugated CTXb (cholera toxin B 
subunit) (extracted from [121]). d) Ultrathin sections of HeLa cells transfected with Flag-tagged 
MyD88. Cytoplasmic aggregates (open arrows) and nuclear aggregates (closed arrows) were 
observed in transfected cells (extracted from [122]). Refer to cited publications for details. 
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In the case of the pseudo-kinase, the linker region is particularly rich in aliphatic / 
aromatic residues, and Aggrescan identifies streches Asn123-Ala130, Thr133-Val137, and Leu148-Ile158 
as potential hot spots for aggregation, while ProA maxima were predicted between residues 120-
134 and 146-156. In the case of IRAK-4, however, the presence of the linker did not influence the 
solubility of the different recombinant variants, as both the DD-only and the linker-extended 
variants were repeatedly recovered from the insoluble fractions in overexpression experiments 
(see Table 4.1). The fact that our IRAK-4(S) recombinant fragment is expressed in inclusion 
bodies is in striking contrast with the recent work of Lasker and co-workers, in which IRAK-4 
DD could be expressed as a soluble protein in E. coli [111]. A possible explanation for this 
contradiction comes from the fact that the recombinant form designed by Lasker and co-workers 
comprises residues 1-113, and thus includes a few extra polar residues C-terminally of the DD 
module (e.g. Thr108 and Thr111), compared to our designed variant IRAK-4(S). However, although 
the formation of IBs has been found to be affected by many factors (e.g. the amino acid sequence 
of the recombinant protein, the induction temperature, the culture condition, the rate of protein 
production and folding, and the availability of essential chaperones [252-256]), it has been 
recently proposed that other factors besides amino acid composition and high concentrations of 
overexpressed protein, play a major role in formation of such aggregated structures [257]. The 
lack of a thorough understanding of the formation of IBs in E. coli make it difficult to predict 
whether a recombinant protein will be soluble, partially or completely deposited into IBs. 
For urea-extracted fractions of MyD88 and IRAK recombinant fragments, most of the 
sixteen refolding conditions routinely tested were successful and large quantities of properly 
folded recombinant proteins could be recovered in this maner. These findings suggest that these 
aggregates contain properly folded DDs and/or native-like folding intermediates that are easily 
forced into the correct 3D conformation in the presence of specific chaotropic agents and 
detergents. In this regard, of course, the fact that all these DDs are single-domain, all α-helical 
proteins with a rather simple topology, and which in addition lack disulfide bridges, greatly 
facilitates adoption of the proper 3D configuration. Correct folding of these fragments was 
directly demonstrated  by the fact that only Glu-Xxx scissile peptide bonds within the irregular C-
terminal tails of the linker-containing variants of MyD88 and IRAK proteins, but not those within 
their globular death domains, are susceptible to Glu-C cleavage (Figure 4.3). The ultimate proof 
of the native-like conformation of recombinantly expressed DD variants of MyD88 was the 
demonstration of specific interactions with natural IRAK-4 kinase from monocyte extracts 
(Figure 4.12). 
In line with our current findings, aggregation has been also found in other members of the 
DD superfamily (see Figure 5.2): (i) DED-dependent filaments were detected in the cytoplasm of 
cells overexpressing caspase-8 or FADD, and these aggregates were almost completely insoluble 
in two commonly used non-ionic detergents, NP-40 and Triton X-100 [258]. Further, (ii) 
 Discussion 
 
125 
 
 
Figure 5.2 Aggregation is a common feature of members of the DD superfamily. a) HeLa 
cells transfected with the DED-containing prodomain of caspase-8, fused to GFP, and 
immunostained. A distinctive cytoplasmic filament network can be observed (from [258]). b) The 
same cells were transfected with the DED domain of FADD either fused to GFP (left panel) or 
without any epitope tag (right panel). Numerous filaments could also be detected by 
immunostaining (from [258]). c) NIH-3T3 cells were transfected with a GFP fusion protein 
consisting of the prodomain region of caspase-2, and photographed using a fluorescence 
microscope. The CARD-GFP fusion protein appeared as discrete filamentous structures inside the 
nucleus (from [259]). d) Fluorescence confocal micrographs of HeLa cells expressing a bcl10 
truncated protein, containing only the CARD domain. Notice the clear pattern of discrete and 
interconnecting cytoplasmic filaments exhibited by this form, resembling the DED filaments 
shown in (a) (from [260]). e) COS cells were transfected with a GFP construct containing the 
CARD domain of caspase-2, directly fused to the caspase domain. Cells were fixed and analyzed 
by confocal microscopy. As it can be observed, the CARD-containing GFP fusion protein forms 
large aggregates in the cytoplasm (from [261]). f) HEK293T cells transfected with a FLAG-
tagged RAIDD-CARD construct were fixed, immunostained, and observed by fluorescence 
microscopy. The RAIDD-CARD appears as an extensive filamentous network within the 
cytoplasm, sometimes appearing as lariat structures around the nucleus (from [262]). g) PC12 
cells transfected with a pCDNA3 vector encoding RAIDD were fixed, stained and visualized by 
confocal microscopy. Overexpressed RAIDD is localized predominantly within a perinuclear 
cytoplasmic region, forming aggregates of a spherical shape (left panel). Of note, this RAIDD-
induced aggregates are relatively insoluble, as the same cells transfected with rat RAIDD and 
briefly exposed to detergent still showed a perinuclear immunostaining pattern (right panel), 
indicating that these RAIDD aggregates are resistant to detergent extraction (from [263]). 
 
overexpressed caspase-2 and its isolated CARD module form large aggregates that are visualized 
as discrete dot- or filament-like structures by fluorescence microscopy [259, 261]. Likewise, (iii), 
similar CARD-dependent filamentous or spherical aggregates have been reported for its adaptors, 
RAIDD [262, 263], and bcl10 [260]. Of particular note, the recently presented crystal structure of 
the oligomeric RAIDD-DD•PIDD-DD complex reveals an intricate asymmetric arrangement of 
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seven RAIDD and five PIDD death modules [264], as it will be discussed below. Finally, and 
highlighting the possibility of reverting multimerization with minimal structural changes, (iv) 
FADD aggregates at neutral pH in solution while the conservative point mutant F25Y remains 
monomeric even at high protein concentrations [100, 245]. 
Given that TLR engagement is followed by receptor oligomerization to form 
“receptosomes” that in turn recruit MyD88 [72], and that overexpressed MyD88 automatically 
induces death domain-dependent activation of downstream signaling pathways [30, 121, 123, 
124], we consider that multimerization of our recombinant proteins reflects the in vivo signaling 
pathway. 
 
5.2 Death Domain Interactions Between MyD88 and IRAK Proteins 
 
Although it is generally accepted that MyD88 acts by recruiting protein kinases of the 
IRAK family through interactions between their respective DDs, it has not been unambiguously 
established whether additional cofactors are necessary for MyD88-mediated IRAK recruitment in 
vivo, and the specific residues involved in such interactions have been only partially 
characterized. Our current findings directly confirm that the DD alone, eventually extended by the 
more N-terminal portion of the linkers suffices for complex formation in vitro. These findings, in 
turn, strongly suggest that the bipartite adaptor alone can recruit IRAK-4 and IRAK-M to its 
membrane-proximal complexes with IL-1R / TLR in vivo (see Figures 4.10, 4.20 and 4.22). 
Further, our results unambiguously establish that the C-terminal TIR (MyD88) and kinase (IRAK) 
domains are dispensable for complex formation. 
In the absence of added detergents, we have repeatedly observed only partial complex 
formation between MyD88(L) and IRAK-4(L) (Figure 4.7), probably because aggregation of 
individual DDs interferes with heterodimer formation in vitro. As previously discussed for the 
individual components, large aggregates of purified MyD88•IRAK-4 complexes were also 
observed by gel filtration and AUC analyses (see Figures 4.17 and 4.18). Notably, a decreased 
tendency for aggregation was observed when complexating the linker-extended recombinant 
variant of the adaptor with the truncated variant IRAK-4 K115X, and also the linker-extended 
variant of IRAK-4 with the truncated variant MyD88 E143X, suggesting that residues beyond 
Lys115, in the kinase linker, and Glu143, in the adaptor, may play an important role in protein 
aggregation. 
In order to limit formation of large aggregates, we combined the use of low protein 
concentrations and specific non-ionic detergents (Figure 4.8), which allowed quantitative 
formation of the MyD88(L)•IRAK-4(L) complex in solution (see Figure 4.10a). Interestingly, and 
as can be seen in this figure, no heterocomplex was detected at very low IRAK-4 concentrations, 
and the MyD88(L) linker was partially cleaved by a contaminating protease. Since degradation 
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was prevented at the higher IRAK-4(L) concentrations that support complex formation, our 
results suggest protection of the linkers in the MyD88(L)•IRAK-4(L) heterodimer (discussed 
below). In addition, we have established co-renaturation of MyD88 and either IRAK-4 or IRAK-
M recombinant death domains as a novel method for complex formation, providing a simple 
means for analysis of DD-mediated interactions while minimizing the effects of aggregation (see 
Figures 4.10b and 4.22). Notably, the MyD88(L)•IRAK-4(L) complex bound more tightly to the 
metal affinity matrix than the free DD of the adaptor, pointing to formation of dimers or higher 
order aggregates of the heterodimer. In this regard, as previously mentioned, MyD88 is known to 
dimerize following receptor recruitment in vivo [73], and recent evidence indicates that enforced 
adaptor dimerization suffices to trigger signaling [124]. 
In our studies to determine whether the interdomain connector of MyD88 is required for 
complex formation with IRAK proteins, we have demonstrated not only that IRAK-M is able to 
associate with MyD88 (Figures 4.20 and 4.22), but also that residues beyond Glu143 of the DD-
TIR linker of the adaptor are not required for complex formation with IRAK-M (see Figure 4.22). 
IRAK-M interactions with MyD88 are of particular interest, as the pseudo-kinase has been shown 
to play an inhibitory role in the TLR/IL-1R signaling pathway [136]. However, the mechanism(s) 
underlying this inhibitory function of the pseudo-kinase are still speculative. In this regard, 
several studies suggest that IRAK-M does not prevent IRAK-1 or IRAK-4 recruitment to the 
TLR/IL-1R·MyD88 complexes, but inhibits dissociation of the activated kinases from the 
receptor complex and therefore blocks LPS-induced NF-κB activation [85, 125, 127, 129, 130, 
132, 136, 147, 200, 265]. IRAK-M has been recently speculated to bind to IRAK-2, which does 
not contact MyD88 in the reported crystal structure, to prevent IRAK-2 or IRAK-1 dissociation 
and signaling [178]. In fact, most IRAK-4 residues reported to interact with MyD88 by Lin and 
co-workers [178] are not conserved in IRAK-M, except perhaps for a limited similarity at the type 
II interface (see Figure 5.3), which would indirectly support this theory. On the other hand, our 
results unambiguously establish that IRAK-M is able to interact directly with MyD88, in line with
 
 
Figure 5.3 Partial sequence comparison between human IRAK-4 and IRAK-M. Notice that 
most IRAK-4 residues reported by Wu and co-workers to be involved in type I (in yellow), type II 
(in purple) and type III (in green) interactions with MyD88 [178] are not conserved in IRAK-M. 
This observation suggests that IRAK-M does not compete with IRAK-4 for MyD88 binding (see 
text). Conserved residues are written between both sequences. Similar residues are marked with +. 
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previous work showing specific MyD88–IRAK-M interactions [137]. Future studies are needed to 
clarify if IRAK-M down-regulates TLR signaling by competing with kinases IRAK-1 and IRAK-
4 for MyD88 binding, or if all three kinases can be simultaneously attached to the adaptor. 
Focusing more specifically on the analysis of MyD88–IRAK-4 interactions, we first 
demonstrated that the full DD-TIR linker of MyD88 is dispensable for IRAK-4 binding, as 
MyD88(S) forms a stable complex with IRAK-4(L) (Figure 4.11a), and pulls down the natural 
kinase from monocyte extracts (Figure 4.12). Previous results had indicated that residues 110 to 
154 of MyD88 are strictly required for interactions between IRAK-4 and the adaptor. Indeed, the 
truncated variant MyD88, MyD88s, lacking residues Glu110-Leu154, is unable to recruit the kinase 
to the IL-1R complex (see refs. [79, 169] and Figure 4.1). The missing stretch in MyD88s 
comprises the C-terminal extra α-helix of the adaptor death domain and almost the complete DD-
TIR linker. One possible explanation for the inactivity of this linker-less variant is that 
juxtaposition of DD and TIR domains compromises IRAK-4 recruitment because the TIR domain 
covers an important binding site on the death domain of the adaptor, thus interfering with DD-
mediated heterodimer formation. We note, however, that lack of the interdomain linker does not 
impair heterodimerization of MyD88 and MyD88s [169]. Further, our modeling experiments 
suggest that the two globular domains would remain fairly independent in MyD88s, and the TIR 
domain would not approach the putative IRAK-4-binding site on the adaptor moiety (see below). 
In light of current structural and functional evidence for the Drosophila Tube•Pelle complex 
[174], our observation of similar binding to IRAK-4 by both MyD88(S) and MyD88(L) strongly 
suggests an alternative explanation, namely, that the C-terminal helix of MyD88 death domain 
and surrounding residues (Glu110 to Gln120) play a major role in IRAK-4 recruitment. In support of 
our hypothesis, the mutated variant Y116C in murine MyD88 results in reduced immune 
responses to several pathogen-associated ligands [266]. It is important to stress that the residue 
topologically equivalent to Tyr116 in Pelle, Tyr128, engages in van-der-Waals interactions with the 
Tube tail [174]. Finally, we note that the aromatic Tyr116 and surrounding residues are conserved 
in MyD88 from different species (see Appendix II), also supporting a functional role of helix α7. 
Although the affinity of IRAK-4 death domain for MyD88 could not be assessed by SPR 
due to non-specific binding of IRAK-4(L) to the surface of the sensor chip (Figure 4.13), 
incubation of purified MyD88(L) or MyD88(S) with increasing amounts of human monocyte 
extracts demonstrated quantitative, saturable binding of natural IRAK-4 by the recombinant 
death-domain of the adaptor (Figure 4.12). As mentioned before, the fact that both recombinant 
forms of MyD88 interact with native IRAK-4 corroborates that the DD-TIR linker of the adaptor 
(residues 121-158) is not required for kinase binding. Incomplete pull-down of the downstream 
kinase by MyD88(S) probably results from the higher tendency to self-aggregation of this 
recombinant variant (see Figure 4.5), and/or from partial unfolding of helix α7 in the absence of 
most of the DD-TIR linker. 
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On the other hand,the DD-only variant of the adaptor, MyD88(S), bound only weakly to 
IRAK-4(S), as compared to IRAK-4(L) (Figure 4.11), indicating that the DD-kinase connector of 
IRAK-4 is important for heterodimer formation. Tube residues of the linker that engage in 
important interactions with Pelle are located just 10 to 20 positions downstream of the globular 
death domain (see [174]; this stretch is boxed in Figure 4.3c). In a similar manner, residues of the 
PEA-15 tail involved in ERK binding are clustered about 30 to 40 positions from the end of the 
globular DED moiety [96]. Therefore, we speculated that IRAK-4 residues proximal to the helical 
death domain might also be critical for complex formation, while the more C-terminal region 
could be less relevant in this regard. Indeed, Glu-C digestions of the MyD88(S)•IRAK-4(L) 
complex showed that presence of the adaptor completely abolishes proteolysis of the Glu116-Ala117 
peptide bond, while the more C-terminal Glu143-Leu144 site is hydrolyzed as in free IRAK-4(L), 
albeit with slower kinetics (compare Figures 4.3c and 4.14). On the other hand, 
chymotrypsinolysis of free and adaptor-bound IRAK-4(L) proceded following essentially 
identical kinetics (see Figure 4.15), indicating that the Phe127-Glu128 site is not protected in the 
MyD88•IRAK-4 complex. Further, and since the truncated variant IRAK-4 K115X was able to 
form a stable complex with both MyD88(S) and MyD88(L) (see Figure 4.16 and Appendix XI), 
we conclude that residues up to Lys115 in the DD-kinase linker of IRAK-4, and not beyond, are 
critical for recruitment by MyD88. 
With the aim of gaining more insight on the structure of MyD88 and IRAK death 
domains, as well as on their interactions, we performed crystallization trials of several of the 
expressed recombinant fragments. However, although protein crystals of MyD88(L) and MyD88 
E143X have been obtained (Tables 4.5 and 4.6, Figure 4.19, and Appendix XI), only crystals of 
the truncated form showed diffraction patterns ordered enough for data collection, most probably 
because residues beyond Glu143 in the DD-TIR linker of the adaptor are flexibly disordered and 
therefore interfere with regular lattice formation. Analysis of the obtained data suggested the 
presence of three protein molecules in the asymmetric unit of MyD88 E143X crystals, in line with 
our previous observations on MyD88 having a strong tendency for self-aggregation. However, we 
have not been yet able to solve these structures by molecular replacement, probably because of 
unfolding of the DD upon prolongued incubation at room temperature, as previously reported for 
the protein kinase Pelle [248]. Awaiting new, clarifying crystallographic results, we propose a 
docking model of the MyD88-IRAK-4 heterodimer, discussed below. 
 
5.3 A Proposed Mechanism for MyD88•IRAK-4 Complex Assembly 
 
Although our biochemical and biophysical observations on MyD88 interactions with 
IRAK proteins have not be yet supported by clear crystallographic results, we wondered whether 
available structural and functional information could be used to generate a docking model of the 
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MyD88•IRAK-4 heterodimer (see section 3.12 in Materials and Methods). The results discussed 
above strongly suggested a topological equivalence of MyD88-Pelle and IRAK-4-Tube pairs 
[174], and would in particular imply that IRAK-4 tail residues are “clamped” between helix α7 
and the main globular death domain of the adaptor in a similar manner as Tube binding to Pelle 
[174] (see Appendix II and compare Figures 1.9 and 5.2a). Nevertheless, it must be stressed that 
several residues involved in important intermolecular contacts in the Tube•Pelle heterodimer are 
not conserved in IRAK-4•MyD88 (see Appendix II). For instance, Glu50 (Tube) and Arg35 (Pelle) 
form a salt bridge in the Drosophila complex, but are replaced by proline and alanine/valine in 
IRAK-4 and MyD88, respectively. Further, only two of the six basic residues that surround the 
tail-binding cleft in Pelle are conserved in MyD88. Finally, the tail sequences of Tube and IRAK-
4 appear to be only marginally related (see Figure 4.3c). These differences, altogether, preclude a 
straightforward adoption of the Tube•Pelle structure as template for modeling the mammalian 
MyD88•IRAK-4 complex. 
The Tube-Pelle interface belongs to type II of the three topologically distinct DD-DD 
interfaces [267]. The recently solved crystal structure of the heterocomplex between death 
domains of RAIDD and PIDD [264] demonstrated that these interfaces represent most, if not all, 
possible interaction modes within the death domain superfamily. Importantly, the structural 
analysis revealed different subtypes within each of these interaction forms. It is also noteworthy 
that the Pelle-Tube interface shows considerable plasticity, as revealed by significant differences 
between the two independent complex molecules found in the asymmetric unit [174]. Closer 
examination of the RAIDD-PIDD type II interface reveals that a basic arginine side chain at the 
C-terminal end of RAIDD helix α4 forms a strong salt bridge with an aspartate of the α5-α6 linker 
in PIDD. Interestingly, these residues possess counterparts in MyD88 (Arg81) / IRAK-4 (Glu92). 
However, residues that follow the latter glutamate are not polar/charged as in PIDD but 
aromatic/aliphatic (Phe-Phe-Ala in the human kinase). They closely resemble the topologically 
equivalent Tube triplet, Leu141-Phe142-Ser143, of which Phe142 and Ser143 are critical for Pelle 
binding [174]. Thus, it is conceivable that the MyD88•IRAK-4 heterodimer combines elements 
from both RAIDD-PIDD and Pelle-Tube type II interfaces. Along these lines, we notice that the 
nature of type I contacts differs between the procaspase-9 CARD•Apaf-1 CARD complex, which 
is mediated by complementary electrostatic fields [268], and the network of hydrophobic and 
hydrogen bond interactions that stabilize the topologically equivalent RAIDD DD•PIDD DD 
interface [264]. 
Unbiased predictions of surface areas of MyD88 and IRAK-4 death domains that are 
important for protein-protein interactions also support our model. For MyD88, the PPI-Pred 
server identified the cluster of polar aromatic residues donated by helices α2, α3, and their 
connecting loop, as the most likely protein-protein binding site (see Appendix III). This region 
includes residue Phe56, which has been shown to be implied in DD-mediated adaptor dimerization 
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Figure 5.4 Hypothetical model of death domain-mediated heterocomplex formation between 
MyD88 and IRAK-4. a and b) Three-dimensional models of death domains from human MyD88 
and IRAK-4. Major α-helices and the N- and C-termini of both modules are marked. The highest 
scoring patch in MyD88 appears to correspond to the MyD88–MyD88 interaction area, as 
replacement of Phe56 by an asparagine is known to impair DD-mediated adaptor dimerization 
[73]. On the other hand, replacement of Tyr116 by a cysteine compromises immune responses 
against several pathogen-related molecules [266]; its close distance to the last residue included in 
the second highest patch (Ser108) and the fact that the residue topologically equivalent in Pelle, 
Tyr128, engages in van-der-Waals interactions with the Tube tail in the Tube•Pelle complex [174], 
suggests that it belongs to the IRAK-4 binding surface. c) Putative MyD88•IRAK-4 heterodimer, 
modeled on the basis of the type II interface observed in the RAIDD•PIDD structure [264]. The 
structures of Pelle DD free in solution [269] and bound to the adaptor, Tube [174], are essentially 
identical; similar observations have been made by comparing the structures of free [112] and 
PIDD-bound [264] RAIDD death domains. Therefore, death domain-mediated heterodimerization 
would appear to occur without major structural rearrangements, as an assemblage of rather rigid 
modules. In all panels, selected residues within the two highest scoring patches identified by PPI-
Pred are indicated with their side chain atoms, colored and labeled yellow and green (MyD88) or 
blue and pink (IRAK-4), respectively. 
 
[73] (these residues are clustered on "top" of the molecule in Figure 5.4a). In line with our 
hypothesis, Arg81 ranked on top of the second highest scoring patch, which also included nearby 
polar / aliphatic residues from helix α4, but also a number of basic side chains from the 
neighboring helix α1 (Arg28, Arg30, Arg31), as well as the more distant Ser108. Importantly, the 
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close distance of Tyr116 to this serine residue, and the fact that the residue topologically equivalent 
in Pelle (Tyr128) engages in van-der-Waals interactions with the Tube tail in the Tube•Pelle 
complex [174], suggests that it belongs to the IRAK-4 binding surface. 
For IRAK-4 DD, the expected MyD88-interactive region was also identified as the 
second highest scoring area (see Appendix IV). This region includes Glu92 and neighboring 
exposed aromatic side chains (Phe93, Phe94), and several charged or aromatic exposed residues 
from helix α1 (e.g., Lys21, Asp24, Phe25; see Figure 5.4b). Interestingly, the most likely protein-
protein interaction site for this domain (to the right in Figure 5.4b) involves a distinct cluster of N-
terminal (e.g., Arg12, Cys13) and nearby residues from helix α1 (e.g., Val16, Leu18) but in particular 
from α4 (e.g., Glu69, Phe72, Asp73, and Thr76). This patch is thus topologically equivalent to the 
IRAK-4 binding site on MyD88. 
To verify that the MyD88-IRAK-4 interactive mode is compatible with a type II interface, 
we superimposed our models of MyD88 and IRAK-4 death domains on those of the 
corresponding RAIDD•PIDD heterodimer. Inspection of the generated structure after rigid-body 
refinement revealed that the predicted interactions can be simultaneously satisfied in the putative 
MyD88 DD•IRAK-4 DD complex (Figure 5.4c). In support of our model, we notice that adaptor 
dimerization would not interfere with IRAK-4 recruitment, in line with experimental 
observations. Given that the structures of Pelle DD free in solution [269] and bound to the 
adaptor, Tube [174], are essentially identical, and that similar observations have been made by 
comparing the structures of free [112] and PIDD-bound [264] RAIDD death domains, death 
domain-mediated heterodimerization appears to occur without major structural rearrangements, as 
an assemblage of rather rigid modules. 
There is ample experimental supporting a scaffolding role for death domains of IRAK 
proteins, while the actual catalytic function is performed by the C-terminal kinase domain. 
Indeed, truncated IRAK-1 and 4 variants that consist of the death domain, eventually extended by 
the linker to the kinase domain have a potent negative-dominant effect in overexpression 
experiments [74, 138]. On the other hand, deletion of IRAK-1 DD abolishes all downstream 
signaling activities [270]. In this regard, the TLR-MyD88-IRAK system represents a counterpart to 
the Fas-FADD-procaspase-8/10 extrinsic apoptotic pathway, where the bipartite adaptor, FADD, 
regulates formation of the multimeric death-inducing signaling complex (DISC) by binding Fas 
via death domain-mediated interactions. Two markedly different crystal structures of the complex 
between DDs from Fas and FADD have been recently presented. In one of the structures, Scott 
and co-workers show a Fas•FADD DD complex with a tetrameric arrangement of four FADD 
DDs bound to four Fas DDs, in which Fas provides all contacts [271] (see Figure 5.5a). In striking 
contrast, Wang and co-workers reported later a Fas•FADD death domain complex composed of 
two layers, with five Fas DD molecules in the “upper” layer and five FADD DD molecules in the
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Figure 5.5 Different arrangements of death domain heterodimers. a) Tetrameric arrangement 
of the Fas/FADD DD complexes reported by Scott and co-workers [271]. Contacts between the 
complexes are solely mediated by Fas molecules. One Fas•FADD DD complex is displayed in 
green (Fas) and blue (FADD) ribbons, while the remaining three complexes are colored red, 
magenta and blue (the latter, in surface representation). b) Alternative Fas•FADD DD complex 
composed of two layers, with five Fas DD molecules in the “upper” layer and five FADD DD 
molecules in the “lower” one, reported by Wang and co-workers [247]. The Fas molecules are 
shown in warm, and the FADD DD molecules in cold colors. c) Model of the MyD88•IRAK-4 
DD complex proposed in this work, in which only two MyD88•IRAK-4 heterodimers are 
sufficient to allow cross-phosphorylation and activation of the kinase moieties of adaptor-bound 
IRAK-4. MyD88 and IRAK-4 molecules are shown in purple and green, respectively. Notice the 
topologically equivalence with the arrangement of Fas and FADD DD modules shown in (a), as 
opposed to the Fas•FADD and MyD88•IRAK-4•IRAK-2 DD complexes shown in (b) and (d), 
respectively. d) Ribbon diagram of the MyD88•IRAK-4•IRAK-2 DD complex reported by Lin 
and co-workers [178], composed of 6 MyD88 molecules (in cold colors), 4 IRAK-4 molecules (in 
earth-tone colors) and 4 IRAK-2 molecules (in warm colors), in a tower-shaped arrangement. The 
planar arrangement of the complex is also shown. 
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“lower” one [247] (see Figure 5.5b), similar to the layered structure of the oligomeric PIDD 
DD•RAIDD DD complex [264]. Similar to this second Fas•FADD DD complex, the recent 
structure of the MyD88•IRAK-4•IRAK-2 DD complex presented by Lin and co-workers reveals a 
tower-shaped structure composed of four layers [178] (see Figure 5.5d). In this arrangement, 6 
MyD88 DD molecules form the two bottom layers, 4 IRAK-4 DD molecules comprise the middle 
layer, and 4 IRAK-2 DD molecules form the top layer. However, the existence of two very 
different experimental structures of Fas•FADD DD complexes suggests that the molecule 
arrangement of MyD88 and IRAK-4 DD molecules proposed by Lin and co-workers is only one 
possible solution, and not necessarily the most relevant from a physiological point of view, in 
particular in cases of low cytosolic concentrations of MyD88 and/or IRAK kinases. In fact, our 
proposed arrangement of MyD88 and IRAK-4 DD modules is more similar to the crystal structure 
of the Fas•FADD DD complex proposed by Scott and co-workers, since only two MyD88·IRAK-
4 heterodimers are sufficient to allow cross-phosphorylation and activation of the kinase moieties 
of adaptor-bound IRAK-4 (see Figure 5.5c). This structure entails a much more simple 
arrangement of molecules, probably more suitable in the context of natural membrane association. 
Structural and functional investigations now in progress should refine this model and identify 
residues of both moieties involved in heterodimer formation, as well as in recruitment of the 
downstream kinase IRAK-1. 
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6.1 Conclusions 
 
1) The death domains (DDs) of the human adaptor, MyD88, and of the (pseudo)kinases 
IRAK-1, IRAK-4 and IRAK-M can be expressed as heterologous proteins in Escherichia 
coli. 
 
• Both DD-only variants and forms C-terminally extended by different lengths of the 
linkers to the TIR or (pseudo)kinase modules, respectively, were overexpressed at 
high yields and purified to homogeneity. 
 
2) Renaturation of urea-denatured inclusion bodies allows large quantities of recombinant 
DD variants of MyD88 and IRAK proteins to fold into their native-like conformations. 
 
• Only Glu-Xxx scissile peptide bonds within the irregular C-terminal tails of the 
linker-containing variants of MyD88 and IRAK proteins, but not those within their 
globular death domains, are susceptible to Glu-C cleavage. 
 
• Both the DD-only variant of the adaptor, MyD88(S), renatured form urea-solubilized 
inclusion bodies, and the linker-extended form MyD88(L) pull down natural, full-
length IRAK-4 from human monocyte extracts. 
 
3) The isolated death domains of MyD88 and IRAK proteins tend to form large aggregates 
in solution. 
 
• MyD88(S) has a stronger tendency for self-aggregation than the linker-containing 
variant of the adaptor, suggesting that the DD-TIR linker is important for adaptor 
solubility in the cell cytoplasm. 
 
• The linker-extended recombinant variants IRAK-1(L) and IRAK-M(L) have a 
stronger tendency for self-aggregation than the DD-only variants of the proteins, 
suggesting that the unstructured DD-(pseudo)kinase linkers are prone to aggregate 
formation per se. 
 
• The combined used of specific non-ionic detergents and low protein concentrations 
decreases formation of large aggregates between these DDs. 
 
4) Co-renaturation of MyD88 and IRAK recombinant death domains results in correct 
protein folding, and could be established as a novel method for complex formation. 
 
 Conclusions 
 
 
138 
 
5) The isolated death domains of MyD88 and IRAK-4 strongly interact with each other. 
 
• Both forms of recombinant MyD88 bind to the linker-extended variant of IRAK-4 
death domain. 
 
• Residues Glu110-Gln120, which include the C-terminal helix α7 of MyD88, but not the 
irregular DD-TIR linker, are required for IRAK-4 recruitment, which explains the 
inability of naturally-occurring truncated variant MyD88s (lacking residues Glu110-
Leu154) to recruit the kinase to the IL-1R complex. 
 
• Residues up to Lys115 in the DD–kinase linker of IRAK-4, and not beyond, are 
needed for strong interactions with the adaptor, and therefore IRAK-4(S) (residues 
Thr6-Lys107) does not form a stable complex with the adaptor. 
 
6) Our experimental results and the topological equivalence of MyD88-Pelle and IRAK-4–
Tube pairs suggest a possible MyD88•IRAK-4 complex in which the kinase tail residues 
are “clamped” between helix α7 and the main globular death domain of the adaptor in a 
similar manner as Tube binding to Pelle. 
 
• The MyD88•IRAK-4 heterodimer appears to combine elements from both RAIDD-
PIDD and Pelle-Tube type II interfaces. 
 
• We propose an arrangement of MyD88 and IRAK-4 DD modules in which only two 
MyD88•IRAK-4 heterodimers are sufficient to allow cross-phosphorylation and 
activation of the kinase moieties of adaptor-bound IRAK-4. 
 
7) IRAK-M is able to associate with MyD88 through interactions between their death 
domains. 
 
• Residues beyond Glu143 in the MyD88 DD-TIR linker, at least, are dispensable for 
IRAK-M recruitment by the adaptor. 
 
• The inhibitory role of IRAK-M on innate immune responses does not seem to result 
from competition with IRAK-4 for complex formation with MyD88, as IRAK-4 
residues in contact with MyD88 are not conserved in IRAK-M. 
 
• Rather, IRAK-M might exert its inhibitory role by stabilizing the MyD88-IRAK-1 
complex. 
  
6.2 Conclusiones 
 
1) Los dominios DD de la proteína adaptadora humana, MyD88, y de las (pseudo)quinasas 
IRAK-1, IRAK-4 e IRAK-M se pueden expresar como proteínas heterólogas en 
Escherichia coli. 
 
• Tanto las variantes compuestas únicamente por el dominio DD, como las formas 
extendidas en el extremo C-terminal por diferentes fragmentos del conector DD-TIR 
o DD-(pseudo)quinasa, respectivamente, se sobreexpresaron en grandes cantidades y 
se purificaron a homogeneidad. 
 
2) La renaturalización de los cuerpos de inclusión desnaturalizados con urea permite el 
plegamiento de grandes cantidades de las variantes recombinantes de MyD88 e IRAK 
DDs, en sus conformaciones nativas. 
 
• Sólo los enlaces peptídicos Glu-Xxx que se encuentran en los conectores irregulares 
C-terminales de las variantes extendidas de MyD88 e IRAK, pero no aquellos que se 
encuentran en sus dominios globulares, son susceptibles de ser hidrolizados por la 
proteinasa Glu-C. 
 
• Tanto la variante compuesta únicamente por el DD del adaptador, MyD88(S), 
renaturalizada a partir de cuerpos de inclusión solubilizados en urea, como la forma 
extendida por el conector, MyD88(L), reclutan la quinasa IRAK-4 natural de 
extractos de monocitos humanos. 
 
3) Los dominios globulares aislados de MyD88 y de las proteínas IRAK tienden a formar 
grandes agregados en disolución. 
 
• MyD88(S) tiene una mayor tendencia a la auto-agregación que la variante del 
adaptador extendida por el conector, lo que sugiere que el conector DD-TIR es 
importante para la solubilidad de MyD88 en el citoplasma celular. 
 
• Las variantes recombinantes IRAK-1(L) e IRAK-M (L), extendidas por el conector, 
tienen mayor tendencia a la auto-agregación que las variantes de estas proteínas que 
contienen únicamente el dominio DD, lo que sugiere que los conectores carentes de 
estructura secundaria DD-(pseudo)quinasa son propensos a la formación de 
agregados per se. 
 
• El uso combinado de detergentes no iónicos específicos y de bajas concentraciones de 
proteína, disminuye la formación de grandes agregados entre estos dominios DD. 
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4) La co-renaturalización de los dominios DD recombinantes de MyD88 y las proteínas 
IRAK  permite el plegamiento apropiado de las proteínas, y se ha podido establecer como 
un nuevo método para la formación de complejos. 
 
5) Los dominios DD aislados de MyD88 e IRAK-4 interaccionan fuertemente entre sí. 
 
• Las dos formas recombinantes de MyD88 se unen a la variante del dominio DD de 
IRAK-4 extendida por el conector. 
 
• Los residuos Glu110-Gln120, que incluyen la hélice C-terminal α7 de MyD88 pero no el 
conector irregular DD-TIR, son necesarios para el reclutamiento de IRAK-4, lo que 
explica la incapacidad de la variante natural truncada MyD88s (que carece de los 
residuos Glu110-Leu154) para reclutar la quinasa al complejo IL-1R 
 
• Los residuos hasta Lys115 en el conector DD-quinasa de IRAK-4, y no más allá, son 
necesarios para establecer interacciones fuertes con el adaptador y, por tanto, IRAK-
4(S) (residuos Thr6-Lys107) no forma un complejo estable con el adaptador 
 
6) Nuestros resultados experimentales y la equivalencia topológica de los pares MyD88-
Pelle e IRAK-4-Tube sugieren un posible complejo MyD88•IRAK-4, en el cual los 
residuos de la cola de la quinasa se insertan entre la hélice α7 y el dominio principal DD 
del adaptador, de manera similar a la unión de Tube con Pelle. 
 
• . El heterodímero MyD88•IRAK-4 parece combinar elementos de las superficies de 
contacto de tipo II de RAIDD-PIDD y de Pelle-Tube. 
 
• Proponemos una disposición de los dominios DD de MyD88 e IRAK-4 en la cual 
sólo dos heteodímeros MyD88•IRAK-4 son suficientes para permitir la fosforilación 
cruzada y activación de los dominios quinasa de la IRAK-4 unida al adaptador. 
 
7) IRAK-M es capaz de asociarse a MyD88 a través de interacciones entre sus dominios DD. 
 
• Los residuos más allá de Glu143 en el conector DD-TIR de MyD88, como mínimo, 
son dispensables para el reclutamiento de IRAK-M por el adaptador. 
 
• El papel inhibidor de IRAK-M en las respuestas inmunes innatas no parece deberse a 
la competición con IRAK-4 por la formación del complejo con MyD88, ya que los 
residuos de IRAK-4 en contacto con MyD88 no están conservados en IRAK-M. 
 
• En cambio, IRAK-M podría ejercer su papel inhibidor estabilizando el complejo 
MyD88-IRAK-1. 
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Appendix I 
Structure and Classification of Amino Acids 
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Appendix II 
Structure-Based Sequence Alignment of  Death Domains from MyD88 and IRAK-4 
Numberings on top of the alignments correspond to the human proteins. The inserted sequence in the α2-α3 
loop of Tube has been omitted for simplicity; the limits of this insertion are indicated by residues given in 
lower-case letters. The positions of major helices given below the sequences of Tube, Pelle and IRAK-4 
follow DSSP analysis of reported structures (PDB codes 1D2Z and 2A9I, respectively). Residues conserved 
in all DDs from MyD88 and IRAK-4 are white with red shading; also marked in Tube and Pelle. Similar 
residues in helix α7 from Pelle and MyD88 are white with blue shading. Other conservative substitutions are 
shaded in grey. The C-terminal end of death domain in truncated variant MyD88s is indicated. Relevant 
mutants in MyD88 are marked with arrows: replacement of Phe56 in the human cofactor to Asn (mutant 
MyD88-lpr) prevents adaptor dimerization, while mutation Tyr116→Cys in mouse MyD88 (mutant Lkd) 
results in reduced immune responses to various pathogen-associated ligands. Residues that engage in 
important intermolecular contacts in Tube and Pelle are bold and underlined. TETNG: Tetraodon 
nigroviridis. XENLA: Xenopus laevis. XENTR: Xenopus tropicalis. 
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Appendix III 
Putative protein-protein interaction sites in MyD88 death domain 
Interactions were predicted with PPI-Pred. Only the most probable binding site (left columns) and the second 
highest scoring patch (right columns) are given. The ten top-scoring residues in each region are shadowed. 
 
 
Residue Rank Secondary 
structure 
Predicted 
function Residue Rank 
Secondary 
structure 
Predicted 
function 
Thr41 20 α1-α2 
H 
O 
M 
O 
D 
I 
M 
E 
R 
I 
Z 
A 
T 
I 
O 
N 
Leu20 13 N-term 
I 
R 
A 
K 
4 
 
B 
I 
N 
D 
I 
N 
G 
Ala45 19 α1-α2 Pro21 10 N-term 
Asp46 18 α1-α2 Ala23 8 N-term 
Thr48 12 α2 Ala24 12 N-term 
Trp47 9 α2 Leu25 17 N-term 
Ala49 15 α2 Asn26 19 N-term 
Ala51 8 α2 Met27 16 α1 
Glu52 7 α2 Arg28 18 α1 
Glu53 14 α2 Val29 20 α1 
Asp55 6 α2-α3 Arg30 11 α1 
Phe56 4 α2-α3 Arg31 15 α1 
Glu57 3 α3 Arg73 3 α4 
Tyr58 1 α3 Leu74 4 α4 
Glu60 11 α3 Leu75 5 α4 
Ile61 2 α3 Asp76 2 α4 
Arg62 5 α3 Gln79 9 α4 
Glu65 10 α3 Gly80 6 α4 
Asp69 16 α3-α4 Arg81 1 α4 
Trp78 13 α4 Gly83 7 α4-α5 
Leu96 17 α5-α6 Ser108 14 α6-α7 
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Appendix IV 
Putative protein-protein interaction sites in IRAK-4 death domain 
Interactions were predicted with PPI-Pred. Only the most probable binding site (left columns) and the second 
highest scoring patch (right columns) are given. The ten top-scoring residues in each region are shadowed. 
 
 
Residue Rank Secondary 
structure 
Predicted 
function Residue Rank 
Secondary 
structure 
Predicted 
function 
Val11 10 N-term 
I 
R 
A 
K 
1 
 
B 
I 
N 
D 
I 
N 
G 
Lys21 2 α1 
M 
y 
D 
8 
8 
 
B 
I 
N 
D 
I 
N 
G 
Arg12 2 N-term Asp24 5 α1 
Cys13 1 N-term Phe25 6 α1 
Leu14 3 N-term Pro28 11 α1- α2 
Asn15 4 N-term Gln29 15 α1- α2 
Val16 6 α1 Gly31 16 α2 
Leu18 7 α1 Lys34 14 α2 
Ile19 11 α1 Asn91 10 α5- α6 
Arg20 12 α1 Glu92 9 α5- α6 
Ser68 15 α4 Phe93 13 α5- α6 
Glu69 16 α4 Phe94 8 α6 
Leu71 14 α4 Ala95 7 α6 
Phe72 9 α4 Pro96 12 α6 
Asp73 13 α4 Ser98 3 α6 
Thr76 5 α4 Leu99 1 α6 
Leu100 8 α6 Val105 4 DD-kinase 
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Appendix V 
pET-3a Restriction Map 
 
 
 
Novagen (www.merck-chemicals.com) 
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Appendix VI 
DNA Sequences of MyD88 and IRAK Recombinant Fragments 
All inserts cloned at the Nde I and BamH I sites of the T7 promoter region of the expression plasmid pET-3a 
 
Synthetic 
 gene DNA sequence (5’-3’) 
MyD88(S) 
catcaccaccatcaccacacctcttctctgccactggctgcactgaacatgcgtgtacgtcgtcgtctgtccctgttcctgaacgtacgta
cccaggttgctgcagactggactgcactggctgaagagatggacttcgaatacctggaaatccgtcagctcgaaactcaggcagatc
caactggtcgtctgctcgatgcatggcagggtcgtccaggtgcatctgttggtcgtctgctcgaactgctcaccaaactgggtcgtgac
gatgtgctcctggaactgggtccgtctatcgag 
MyD88(L) 
catcaccaccatcaccacacctcttctctgccactggctgcactgaacatgcgtgtacgtcgtcgtctgtccctgttcctgaacgtacgta
cccaggttgctgcagactggactgcactggctgaagagatggacttcgaatacctggaaatccgtcagctcgaaactcaggcagatc
caactggtcgtctgctcgatgcatggcagggtcgtccaggtgcatctgttggtcgtctgctcgaactgctcaccaaactgggtcgtgac
gatgtgctcctggaactgggtccgtctatcgaggaagactgccagaaatacatcctgaaacagcagcaggaagaagccgagaaacc
actgcaggttgcagctgttgacagctctgtaccacgtacggctgaactggctggtatcaccactctcgatgacccactgggtcacatg 
IRAK-1(S) 
catatgggcgcccagcacttcctgtacgaggttccaccgtgggtaatgtgccgtttctacaaagttatggacgcgctggaaccggctg
actggtgtcagtttgcagccctcatcgttcgcgatcagaccgaactgcgtctgtgcgaacgttctggtcagcgcactgcgtctgttctgt
ggccgtggatcaaccgcaacgctcgtgttgcagacctggtgcacatcctgacgcatctgcagctgctgcgtgctcgtgatatcatcac
cgcatggcatccgccggcgtaaggatcc 
IRAK-1(L) 
catatgggtgcgcagcacttcctctacgaagtaccaccgtgggttatgtgccgtttctacaaagtgatggacgccctggaaccggctga
ttggtgccagttcgcagcgctgatcgttcgcgaccagaccgaactgcgtctgtgcgaacgctctggtcagcgtaccgcgtctgtgctct
ggccgtggatcaaccgcaacgcgcgtgtcgccgatctggtgcacatcctgactcacctgcagctgctgcgtgctcgtgacatcatcac
cgcttggcatccgccggcaccactgccgtctccgggtactaccgctccacgtccgtccagcattccggctccggcagaagcggaag
cgtggtctccgcgtaaactgccgtcctctgcgagcactttcctgtctccggcatttccaggctctcagacccattctggtccggaactgg
gtctcgttccgtctccggcctctctgtggccgccgccaccatctccagctccgtccagcaccaaaccaggcccggagagctctgtaag
cctgctgcagggtgcacgtccgttcccgttttgctggccactgtgcgagatctctcgtggcacgcacaactaaggatcc 
IRAK-4(S) 
gactacaaagacgacgacgataaaggcactccgtctacctacgtacgttgcctgaacgtaggtctcatccgcaaactgagcgacttca
tcgacccacaggaaggttggaaaaaactggcagttgccatcaaaaaaccgtctggtgatgaccgttacaaccagttccacattcgtcg
tttcgaagctctgctgcagactggcaaatctccgacttctgagctcctgtttgactggggtaccacgaactgtaccgtaggtgatctggtt
gatctgctcatccagaacgagttctttgctccagcttctctcctgctgccagatgcagttccgaaa 
IRAK-4(L) 
gactacaaagacgacgacgataaaggcactccgtctacctacgtacgttgcctgaacgtaggtctcatccgcaaactgagcgacttca
tcgacccacaggaaggttggaaaaaactggcagttgccatcaaaaaaccgtctggtgatgaccgttacaaccagttccacattcgtcg
tttcgaagctctgctgcagactggcaaatctccgacttctgagctcctgtttgactggggtaccacgaactgtaccgtaggtgatctggtt
gatctgctcatccagaacgagttctttgctccagcttctctcctgctgccagatgcagttccgaaaactgcgaacactctgccgtctaaag
aggcgattactgtgcagcagaaacagatgccgttttgcgacaaagaccgtaccctgatgactccagttcagaacctcgaacagagcta
catgccaccggattcctcttctccagagaacaaaagcctggaagtatccgatacccgtttccactctttctccttctacgagctgaaaaac
gtcaccaacaacttcgatgaacgtccgatc 
IRAK-M (S) 
catatggaacagaaactgatcagcgaagaagatctgacgctgctgttcgatctcccaccagcgctgctgggcgaactgtgcgctgttc
tggacagctgtgatggtgcactgggttggcgtggtctggctgaacgtctgtcctcttcttggctcgacgtgcgtcatatcgagaaatacg
tcgatcagggcaaatccggtactcgtgagctgctctggtcttgggcgcagaaaaacaaaaccattggcgacctcctgcaggtactgca
ggaaatgggtcaccgtcgtgcaatccacctgatcaccaactatggtgccgttctgtaaggatcc 
IRAK-M 
(L) 
catatggaacagaactgatctccgaagaggatctgacgctgctctttgatctgccgccagctctgctgggtgaactgtgcgcagtactg
gactcttgtgatggtgcactcggttggcgtggtctggcagaacgtctgtcttctagctggctggatgtccgtcacatcgagaaatacgtt
gaccagggcaaaagcggtactcgtgaactgctgtggtcttgggcccagaaaaacaaaaccatcggtgacctgctccaggttctgcag
gaaatgggtcatcgtcgcgctatccacctgatcaccaactacggtgctgttctgtctccgtccgagaaatcctaccaggaaggtggtttc
ccgaacatcctcttcaaagaaaccgctaacgtgactgttgacaacgtgctgattccggaacacaacgagaaaggcgtactgctcaaat
cctctatcagcttccagaacatcattgaaggtacccgtaactaaggatcc 
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Appendix VII 
Buffers and Solutions 
All solutions prepared in distilled water, unless specified otherwise. 
Abbreviations: 
2-ME: 2-mercaptoethanol. EDTA: Ethylenediaminetetraacetic acid. PMSF: Phenyl-methyl sulphoxide. 
SDS: Sodium dodecyl sulfate. TEMED: Tetramethylethylenediamine. Tris: 2-Amino-2-(hydroxymethyl)propane-
1,3-diol. β-OG: n-octyl-β-D-glucopyranoside 
BACTERIAL CULTURE MEDIA 
LB (Luria Bertani) medium 
1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
pH 7.0 
SOB (Super Optimal broth) medium 
2% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
pH 7.0 
SOC (Super Optimal broth with Catabolite repression) medium 
20 mM Glucose in SOB medium 
LB/Agar 
1.5% (w/v) Agar in LB medium 
CELL CULTURE MEDIA 
PBS (Phosphate Buffered Saline) 
137 mM NaCl 
22.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4 
Cell Lysis Buffer 
10 mM Imidazole 
500 mM NaCl 
0.5% (v/v) Triton X-100 
0.2 mM Sodium orthovanadate 
0.2 mM PMSF 
2 mM Sodium azide 
pH 7.3 
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PROTEIN EXTRACTION 
B-PER solution 
10 mM MgCl2 
20 mM 2-ME 
1 mM EDTA 
200 mM NaCl 
10 mM Imidazole 
B-PER® reagent (Thermo Scientific) up to final volume 
Extraction buffer 
25 mM Sodium phosphate 
200 mM NaCl 
10 mM 2-ME 
500 µM EDTA 
0.5% (w/v) β-OG 
pH 7.8 
Ni-NTA PURIFICATION OF RECOMBINANT FRAGMENTS 
Binding buffer 
25 mM Sodium phosphate 
300 mM NaCl 
5 mM 2-ME 
0.5% β-OG 
pH 7.8 
Wash buffer 
25 mM Sodium phosphate 
300 mM NaCl 
5 mM 2-ME 
0.5% β-OG 
10 mM Imidazole 
pH 7.8 
Elution Buffer 
25 mM Sodium phosphate 
300 mM NaCl 
5 mM 2-ME 
0.5% β-OG 
500 mM Imidazole 
pH 7.8 
FPLC PURIFICATION OF RECOMBINANT FRAGMENTS 
Gel filtration buffer 
20 mM Tris pH 7.4 
100 mM NaCl 
0.1% β-OG 
 Appendix VII 
 
 
157 
 
GEL ELECTROPHORESIS UNDER DENATURING CONDITIONS 
Sample buffer 
50 mM Tris-Cl 
2% (w/v) SDS 
10% (v/v) Glycerol 
0.01 % (v/v) Bromophenol blue 
pH 6.8 
Reducing sample buffer 
50 mM Tris-Cl 
2% (w/v) SDS 
10% (v/v) Glycerol 
200 mM DTT 
0.01 % (v/v) Bromophenol blue 
pH 6.8 
Tris-tricine gels: 
Separating 
12% (v/v) Bis-acrylamide 
1 M Tris 
0.1% (w/v) SDS 
10% (v/v) Glycerol 
0.15% (w/v) Ammonium persulfate 
0.047% (v/v) TEMED 
pH 8.45 
Stacking 
4.5% (v/v) Bis-acrylamide 
0.75 M Tris 
0.07% SDS 
0.06% (w/v) Ammonium persulfate 
0.12% (v/v) TEMED 
pH 8.45 
Cathode buffer 
0.1 M Tris 
0.1 M Tricine 
0.1% (w/v) SDS 
Anode buffer 
0.2 M Tris-Cl 
pH 8.9 
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Tris-glycine gels: 
Separating 
12 % (w/v) Bis-acrylamide 
0.375 M Tris 
0.2% (w/v) SDS 
0.05% (w/v) Ammonium persulfate 
0.05% (v/v) TEMED 
pH 8.8 
Stacking 
9.36 % Bis-acrylamide 
0.2 M Tris 
0.16 % (w/v) SDS 
0.04% (w/v) Ammonium persulfate 
0.08% (v/v) TEMED 
pH 7.0 
Running buffer 
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
GEL ELECTROPHORESIS UNDER NATIVE CONDITIONS 
Native sample buffer 
50 mM Tris-Cl 
10% (v/v) Glycerol 
0.01% (v/v) Bromophenol blue  
pH 6.8 
Separating 
11% Bis-acrylamide 
0.5 M Tris 
0.022% (w/v) Ammonium persulfate 
0.055% TEMED 
pH 8.8 
Stacking 
4.5% (v/v) Bis-acrylamide 
375 mM Tris 
0.06% (w/v) Ammonium persulfate 
0.12% (v/v) TEMED 
pH 8.8 
Running buffer 
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
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PROTEIN GEL STAINING 
Coomassie Blue Staining: 
Coomassie stain solution 
10% (v/v) Acetic acid 
50% (v/v) Methanol 
0.25% (w/v) Coomassie dye R-250 
Destaining solution I 
10% (v/v) Acetic acid 
50% (v/v) Methanol 
Destaining solution II 
10% (v/v) Acetic acid 
7% (v/v) Methanol 
Silver staining: 
Fixative solution 
30% (v/v) Ethanol 
10% (v/v) Acetic acid 
Silver staining solution 
0.2% (w/v) Silver nitrate 
0.02% (v/v) Formaldehyde 
Developer solution 
6% (w/v) Sodium carbonate 
0.05 % (v/v) Formaldehyde 
0.0004% (w/v) Sodium thiosulfate 
WESTERN BLOT 
Transfer buffer 
0.05 M Tris 
0.4 M Glycine 
0.5% SDS 
20% Methanol 
Blocking solution 
5% (w/v) Non-fat dry milk in TBS 
TBS (Tris-buffered saline) 
10 mM Tris 
100 mM NaCl 
pH 7.0 
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SURFACE PLASMON RESONANCE 
SPR running buffer 
25 mM Sodium phosphate 
200 mM NaCl 
0.0005% (v/v) Surfactant P20  
50 µM EDTA 
pH 7.8 
ANALYTICAL ULTRACENTRIFUGATION 
Buffer 1 
25 mM Sodium phosphate 
300 mM NaCl 
0.5% β-OG 
1 M Imidazole 
pH 7.8 
Buffer 2 
25 mM Sodium phosphate 
300 mM NaCl 
5 mM 2-ME 
0.5% β-0G 
500 mM Imidazole 
pH 7.8 
Buffer 3 
20 mM Tris 
1 M NaCl 
pH 8.0 
Buffer 4 
9.69 mM Sodium phosphate 
12.248 mM Tris pH 8.0 
728.68 mM NaCl 
0.1938% β-OG 
387.6 mM Imidazole 
pH 7.8 
Buffer 5 
25 mM Sodium phosphate 
264 mM NaCl 
11 mM KCl 
2.2 mM MgCl2 
2.2 mM CaCl2 
440 mM Sucrose 
pH 7.0
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Appendix VIII 
FoldIt Screen 
Abbreviations: 
DTT: Dithiothreitol. EDTA: Ethylenediaminetetraacetic acid. GSH: Reduced glutathione. GSSG: 
Oxidized glutathione. MES: 2-(N-morpholino)ethanesulfonic acid. PEG3350: Polyethylene glycol 
(molecular weight: 3350 Da). Tris: 2-Amino-2-(hydroxymethyl)propane-1,3-diol. 
 
Formulations 
FoldIt 
# Buffer Salt 
PEG3350 
(% w/v) 
Guanidine 
HCl Cation/ Chelator 
Polar & Nonpolar 
Additives 
1 55 mM Tris pH 8.2 264 mM NaCl,  11 mM KCl 0.055% 0 mM 1.1 mM EDTA none 
2 55 mM MES pH 6.5 10.56 mM NaCl, 0.44 mM KCl none 550 mM 2.2 mM MgCl2, 2.2 mM CaCl2 none 
3 55 mM MES pH 6.5 10.56 mM NaCl, 0.44 mM KCl 0.055% 550 mM 1.1 mM EDTA 440 mM Sucrose 550 mM L-Arginine 
4 55 mM Tris pH 8.2 264 mM NaCl,  11 mM KCl none 0 mM 2.2 mM MgCl2, 2.2 mM CaCl2 
440 mM Sucrose 
550 mM L-Arginine 
5 55 mM MES pH 6.5 264 mM NaCl,  11 mM KCl none 0 mM 2.2 mM MgCl2, 2.2 mM CaCl2 440 mM Sucrose 
6 55 mM Tris pH 8.2 10.56 mM NaCl, 0.44 mM KCl 0.055% 550 mM 1.1 mM EDTA 440 mM Sucrose 
7 55 mM Tris pH 8.2 10.56 mM NaCl, 0.44 mM KCl none 550 mM 2.2 mM MgCl2, 2.2 mM CaCl2 550 mM L-Arginine 
8 55 mM MES pH 6.5 264 mM NaCl,  11 mM KCl 0.055% 0 mM 1.1 mM EDTA 550 mM L-Arginine 
9 55 mM MES pH 6.5 264 mM NaCl,  11 mM KCl 0.055% 550 mM 2.2 mM MgCl2, 2.2 mM CaCl2 440 mM Sucrose 
10 55 mM Tris pH 8.2 10.56 mM NaCl, 0.44 mM KCl none 0 mM 1.1 mM EDTA 440 mM Sucrose 
11 55 mM Tris pH 8.2 10.56 mM NaCl, 0.44 mM KCl 0.055% 0 mM 2.2 mM MgCl2, 2.2 mM CaCl2 550 mM L-Arginine 
12 55 mM MES pH 6.5 264 mM NaCl,  11 mM KCl none 550 mM 1.1 mM EDTA 550 mM L-Arginine 
13 55 mM Tris pH 8.2 264 mM NaCl,  11 mM KCl none 550 mM 1.1 mM EDTA none 
14 55 mM MES pH 6.5 10.56 mM NaCl, 0.44 mM KCl 0.055% 0 mM 2.2 mM MgCl2, 2.2 mM CaCl2 none 
15 55 mM MES pH 6.5 10.56 mM NaCl, 0.44 mM KCl none 0 mM 1.1 mM EDTA 440 mM Sucrose 550 mM L-Arginine 
16 55 mM Tris pH 8.2 264 mM NaCl,  11 mM KCl 0.055% 550 mM 2.2 mM MgCl2, 2.2 mM CaCl2 
440 mM Sucrose 
550 mM L-Arginine 
FoldIt Additions - Pipetting and Dilution Table for FoldIt 
FoldIt 
# 
FoldIt 
Volume 0.1 M DTT 
30 mM Lauryl 
Maltoside 100 mM GSH 
10 mM 
GSSG Ligand Protein 
1 950 µl 10 µl - - - up to 10 mM ~50 µL 
2 950 µl - 10 µl 10 µl 10 µl - ~50 µL 
3 950 µl - - 10 µl 10 µl up to 10 mM ~50 µL 
4 950 µl 10 µl 10 µl - - - ~50 µL 
5 950 µl - - 10 µl 10 µl up to 10 mM ~50 µL 
6 950 µl 10 µl 10 µl - - - ~50 µL 
7 950 µl 10 µl - - - up to 10 mM ~50 µL 
8 950 µl - 10 µl 10 µl 10 µl - ~50 µL 
9 950 µl 10 µl - - - - ~50 µL 
10 950 µl - 10 µl 10 µl 10 µl up to 10 mM ~50 µL 
11 950 µl - - 10 µl 10 µl - ~50 µL 
12 950 µl 10 µl 10 µl - - up to 10 mM ~50 µL 
13 950 µl - - 10 µl 10 µl - ~50 µL 
14 950 µl 10 µl 10 µl - - up to 10 mM ~50 µL 
15 950 µl 110 µl - - - - ~50 µL 
16 950 µl - 10 µl 10 µl 10 µl up to 10 mM ~50 µL 
(modified from the work of N. Armstrong and co-workers [214]) 
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Appendix IX 
Detergent Screen 1 Formulation (Hampton Research) 
Abbreviations: 
CMC, Critical micelle concentration. MW, Molecular Weight in Da. 
 
Reagent # Detergent Description MW (Da) CMC (mM) 
1 C12E9 nonaethylene glycol monododecyl ether ~583 0.05 
2 C12E8 octaethylene glycol monododecyl ether 538.8 0.11 
3 n-Dodecyl-β-D-maltoside dodecyl-β-D-maltopyranoside 510.6 0.17 
4 Sucrose monolaurate lauric acid sucrose ester 524.6 0.30 
5 CYMAL-6 cyclohexyl-hexyl-β-D-maltoside 508.5 0.56 
6 TRITON X-100 nonaethylene glycol octylphenol ether 650 0.90 
7 CTAB cethyltrimethylammonium bromide 364.46 1.00 
8 Deoxy BigChap N,N-bis-(3-D-glucoamidopropyl)- deoxycholamine 862.1 1.40 
9 n-Decyl-β-D-maltoside decyl-β D-maltopiranoside 482.6 1.80 
10 LDAO lauryldimethylamine oxide 229.41 2.0 
11 CYMAL-5 cyclohexyl-pentyl-β-D-maltoside 494.5 5.0 
12 ZWITTERGENT® 3-12 3- (dodecyldimethylammonio)propane-1-
sulfonate 335.6 4.0 
13 Nonyl-β-D-glucoside β-D-glucopyranoside 306.4 6.50 
14 1-s-Octyl-β-D-
thioglucoside octyl-β-Dthioglucopyranoside / OSG 308.4 9.00 
15 DDAO N,N-dimethyldecylamine-β-oxide 201.35 10.40 
16 HECAMEG methyl-6-O-(N-heptylcarbamoyl)-α-D-glucopyranoside 335.4 19.50 
17 n-Ocytanylsucrose n-octanoyl-β-D-fructofuranosyl-α-D-glucopyranoside 468.5 24.40 
18 n-Heptyl-β-D-thioglucoside n-heptyl-β-D-thioglucopyranoside 294.4 30 
19 n-Octyl-β-D-glucoside octyl-β-D-glucopyranoside / BOG 292.4 20 
20 CYMAL-3 cyclohexyl-propyl-β-D-maltoside 466.5 34.5 
21 CHEGA- 10 cyclohexylbutanoyl-N-hydroxyethylglucamide 377.5 35 
22 ZWITTERGENT® 3-10 3-(decyldimethylammonio)propane-1-
sulfonate 307.5 40 
23 MEGA-8 (octanoyl-N-methylglucamide 321.4 79 
24 n-Hexyl-β-D-glucoside hexyl-β-D-glucopyranoside 264.3 250 
Hampton Research Corp. (www.hamptonresearch.com) 
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Appendix X 
Crystallization Conditions 
Abbreviations: 
Alcohols: 1,6-Hexanediol; 1-Butanol; 1,2-Propanediol (racemic); 2-Propanol; 1,4-Butanediol; 1,3-
Propanediol. Ethylene glycols, Diethileneglycol; Triethyleneglycol; Tetraethyleneglycol; 
Pentaethyleneglycol. Monosaccharides, D-Glucose; D-Mannose; D-Galactose; L-Fructose; D-Xylose; N-
acetyl-D-glucosamine. Amino acids: L-Na-glutamate; Alanine (racemic); Glycine; Lysine HCl (racemic); 
Serine (racemic). Bicine: N,N-Bis(2-hydroxyethyl)glycine. Buffer 1 (1.0 M, pH 6.5): Imidazole; Sodium 
cacodylate; MES (acid); Bis-Tris. Buffer 2 (1.0 M, pH 7.5): Sodium HEPES; MOPS (acid). Buffer 3 (1.0 
M, pH 8.5): Tris (base); Bicine. Carboxylic acids: Na-formate; NH4-acetate; Na3-Citrate; NaK-Tartrate 
(racemic); Na-oxamate. CTAB: Cetyltrimethylammonium bromide. Divalents: MgCl2; CaCl2. EDO_P8K 
(60 %): Ethylene glycol; PEG 8K. GOL_P4K (60%), Glycerol; PEG 4K. Halogens: NaF; NaBr; NaI. 
HEPES: 2-(4-(2-Hydroxyethyl)-1-piperazinyl)ethanesulfonic Acid. MES: 2-(N-morpholino)ethanesulfonic 
acid. MME: Monomethylether. MOPS: 3-(N-Morpholino)-propanesulfonic acid. MPD: 2,4-Methyl 
pentanediol. MPD_P1K_P3350 (75%), MPD (racemic); PEG 1K; PEG 3350. NPS (Nitrate Phosphate 
Sulfate): NaN03; Na2HPO4; (NH4)2SO4. P550MME_P20K (60%): PEGMME 550; PEG 20K. PEG: 
Polyethylene glycol (molecular weight in Da. 1.5K, 4K and 8K, in KDa). Tris: 2-Amino-2-
(hydroxymethyl)propane-1,3-diol. β-OG: n-octyl-β-D-glucopyranoside 
 
 
 
PROTEIN SOLUTIONS 
Buffer Formulation pH 
Tris-based buffer 
20 mM Tris 
100 mM NaCl 
0.1% β-OG 
7.4 
HEPES-based buffer 
10 mM HEPES 
100 mM NaCl 
0.1% β-OG 
0.1 mM DTT 
7.2 
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STRUCTURE SCREEN 1 (MOLECULAR DIMENSIONS) 
Tube # Salt Buffer pH Precipitant 
1 0.02 M Calcium chloride 0.1 M Sodium acetate 4.6 30 % v/v MPD 
2 0.2 M Ammonium acetate 0.1 M Sodium acetate 4.6 30 % w/v PEG 4K 
3 0.2 M Ammonium sulfate 0.1 M Sodium acetate 4.6 25 % w/v PEG 4K 
4 None 0.1 M Sodium acetate 4.6 2.0 M Sodium formate 
5 None 0.1 M Sodium acetate 4.6 2.0 M Ammonium sulfate 
6 None 0.1 M Sodium acetate 4.6 8 % w/v PEG 4K 
7 0.2 M Ammonium acetate 0.1 M Tri-sodium citrate 5.6 30 % w/v PEG 4K 
8 0.2 M Ammonium acetate 0.1 M Tri-sodium citrate 5.6 30 % v/v MPD 
9 None 0.1 M Tri-sodium citrate 5.6 20 % v/v 2-Propanol, 20% w/v PEG 4K 
10 None 0.1 M Tri-sodium citrate 5.6 1.0 M Ammonium dihydrogen phosphate 
11 0.2 M Calcium chloride 0.1 M Sodium acetate 4.6 20 % v/v 2-Propanol 
12 None 0.1 M Sodium cacodylate 6.5 1.4 M Sodium acetate 
13 0.2 M Tri-sodium citrate 0.1 M Sodium cacodylate 6.5 30 % v/v 2-Propanol 
14 0.2 M Ammonium sulfate 0.1 M Sodium cacodylate 6.5 30 % w/v PEG 8K 
15 0.2 M Magnesium acetate 0.1 M Sodium cacodylate 6.5 20 % w/v PEG 8K 
16 0.2 M Magnesium acetate 0.1 M Sodium cacodylate 6.5 30 % v/v MPD 
17 None 0.1 M Imidazole 6.5 1.0 M Sodium acetate 
18 0.2 M Sodium acetate 0.1 M Sodium cacodylate 6.5 30 % w/v PEG 8K 
19 0.2 M Zinc acetate 0.1 M Sodium cacodylate 6.5 18 % w/v PEG 8K 
20 0.2 M Calcium acetate 0.1 M Sodium cacodylate 6.5 18 % w/v PEG 8K 
21 0.2 M Tri-sodium citrate 0.1 M Na HEPES 7.5 30 % v/v MPD 
22 0.2 M Magnesium chloride 0.1 M Na HEPES 7.5 30 % v/ v 2-Propanol 
23 0.2 M Calcium chloride 0.1 M Na HEPES 7.5 28 % v/v PEG 400 
24 0.2 M Magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
25 0.2 M Tri-sodium citrate 0.1 M Na HEPES 7.5 20 % v/v 2-Propanol 
26 None 0.1 M Na HEPES 7.5 0.8 M K/Na tartrate 
27 None 0.1 M Na HEPES 7.5 1.5 M Lithium sulfate 
28 None 0.1 M Na HEPES 7.5 0.8 M Na dihydrogen phosphate/ 0.8 M K dihydrogen phosphate 
29 None 0.1 M Na HEPES 7.5 1.4 M Tri-sodium citrate 
30 None 0.1 M Na HEPES 7.5 2 % v/v PEG 400, 2.0 M Ammonium 
sulfate 
31 None 0.1 M Na HEPES 7.5 10 % v/v 2-Propanol, 20% w/v PEG 4K 
32 None 0.1 M Tris 8.5 2.0 M Ammonium sulfate 
33 0.2 M Magnesium chloride 0.1 M Tris 8.5 30 % w/v PEG 4K 
34 0.2 M Tri-sodium citrate 0.1 M Tris 8.5 30 % v/v PEG 400 
35 0.2 M Lithium sulfate 0.1 M Tris 8.5 30 % w/v PEG 4K 
36 0.2 M Ammonium acetate 0.1 M Tris 8.5 30 % v/v 2-Propanol 
37 0.2 M Sodium acetate 0.1 M Tris 8.5 30 % w/v PEG 4K 
38 None 0.1 M Tris 8.5 8 % w/v PEG 8K 
39 None 0.1 M Tris 8.5 2.0 M Ammonium dihydrogen phosphate 
40 None None - 0.4 M K/Na Tartrate 
41 None None - 0.4 M Ammonium dihydrogen phosphate 
42 0.2 M Ammonium sulfate None - 30 % w/v PEG 8K 
43 0.2 M Ammonium sulfate None - 30 % w/v PEG 4K 
44 None None - 2.0 M Ammonium sulfate 
45 None None - 4.0 M Sodium formate 
46 0.05 M Potassium dihydrogen phosphate None - 20 % w/v PEG 8K 
47 None None - 30 % w/v PEG 1.5K 
48 None None - 0.2 M Magnesium formate 
49 1.0 M Lithium sulfate None - 2 % w/v PEG 8K 
50 0.5 M Lithium sulfate None - 15 % w/v PEG 8K 
Molecular Dimensions (www.moleculardimensions.com) 
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Molecular Dimensions (www.moleculardimensions.com) 
 
 
STRUCTURE SCREEN 2 (MOLECULAR DIMENSIONS) 
Tube # Salt Buffer pH Precipitant 
1 0.1 M Sodium chloride 0.1 M Bicine 9.0 30 % v/v PEG 550 MME 
2 None 0.1 M Bicine 9.0 2.0 M Magnesium chloride 
3 None 0.1 M Bicine 9.0 2 % v/v 1,4-Dioxane/10 % w/v PEG 20,000 
4 0.2 M Magnesium chloride 0.1 M Tris 8.5 3.4 M 1,6-Hexanediol 
5 None 0.1 M Tris 8.5 25 % v/v Tert-butanol 
6 0.01 M Nickel chloride 0.1 M Tris 8.5 1.0 M Lithium sulfate 
7 1.5 M Ammonium sulfate 0.1 M Tris 8.5 12 % v/v Glycerol 
8 0.2 M Ammonium dihydrogen phosphate 0.1 M Tris 8.5 50 % v/v MPD 
9 None 0.1 M Tris 8.5 20 % v/v Ethanol 
10 0.01 M Nickel chloride 0.1 M Tris 8.5 20 % w/v PEG 2000 MME 
11 0.5 M Ammonium sulfate 0.1 M Na HEPES 7.5 30 % v/v MPD 
12 None 0.1 M Na HEPES 7.5 10 % w/v PEG 6000, 5% v/v MPD 
13 None 0.1 M Na HEPES 7.5 20 % v/v Jeffamine M-600 
14 0.1 M Sodium chloride 0.1 M Na HEPES 7.5 1.6 M Ammonium sulfate 
15 None 0.1 M Na HEPES 7.5 2.0 M Ammonium formate 
16 0.05 M Cadmium sulfate 0.1 M Na HEPES 7.5 1.0 M Sodium acetate 
17 None 0.1 M Na HEPES 7.5 70 % v/v MPD 
18 None 0.1 M Na HEPES 7.5 4.3 M NaCl 
19 None 0.1 M Na HEPES 7.5 10 % w/v PEG 8000, 8 % v/v Ethylene glycol 
20 None 0.1 M MES 6.5 1.6 M Magnesium sulfate 
21 0.1 M Potassium phosphate 
+ 0.1 M Sodium phosphate 0.1 M MES 6.5 2.0 M NaCl 
22 None 0.1 M MES 6.5 12 % w/v PEG 20,000 
23 1.6 M Ammonium sulfate 0.1 M MES 6.5 10 % v/v Dioxane 
24 0.05 M Caesium chloride 0.1 M MES 6.5 30 % v/v Jeffamine M-600 
25 0.01 M Cobalt chloride 0.1 M MES 6.5 1.8 M Ammonium sulfate 
26 0.2 M Ammonium sulfate 0.1 M MES 6.5 30 % w/v PEG 5000 MME 
27 0.01 M Zinc sulfate 0.1 M MES 6.5 25 % v/v PEG 550 MME 
28 None 0.1 M Na HEPES 7.5 20 % w/v PEG 10,000 
29 0.2 M Potassium sodium tartrate 0.1 M Na citrate 5.6 2.0 M Ammonium sulfate 
30 0.5 M Ammonium sulfate 0.1 M Na citrate 5.6 1.0 M Lithium sulfate 
31 0.5 M Sodium chloride 0.1 M Na citrate 5.6 4 % v/v Polyethyleneimine 
32 None 0.1 M Na citrate 5.6 35 % v/v Tert-butanol 
33 0.01 M Ferric chloride 0.1 M Na citrate 5.6 10 % v/v Jeffamine M-600 
34 0.01 M Manganese chloride 0.1 M Na citrate 5.6 2.5 M 1,6-Hexanediol 
35 None 0.1 M Na acetate 4.6 2.0 M NaCl 
36 0.2 M Sodium chloride 0.1 M Na acetate 4.6 30 % v/v MPD 
37 0.01 M Cobalt chloride 0.1 M Na acetate 4.6 1.0 M 1,6-cl 
38 0.1 M Cadmium chloride 0.1 M Na acetate 4.6 30 % v/v PEG 400 
39 0.2 M Ammonium sulfate 0.1 M Na acetate 4.6 30 % w/v PEG 2000 MME 
40 2.0 M Sodium chloride None None 10 % w/v PEG 6000 
41 0.01 M CTAB None None 0.5 M NaCl, 0.1 M MgCl2 
42 None None None 25 % v/v Ethylene glycol 
43 None None None 35 % v/v Dioxane 
44 2.0 M Ammonium sulfate None None 5 % v/v 2-Propanol 
45 None None None 1.0 M Imidazole pH 7.0 
46 None None None 10 % w/v PEG 1000, 10 % w/v PEG 8000 
47 1.5 M Sodium chloride None None 10 % v/v Ethanol 
48 None None None 1.6 M Sodium citrate pH 6.5 
49 15 % w/v Polyvinylpyrolidone None None None 
50 2.0 M Urea None None None 
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MORPHEUSTM BOX 1 (MOLECULAR DIMENSIONS) 
Tube # Ligand Buffer pH Precipitant 
1 0.06 M Divalents 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
2 0.06 M Divalents 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
3 0.06 M Divalents 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
4 0.06 M Divalents 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
5 0.06 M Divalents 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
6 0.06 M Divalents 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
7 0.06 M Divalents 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
8 0.06 M Divalents 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
9 0.06 M Divalents 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
10 0.06 M Divalents 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
11 0.06 M Divalents 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
12 0.06 M Divalents 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
13 0.09 M Halogens 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
14 0.09 M Halogens 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
15 0.09 M Halogens 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
16 0.09 M Halogens 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
17 0.09 M Halogens 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
18 0.09 M Halogens 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
19 0.09 M Halogens 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
20 0.09 M Halogens 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
21 0.09 M Halogens 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
22 0.09 M Halogens 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
23 0.09 M Halogens 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
24 0.09 M Halogens 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
25 0.09 M NPS 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
26 0.09 M NPS 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
27 0.09 M NPS 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
28 0.09 M NPS 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
29 0.09 M NPS 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
30 0.09 M NPS 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
31 0.09 M NPS 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
32 0.09 M NPS 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
33 0.09 M NPS 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
34 0.09 M NPS 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
35 0.09 M NPS 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
36 0.09 M NPS 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
37 0.12 M Alcohols 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
38 0.12 M Alcohols 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
39 0.12 M Alcohols 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
40 0.12 M Alcohols 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
41 0.12 M Alcohols 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
42 0.12 M Alcohols 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
43 0.12 M Alcohols 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
44 0.12 M Alcohols 0.1 M Buffer 2 7.5 37.5 % MPD_P1K_P3350 
45 0.12 M Alcohols 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
46 0.12 M Alcohols 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
47 0.12 M Alcohols 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
48 0.12 M Alcohols 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
Molecular Dimensions (www.moleculardimensions.com) 
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MORPHEUSTM BOX 2 (MOLECULAR DIMENSIONS) 
Tube # Ligand Buffer pH Precipitant 
1 0.12 M Ethylene Glycols 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
2 0.12 M Ethylene Glycols 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
3 0.12 M Ethylene Glycols 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
4 0.12 M Ethylene Glycols 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
5 0.12 M Ethylene Glycols 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
6 0.12 M Ethylene Glycols 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
7 0.12 M Ethylene Glycols 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
8 0.12 M Ethylene Glycols 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
9 0.12 M Ethylene Glycols 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
10 0.12 M Ethylene Glycols 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
11 0.12 M Ethylene Glycols 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
12 0.12 M Ethylene Glycols 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
13 0.12 M Monosaccharides 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
14 0.12 M Monosaccharides 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
15 0.12 M Monosaccharides 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
16 0.12 M Monosaccharides 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
17 0.12 M Monosaccharides 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
18 0.12 M Monosaccharides 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
19 0.12 M Monosaccharides 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
20 0.12 M Monosaccharides 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
21 0.12 M Monosaccharides 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
22 0.12 M Monosaccharides 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
23 0.12 M Monosaccharides 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
24 0.12 M Monosaccharides 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
25 0.10 M Carboxylic acids 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
26 0.10 M Carboxylic acids 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
27 0.10 M Carboxylic acids 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
28 0.10 M Carboxylic acids 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
29 0.10 M Carboxylic acids 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
30 0.10 M Carboxylic acids 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
31 0.10 M Carboxylic acids 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
32 0.10 M Carboxylic acids 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
33 0.10 M Carboxylic acids 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
34 0.10 M Carboxylic acids 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
35 0.10 M Carboxylic acids 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
36 0.10 M Carboxylic acids 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
37 0.10 M Amino acids 0.1 M Buffer 1 6.5 30.0% P550MME_P20K 
38 0.10 M Amino acids 0.1 M Buffer 1 6.5 30.0% EDO_P8K 
39 0.10 M Amino acids 0.1 M Buffer 1 6.5 30.0% GOL_P4K 
40 0.10 M Amino acids 0.1 M Buffer 1 6.5 37.5% MPD_P1K_P3350 
41 0.10 M Amino acids 0.1 M Buffer 2 7.5 30.0% P550MME_P20K 
42 0.10 M Amino acids 0.1 M Buffer 2 7.5 30.0% EDO_P8K 
43 0.10 M Amino acids 0.1 M Buffer 2 7.5 30.0% GOL_P4K 
44 0.10 M Amino acids 0.1 M Buffer 2 7.5 37.5% MPD_P1K_P3350 
45 0.10 M Amino acids 0.1 M Buffer 3 8.5 30.0% P550MME_P20K 
46 0.10 M Amino acids 0.1 M Buffer 3 8.5 30.0% EDO_P8K 
47 0.10 M Amino acids 0.1 M Buffer 3 8.5 30.0% GOL_P4K 
48 0.10 M Amino acids 0.1 M Buffer 3 8.5 37.5% MPD_P1K_P3350 
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PROPLEX BOX 1 (MOLECULAR DIMENSIONS) 
Tube # Salt Buffer pH Precipitant 
1 None 0.1 M Tris 8.0 25% v/v PEG 350 MME 
2 0.1 M Calcium acetate 0.1 M MES 6.0 15% v/v PEG 400 
3 0.1 M Lithium chloride 0.1 M Na HEPES 7.5 20% v/v PEG 400 
4 None 0.1 M Tris 8.0 25% v/v PEG 400 
5 None 0.1 M MES 6.5 15% v/v PEG 550 MME 
6 0.2 M Sodium chloride 0.1 M Na/K phosphate 6.5 25% w/v PEG 1000 
7 0.1 M Ammonium sulfate 0.1 M Tris 7.5 20% w/v PEG 1500 
8 0.2 M Ammonium sulfate 0.1 M Sodium acetate 5.5 10% w/v PEG 2000 MME 
9 0.2 M Sodium chloride 0.1 M MES 6.0 20% w/v PEG 2000 MME 
10 0.1 M Potassium chloride 0.1 M Tris 8.0 15% w/v PEG 2000 MME 
11 None 0.1 M Na HEPES 7.5 25% w/v PEG 2000 MME 
12 0.2 M Sodium acetate 0.1 M Sodium citrate 5.5 5% w/v PEG 4000 
13 0.2 M Lithium sulfate 0.1 M Tris 7.5 5% w/v PEG 4000 
14 0.1 M Calcium acetate 0.1 M Sodium acetate 4.5 10% w/v PEG 4000 
15 0.2 M Sodium acetate 0.1 M Sodium citrate 5.5 10% w/v PEG 4000 
16 0.2 M Sodium chloride 0.1 M MES 6.5 10% w/v PEG 4000 
17 0.1 M Magnesium chloride 0.1 M Na HEPES 7.5 10% w/v PEG 4000 
18 None 0.1 M Na HEPES 7.0 10% w/v PEG 4000/10% v/v 2-Propanol 
19 0.2 M Ammonium acetate 0.1 M Sodium acetate 4.0 15% w/v PEG 4000 
20 0.1 M Magnesium chloride 0.1 M Sodium citrate 5.0 15% w/v PEG 4000 
21 None 0.1 M Sodium cacodylate 6.0 15% w/v PEG 4000 
22 0.15 M Ammonium sulfate 0.1 M MES 6.0 15% w/v PEG 4000 
23 None 0.1 M Na HEPES 7.0 15% w/v PEG 4000 
24 0.1 M Magnesium chloride 0.1 M Na HEPES 7.0 15% w/v PEG 4000 
25 0.15 M Ammonium sulfate 0.1 M Tris 8.0 15% w/v PEG 4000 
26 None 0.1 M Sodium citrate 4.5 20% w/v PEG 4000 
27 0.2 M Ammonium acetate 0.1 M Sodium acetate 5.0 20% w/v PEG 4000 
28 0.2 M Lithium sulfate 0.1 M MES 6.0 20% w/v PEG 4000 
29 None 0.1 M Tris 8.0 20% w/v PEG 4000 
30 0.15 M Ammonium sulfate 0.1 M Na HEPES 7.0 20% w/v PEG 4000 
31 None 0.1 M Sodium citrate 5.6 20% w/v PEG 4000/20% v/v 2-Propanol 
32 0.2 M Sodium chloride 0.1 M Tris 8.0 20% w/v PEG 4000 
33 None 0.1 M Sodium cacodylate 5.5 25% w/v PEG 4000 
34 0.15 M Ammonium sulfate 0.1 M MES 5.5 25% w/v PEG 4000 
35 None 0.1 M Sodium cacodylate 6.5 25% w/v PEG 4000 
36 0.2 M Potassium iodide 0.1 M MES 6.5 25% w/v PEG 4000 
37 0.2 M Sodium chloride 0.1 M Na HEPES 7.5 25% w/v PEG 4000 
38 None 0.1 M MES 6.5 10% w/v PEG 5000 MME/12% v/v 1-Propanol 
39 0.1 M Potassium chloride 0.1 M Na HEPES 7.0 15% w/v PEG 5000 MME 
40 0.2 M Ammonium sulfate 0.1 M Tris 7.5 20% w/v PEG 5000 MME 
41 0.1 M Magnesium chloride 0.1 M MES 6.0 8% w/v PEG 6000 
42 0.15 M Sodium chloride 0.1 M Tris 8.0 8% w/v PEG 6000 
43 None 0.1 M Sodium citrate 5.5 15% w/v PEG 6000 
44 0.1 M Magnesium acetate 0.1 M Sodium cacodylate 6.5 15% w/v PEG 6000 
45 None 0.1 M MES 6.5 15% w/v PEG 6000/5% w/v MPD 
46 0.1 M Potassium chloride 0.1 M Na HEPES 7.5 15% w/v PEG 6000 
47 None 0.1 M Tris 8.5 15% w/v PEG 6000 
48 None 0.1 M Tris 8.5 20% w/v PEG 6000 
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PROPLEX BOX 2 (MOLECULAR DIMENSIONS) 
Tube # Salt Buffer pH Precipitant 
1 0.1 M Magnesium acetate 0.1 M Sodium acetate 4.5 8% w/v PEG 8000 
2 None 0.1 M Sodium citrate 5.0 8% w/v PEG 8000 
3 0.2 M Sodium chloride 0.1 M Sodium cacodylate 6.0 8% w/v PEG 8000 
4 None 0.1 M Na HEPES 7.0 8% w/v PEG 8000 
5 None 0.1 M Tris 8.0 8% w/v PEG 8000 
6 0.1 M Calcium acetate 0.1 M Sodium cacodylate 5.5 12% w/v PEG 8000 
7 None 0.1 M Sodium phosphate 6.5 12% w/v PEG 8000 
8 0.1 M Magnesium acetate 0.1 M MOPS 7.5 12% w/v PEG 8000 
9 0.2 M Sodium chloride 0.1 M Na HEPES 7.5 12% w/v PEG 8000 
10 0.2 M Ammonium sulfate 0.1 M Tris 8.5 12% w/v PEG 8000 
11 None 0.1 M Sodium citrate 5.0 20% w/v PEG 8000 
12 0.2 M Ammonium sulfate 0.1 M MES 6.5 20% w/v PEG 8000 
13 None 0.1 M Na HEPES 7.0 20% w/v PEG 8000 
14 0.2 M Lithium chloride 0.1 M Tris 8.0 20% w/v PEG 8000 
15 0.1 M Magnesium acetate 0.1 M MES 6.5 10% w/v PEG 10000 
16 None 0.1 M Na HEPES 7.0 18% w/v PEG 12000 
17 0.1 M Sodium chloride 0.1 M Tris 8.0 8% w/v PEG 20000 
18 None 0.1 M Na HEPES 7.0 15% w/v PEG 20000 
19 None 0.1 M MES 6.5 0.5 M Ammonium sulfate 
20 None 0.1 M Sodium acetate 5.0 1 M Ammonium sulfate 
21 None 0.1 M MES 6.5 1 M Ammonium sulfate 
22 None 0.1 M Tris 8.0 1 M Ammonium sulfate 
23 None 0.1 M Sodium acetate 5.0 1.5 M Ammonium sulfate 
24 None 0.1 M Na HEPES 7.0 1.5 M Ammonium sulfate 
25 None 0.1 M Tris 8.0 1.5 M Ammonium sulfate 
26 None 0.1 M Sodium acetate 5.0 2 M Ammonium sulfate 
27 None 0.1 M Na HEPES 7.0 2 M Ammonium sulfate 
28 None 0.1 M Tris 8.0 2 M Ammonium sulfate 
29 1 M Potassium chloride 0.1 M Na HEPES 7.0 1 M Ammonium sulfate 
30 None 0.1 M Sodium acetate 5.0 2 M Sodium formate 
31 None 0.1 M Tris 7.5 3 M Sodium Formate 
32 None None 7.5 0.8 M Na/K hydrogen phosphate 
33 None None 7.0 1.3 M Na/K hydrogen phosphate 
34 None None 6.5 1.6 M Na/K hydrogen phosphate 
35 None 0.1 M Na HEPES 7.5 1 M Sodium acetate 
36 None 0.1 M Na HEPES 7.0 1 M Sodium citrate 
37 None 0.1 M Sodium citrate 6.0 2 M Sodium chloride 
38 None 0.1 M MES 6.5 1 M Lithium sulfate 
39 None 0.1 M Tris 8.0 1.6 M Lithium sulfate 
40 None None 6.0 1.4 M Sodium malonate 
41 None 0.1 M Tris 8.0 1.2 M Na/K tartrate 
42 None 0.1 M MES 6.5 1.6 M Magnesium sulfate 
43 None 0.1 M Sodium acetate 5.0 2% w/v PEG 4000/15% v/v MPD 
44 50 mM Calcium acetate 0.1 M Sodium cacodylate 6.0 25% v/v MPD 
45 None 0.1 M Imidazole 7.0 50% v/v MPD 
46 50 mM Magnesium chloride 0.1 M MES 6.5 5% w/v PEG 4000/10% v/v 2-Propanol 
47 0.2 M Ammonium acetate 0.1 M Na HEPES 7.5 25% v/v 2-Propanol 
48 0.1 M Sodium chloride 0.1 M Tris 8.0 5% v/v MPD/15% v/v Ethanol 
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Appendix XI 
Supplemental Figures 
 
 
 
 
Supplemental Figure 1 Overexpression of MyD88 E143X and IRAK-4 K115X truncated 
variants. ~500 ng of each protein were analyzed by SDS-PAGE and transferred to a PVDF 
membrane for WB analysis. Novex® Sharp Pre-stained Protein Molecular Weight Standard was 
used to determine the molecular masses, given in kDa. Lane 1, MyD88 E143X variant probed 
with anti-6xHis antibody. Lane 2, IRAK-4 K115X variant probed with anti-FLAG antibody. 
Notice that both proteins migrate approximately as expected from their theoretical masses (see 
Table 4.2). 
 
 
 
 
 
 
Supplemental Figure 2 Gel filtration analysis of MyD88 E143X variant. FPLC analyses were 
performed on MyD88 E143X at a flow of 2 mL/min. MyD88 E143X monomers were calculated 
to elute at ~ 80.7 mL, using the standard curve given in Figure 4.4a. In all cases, MyD88 E143X 
was eluted at ~ 44 mL, corresponding to a MW of 240 kDa (~ 17 protein monomers).  At higher 
concentrations (bottom-right panel), an elution peak appeared at ~ 39 mL, corresponding to a MW 
of ~ 350 kDa (~ 25 monomers). 
 Appendix XI 
 
 
174 
 
 
 
 
 
 
Supplemental Figure 3 Electrophoretic analysis of MyD88(L)•IRAK-4(L) and 
MyD88(L)•IRAK-4 K115X complexes under native conditions. MyD88(L)•IRAK-4(L) (a) and 
MyD88(L)•IRAK-4 K115X (b) complexes were obtained by co-renaturation in Fold-it condition 
5, as explained in Materials and Methods (see Appendix VIII for composition). Samples were run 
in a Tris-glycine gel, pH 8.8, 11% acrylamide, as detailed in Appendix VII. Samples were applied 
as follows: a) lane 1, MyD88(L); lane 2, IRAK-4(L); lane 3, MyD88(L)•IRAK-4(L) complex. b) 
lane 1, MyD88(L); lane 2, IRAK-4 K115X; lane 3, MyD88(L)•IRAK-4 K115X complex. 
 
 
 
 
Supplemental Figure 4 Formation of MyD88 E143X•IRAK-4(L) complex in solution. 
Equimolar ammounts of MyD88 E143X and IRAK-4(L) were incubated for 2 hours at room 
temperature in binding buffer (see Appendix VII) and then Ni-NTA agarose was added to this 
mixture. After centrifugation to remove non-bound material (NB), proteins were washed and 
recovered from the matrix using increasing imidazole concentrations. Samples were separated by 
SDS-PAGE and stained with Coomassie Blue Staining. Notice that IRAK-4(L) is pulled down by 
MyD88 E143X, indicating  MyD88 E143X•IRAK-4(L) complex formation. 
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Supplemental Figure 5 Orthogonal images of diffraction patterns obtained for MyD88(L) 
and MyD88 E143X crystals. All crystals were obtained as described in Results (see Table 4.5). 
a) Diffraction patterns of an MyD88(L) crystal, obtained at orthogonal positions. Although poor 
diffraction is observed for this crystal, it presents typical protein diffraction patterns. b) 
Diffraction patterns of an MyD88 E143X crystal, obtained at orthogonal positions. Although this 
crystal yields poor diffraction results, it also presents typical protein diffraction patterns. 
Diffraction patterns were obtained at the ESRF beamline ID23-1, equipped with an ADSC Q315R 
CCD detector. 
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